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Androgens are essential for the maintenance of male health and wellbeing.  A disturbance in 
androgen signalling has been associated with a number of clinically relevant disorders such 
as cardiovascular disease, diabetes and metabolic disorders as well as infertility. Primarily 
produced in the testis in males, the actions of androgens are mediated through binding to 
androgen receptor (AR), a member of the nuclear receptor superfamily of ligand-activated 
transcription factors. The somatic cells of the testis are known to have a number of key roles 
in both testis function and development and the Sertoli, Leydig and Peritubular Myoid cells 
are known to express AR in adulthood. It is through AR that some testicular functions are 
mediated; for example, the Sertoli cells support of complete spermatogenesis with Sertoli 
cell androgen receptor knockout (SCARKO) testis demonstrating a halt of spermatogenesis 
before meiosis. However, how androgen signalling is impacting testicular function through 
each of the somatic cell types is not yet fully understood.  
Currently, treatments for male reproductive disorders such as hypogonadism (low 
androgens) and infertility are limited to treatment of the symptoms; using androgen 
replacement therapy and in vitro fertilisation techniques. This has been, up until recently, a 
result of a lack of understanding of the causes of these conditions and a lack of resources 
able to treat them, with research suggesting that a genetic component may be responsible 
in a number of cases. However, due to the limited genetic investigation diagnosis of men with 
male reproductive disorders, the wider understanding of the genetics underpinning male 
hypogonadism and infertility is incomplete. 
Developments in technology for the investigation and editing of the genetic code are 
triggering a surge in the exploration of genetic disorders and, in parallel, into the fields of 
gene delivery vectors and editing technologies. These technologies will allow an expansion 
into the knowledge and understanding of genetic disorders whilst simultaneously affording 
the opportunity to exploit this understanding for the development of therapeutics.  
There have been a small handful of previous studies using technologies such as viral vectors 
to target the testicular somatic cells and deliver exogenous transgenes with the purpose of 
both gene editing and repair, all with varying degrees of success. 
Here, techniques to introduce and target the Leydig and Sertoli cells were investigated to 
determine the most appropriate methodology for gene delivery to and manipulation of the 
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testis. Refinement of injections into the interstitial compartment were carried out before 
introducing lentiviral vectors and targeting of Leydig cells was validated and optimised. 
Lentiviral vectors are able to permanently integrate into the host cell. Surprisingly, analysis 
of testis post lentiviral injection determined that the lentiviral targeted Leydig cells began to 
undergo apoptosis one week post injection and were subsequently cleared from the testis 
after ten days. Contrastingly, this was not the case when adenoviral vectors were introduced 
into the interstitial compartment, with Leydig cells continuing to express the delivered 
reporter transgene and, importantly, not expressing markers of apoptosis, ten days post 
injection. This would suggest that using adenoviral vectors to target the Leydig cell 
population in the adult testis would be more appropriate than using lentiviral vectors.  
Previous studies have successfully used lentiviral vectors to target the Sertoli cells in the adult 
testis via the introduction of the particles through the efferent duct. However, this can result 
in damage to efferent duct, resulting in blockages and subsequently the seminiferous 
tubules. To circumvent this, introduction of the lentiviral particles through the rete 
compartment of the testis at a range of lower injection pressures was examined and injecting 
at a lower pressure through the rete testis was found to reduce the likelihood of introducing 
negative impacts on testicular histology when targeting the seminiferous tubules. Using 
these refined methods of introducing lentiviral vectors, targeted Sertoli cells stably expressed 
the delivered transgene for up to one year post injection.  
Using viral vector delivered transgenes for both the investigation of testicular genetic 
disorders and for the development of therapeutics has great potential. To explore this 
potential, we first generated a mouse model in which AR was ablated from both the Leydig 
and Sertoli cells using Cre/LoxP technology, termed the SC-LC-ARKO. Alongside providing a 
potential model to ‘repair’ with viral vectors, the SC-LC-ARKO model also provided an 
additional model for comparison with other models exhibiting ablation of AR from both single 
somatic cell types and double somatic cell types. This further enabled a characterisation of 
the roles of AR in adult testicular function, with results suggesting that loss of AR from more 
than one cell type results in an additive phenotype when compared to single cell knock outs. 
Despite providing further insight into the roles of AR in the testis, further analysis of the Cre 
line used to generate the SC-LC-ARKO model indicated that a small number of Leydig cells 
were expressing the Cre recombinase, resulting in only a small population of Leydig cells with 
ablated AR.  
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Considering this, to explore the potential of rescuing Sertoli cell AR using lentiviral vectors, 
we then utilised an already well characterised Sertoli Cell AR knockout (SCARKO) model. 
Lentiviral vectors expressing mouse AR and monomeric GFP (moeGFP) downstream of a CMV 
promoter were generated and injected into the rete testis of WT and SCARKO adult (day 100) 
males at low pressure. The contralateral testis was injected with a lentiviral vector expressing 
moeGFP alone (also downstream of a CMV promoter) using the same technique.  Analysis of 
testis sections revealed a reintroduction of AR to Sertoli cells in 100% of SCARKO testis 
injected with lentivirus expressing mouse AR. As a result of this re-expression of AR in Sertoli 
cells, 66% of the testis injected with lentivirus expressing mouse AR had evidence of 
morphologically mature elongated spermatids, indicative of ongoing spermatogenesis. These 
results suggest that a rescue of the infertility phenotype reported in previous studies of 
SCARKO testis. Also demonstrated is the reversal of the SCARKO testicular phenotype in 
tubules targeted by the mAR expressing lentiviral vector. This suggests that absence Sertoli 
cell AR throughout development does not have a permanent impact on the Sertoli cells 
capacity to support spermatogenesis in adulthood following rescue of SC AR expression in 
adulthood.  
In summary, the results of these studies have provided a refinement in the methodologies 
for targeting the Sertoli and Leydig cells of the adult testis with viral vectors as well as 
demonstrating successful rescue of a previously reported mouse model exhibiting infertility 
through reintroduction of a functional gene. Alongside this, comparisons of AR knockout 





Currently, cutting edge techniques are being developed to investigate and edit the genome; 
which is ultimately responsible for the formation and function of the body and its processes. 
These techniques have the potential to correct genetic disorders in a number of organ 
systems; known as gene therapy. To access the affected organ systems, researchers have 
also developed systems to deliver the gene therapy to the specific cells in the affected organ 
using viruses. These systems exploit the virus’s ability to enter the body, infect a cell and 
deliver viral DNA. By incorporating the gene therapy into the viral DNA, the virus is, therefore, 
able to deliver gene therapy to a number of different cell types in the body; these viruses are 
known as viral vectors.  
A number of studies have demonstrated the use of viral vectors to target cells in the testicles. 
These studies have demonstrated targeting of the Sertoli cells (the cells responsible for 
supporting sperm production; found in tube structures in the testicle) and the Leydig cells 
(the cells responsible for making the hormone Testosterone, found in the compartment 
outside the tubes known as the interstitial compartment) with the purpose of both gene 
editing and repair, with varying degrees of success.  
Once the best route of injection into the interstitial compartment was determined, we then 
investigated targeting Leydig cells in the testicle using a lentiviral vector; a viral vector from 
the same family as (but not causing) HIV as it is able to permanently infect a cell. It was found 
that after 10 days, the cells infected by the lentiviral vector had undergone cell death and 
were subsequently cleared from the testis, indicating that it may not be a suitable viral vector 
for targeting Sertoli cells. A similar experiment was then conducted using an adenoviral 
vector, a viral vector from the same family as (but not causing) common colds, which only 
temporarily infects cells. Results suggested that using an adenoviral vector to target Leydig 
cells was more appropriate than using lentiviral vectors as cells infected with the adenoviral 
vector did not undergo cell death 10 days post injection.  
To target the Sertoli cells, injections were first optimised to reduce the risks of damage to the 
tube structures in the testicle and found that using injections at a low pressure were the most 
effective. Following injection of lentiviral vectors using the optimised method we were able 
to demonstrate long lasting infection of the Sertoli cells for up to one year with no major 
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negative side effects. This suggested that lentiviral vectors are an ideal delivery system to 
target gene therapy in the Sertoli cells. 
To examine if this was the case, we first generated lentiviral vectors carrying a molecule 
known as Androgen Receptor (AR). AR is a structure located on a cell that responds to 
hormones known as androgens, such as testosterone, acting as a messenger for processes 
such as sperm production and development of the male sexual characteristics. When the 
body is lacking AR it is then unable to respond to testosterone, resulting in infertility, among 
other characteristics. By injecting the lentiviral vector carrying AR into the tube structures of 
a testicle lacking AR, we were able to reintroduce AR to the Sertoli cells and restore the 
production of sperm in an adult infertile mouse.  
In summary, the results of these experiments demonstrate the most appropriate viral vectors 
to target different cell types in the testicles and have used these techniques to introduce 
gene therapy into the testicle of an infertile mouse. In doing so, we were able to restore 
sperm production, demonstrating the potential of the viral vectors for the use of gene 
therapy in the testicles.  In doing so, this demonstrates a technique which could be used in 
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Chapter 1 Introduction 
 
1.1 Testis, Testicular Function & Impacts on Male 
Health 
1.1.1 Structure & Function of the Adult Testis 
The testis in adulthood has two key functions; production of sperm and production of steroid 
hormones, primarily androgens. The cell types responsible for these functions are the Leydig 
cells (LC), for steroidogenesis and the Sertoli cells (SC), for support of spermatogenesis. The 
Leydig and Sertoli cells can be found in two separate compartments of the testis, the former 
being located in the interstitial compartment, and the latter in the tubular compartment of 
the testis (Figure 1.1).  Despite their spatial separation within the testis, these cell types, as 
well as the other cell types found in the testis (namely the Peritubular Myoid (PTM) cells  and 
the Germ cells), conserve closely regulated relationships in order to maintain both 
steroidogenic and spermatogenic functionality of the testis. Disruption to testicular functions 
can result in male infertility and/or hypogonadism, both of which are clinically prevalent 
conditions with a high socioeconomic burden. Infertility affects about 15-20% of couples [1] 
and thus is as prevalent as diabetes, and yet for male factor infertility, 60% of all cases (and 
even 75% in the case of oligozoospermia) remain idiopathic [1]. In addition, up to 25% of 
middle-aged and elderly men have subnormal levels of testosterone [2, 3]. As such there is 
an urgent need to better understand the causes and develop new treatments for these 
conditions that affect millions of men [4]. 




Figure 1.1  Schematic of a cross section of an Adult Testis.  Testicular components are depicted in a 
schematic diagram of the testis. Within the tubular compartment, delimitated by the peritubular 
myoid cells (Green), is the differentiating germ cell populations (white) and the Sertoli cells (orange). 
Within the interstitial compartment, the steroidogenic Adult Leydig cells can be found alongside blood 
vessels. 
1.1.1.1 Sertoli cells 
Sertoli cells are somatic cells of the testis that are located within the tubular compartment 
of the testis, specifically at the basement membrane of the seminiferous tubules (Figure 1.1). 
They are known to be key regulators of testis formation and to be essential for the support 
of germ cell progression through spermatogenesis [5, 6]. Alongside this, Sertoli cells have 
also recently been recognised to have a number of additional roles in testis function, 
including the maintenance of the adult Leydig cell population, retention of peritubular myoid 
cell differentiation and regulation of the testicular microvasculature, confirming the 
importance of this cell type not only for formation of the testis throughout development, but 
also for retaining testicular functions in adulthood [5, 7-9].    
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1.1.1.1.1 Sertoli cell Development 
The presence of Sertoli cells in the testis is crucial not only for their ability to support 
spermatogenesis, but also for the proper formation of the testis during development [5]. At 
10.5 days post coitum (dpc) (in the mouse), activation of the Y chromosome linked testis 
determining gene; Sry in the bipotential gonad initiates the differentiation of Sertoli cells 
from multipotent precursor cells derived from ingressing coelomic epithelium cells [10]. 
Following this, expression of Sox9 by these immature Sertoli cells initiates a cascade of events 
ultimately leading to testis cord formation, differentiation of other testicular cell types 
including the androgen producing foetal Leydig cells and regression of the Mullerian ducts 
through the secretion of anti-Mullerian hormone (AMH) [11].   
In the adult testis, the number of Sertoli cells dictates the finite number of Germ cells that 
the testis can produce. This is because each Sertoli cell has a fixed capacity for the numbers 
of germ cells it can support in adulthood as evident from both a Sertoli cell depleted rat 
model [12] and more recently in a model of partial Sertoli cell ablation [9]. Due to the lack of 
proliferation seen in adult Sertoli cells, the final, maximum number of Sertoli cells must be 
reached before adulthood in order to ensure spermatogenic output is abundant in later life.   
In the rodent, this proliferation occurs during the late embryonic and pre-pubertal stages of 
life with final Sertoli cell number being achieved by postnatal day (pnd) 15-20 in the mouse 
[13, 14]. This proliferation has been to shown to be directly stimulated by a number of 
different factors. In particular, by the gonadotrophins; Follicle Stimulating Hormone (FSH); in 
experiments utilising hypogonadal [14] and transgenic knock outs of FSH receptor (FSHR) and 
the FSH β-subunit (FSHβ), final Sertoli cell number was significantly reduced [15]. An even 
greater reduction in Sertoli cell number was reported in mice with a Sertoli cell specific 
knockout of the Insulin receptor (Insr) and IGF1 receptor (Igf1r)  that was not improved by 
hemicastration (resulting in increased FSH signalling to the remaining testis) [16] revealing 
that the actions of FSH on Sertoli cell proliferation may be mediated by or associated with 
Insulin/IGF1 signalling in Sertoli cells.  
 Increased thyroid hormone signalling (or hyperthyroidism) has been shown to have a 
negative impacts on Sertoli numbers in experimental models [17, 18] and the contrary in 
models of hypothyroidism; with an increase in Sertoli cell numbers, germ cell numbers and 
subsequently, testis weight being reported [19-21]. The effects of thyroid hormones on 
Sertoli cell number is believed to be due to thyroid hormones impacting the duration in which 
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Sertoli cells proliferate and the time of maturation in pre-pubertal testis. This was 
demonstrated by Pitetti et al (2013), who revealed that thyroid hormones act independently 
of insulin/IGFs, modulating the proliferation of Sertoli cells through different pathways, 
following observation of an increase of testis weight and Sertoli cell number recorded in 
Sertoli cell Insr/Igf1r knockout mice with induced transient hypothyroidism [16].  A recent 
study has suggested that the effects of thyroid hormones on Sertoli cell proliferation may be 
associated with inducible Nitric Oxide (iNOS) or at least functioning through similar 
mechanisms [22] 
A reduction in Sertoli cell number was also observed in testicular feminised mice (Tfm); which 
lack a functional androgen receptor (AR) due to a single base pair deletion in the AR gene 
[15], but not in mice with a Sertoli cell specific knockout of AR (SC-ARKO). This, along with 
increasing expression of AR being indicative of Sertoli cell maturation (and is therefore not 
expressed on Sertoli cell during the extent of Sertoli cell proliferation), would suggest that 
androgens are influencing Sertoli cell proliferation, but are doing so indirectly of Sertoli cell 
AR signalling [23, 24]. 
 
1.1.1.1.2 Sertoli Cell Functions 
1.1.1.1.2.1 Formation of the Blood Testis Barrier 
Coinciding with the terminal differentiation of Sertoli cells, the formation of the blood-testis-
barrier (BTB) begins with the increased expression of junctional proteins in Sertoli cells, 
known to be dependent upon stimulation from gonadotrophins and testosterone [25, 26]. 
The role of the BTB is to restrict entry of molecules and specific cell types into the 
seminiferous tubule compartment in order to maintain an appropriate microenvironment for 
the germ cell development and maturation – contributing to the immune privileged status of 
the seminiferous tubules. To do so, Sertoli cell to Sertoli cell tight junctions; composed of 
occludins, claudins and junctional adhesion molecules, form a physical barrier between 
Sertoli cells between the basal compartment/ basal lamina (where the spermatogonia and 
early spermatocytes can be found) and the adluminal compartment (where auto-antigen 
expressing haploid germ cells reside). Absence of a mature BTB can result in degeneration of 
the testicular histology in aged animals (as a result of loss of Occludin [27]) and even sterility 
as seen in Claudin-11 null testis resulting in epithelial disorganisation and detachment of 
Sertoli cell from the basement membrane and adult differentiation in the Sertoli cell as well 
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as a spermatogenic defect in in neighbouring germ cells [28]. The BTB is a dynamic structure 
that undergoes reorganisation during spermatogenesis to allow maturing early 
spermatocytes into the adluminal compartment [29]. The functioning of the BTB is regulated 
by a number of factors including FSH [30] , androgens [31, 32] and a number of cytokines [33, 
34]. Additionally, it has also been suggested that peritubular myoid cells may play a role in 
the functioning of the BTB. This is unsurprising given their location and previously described 
associated functions with Sertoli cells [35, 36], however, the role peritubular myoid cells may 
play in the functioning of this structure is yet to be described.  
1.1.1.1.2.2 Spermatogenesis 
Alongside the development of the BTB, maturation and terminal differentiation of Sertoli 
cells marks the expression of proteins required to support germ cell development in the 
testis. Adult Sertoli cells are well known for their supportive roles throughout 
spermatogenesis, a process that has been shown to be mediated by androgens, FSH and a 
number of other factors (reviewed in [37, 38]).   
Studies utilising either androgen depleted or AR depleted models highlight the importance 
of androgens for complete spermatogenesis, with models exhibiting a disruption in 
spermatogenesis [39, 40] despite there being no functional AR in germ cells [40-56]. In 
particular, these studies have highlighted the requirement of androgen signalling through 
Sertoli cells for the progression of spermatogenesis past meiosis with a halt in 
spermatogenesis being observed in SC-ARKO testis [48, 50]. However, it is not known 
whether this crucial role of Sertoli cell in spermatogenesis is specific to adulthood or whether 
the function of Sertoli cell have been impacted as a result of a reduction in androgen 
signalling through Sertoli cell AR throughout development. Studies attempting to determine 
the specific Sertoli cell roles of AR in adulthood and the post meiotic effects of androgens 
first utilised a tamoxifen inducible ARKO model (iARKO) [44]. However, given the estrogenic 
activity of tamoxifen, the endocrine system of both controls and iARKO animals was 
significantly impacted, making it difficult to elucidate which effects are solely due to the loss 
of AR in the adult. Furthermore, as there is currently no Sertoli cell specific tamoxifen 
inducible Cre available, the ubiquitous inducible Cre resulted in complete loss of AR, making 
it difficult to dissect out the specific roles of Sertoli cell AR.  To circumvent this, another study 
revealed that, by delivering lentiviral vectors carrying Cre recombinase to the Sertoli cell in 
the adult testis, a loss of Sertoli cell AR resulted in the same block at meiosis during 
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spermatogenesis concluding that Sertoli cell AR expression is essential in the adult for 
continuous spermatogenesis [45]. Mouse models with increased levels of Sertoli cell AR 
reveal a reduction in total Sertoli cell numbers and an increase germ cell load for the Sertoli 
cell that remain, resulting in an increases in apoptotic germ cells, indicating that a balance of 
AR signalling is required for male fertility [57]. 
Sertoli cells are direct targets of FSH signalling in the testis given their expression of FSHR. 
Mice lacking gonadotrophins, specifically FSH [53, 58, 59] and FSHR knockouts [23, 47, 60] 
each have significant reductions in germ cell numbers, but do not exhibit complete infertility, 
demonstrating the FSH signalling it not required for in the process of spermatogenesis. Given 
the reductions in germ cell numbers during spermatogenesis, it was determined that FSH 
signalling may be crucial for acquiring the maximum numbers of germ cells during, but not 
for progression of, spermatogenesis.  
The renewal of spermatogonial stem cell in the adult testis has previously been reported to 
be under the regulation of the gonadotropins, in particular, FSH [61, 62]. It was also 
determined that this occurred through gonadotropin stimulation of glial cell line-derived 
neurotrophic factor (GDNF) in the Sertoli cells. However, more recently, conflicting studies 
have reported that gonadotrophins may not be responsible for the stimulation of GDNF 
production in Sertoli cell, supporting another publication describing the negative impacts of 
Gdnf deletion from the peritubular myoid cells on spermatogonial stem cell development 
[63, 64]. This report demonstrated that there were no differences in spermatogonial stem 
cell self-renewal in Fshb knock out mice and has suggested that Sertoli cells may be 
stimulating spermatogonial stem cell renewal through WNT5A signalling and that this was 
negatively regulated by LH through suppressive actions of testosterone [64]. However, the 
mechanisms introduced do not explain the reduction in germ cell numbers seen in testis with 




Chapter 1 Introduction 
7 
 
1.1.1.2 Leydig cells 
Located in the interstitial compartment of the testis (Figure 1.1), Leydig cells are primarily 
responsible for the production of testosterone in the adult male. 
1.1.1.2.1 Leydig Cell Development 
The development of Leydig cell populations in the testis occurs in two separate phases; one 
in foetal life and the other developing during puberty and into adulthood, in the latter, four 
Leydig cell subtypes of development can be observed; Stem Leydig cells, Progenitor Leydig 
cells, Immature Leydig cells and Adult Leydig cells.  
1.1.1.2.1.1 Foetal Leydig Cells 
The foetal population of Leydig cells support the masculinisation of the male foetus through 
the production of androgens, that are converted to testosterone by the Sertoli cells (through 
17β-hydroxysteroid dehydrogenase 3 expression) and the production of Insulin like 3 (Insl3) 
(believed to be responsible for the descent of the foetal testis from the intra-abdominal 
position to the scrotum [65, 66]) [67, 68]. The induction of these cells to produce hormones 
(at around 13dpc in the rodent) begins with expression of Dhh, from developing Sertoli cells 
in the foetal testis, interacting with its receptors on foetal Leydig cells and resulting in a both 
a down regulation of chicken ovalbumin upstream promoter II (COUP-TFII) and up regulation 
of steroidogenic factor 1 (Sf1) dependent steroidogenic enzymes [68, 69]. The regulation of 
androgen production in the foetal rodent testis is yet to be fully described, but appears to 
eventually attain but not depend upon LH responsiveness [70]. Further study into the factors 
responsible for stimulation of foetal Leydig cell provided further evidence into the 
promiscuity of foetal Leydig cell s, though it appears an intact pituitary is still required, other 
factors include adrenocorticotrophic hormone (ACTH), corticotrophin releasing hormone 
(CRH), Platelet derived growth factor subunit A (PDGF-A) and Dhh among others [70, 71].  
1.1.1.2.1.2 Stem Leydig Cells 
It is accepted that the adult Leydig cell progenitor or stem cell is present in the testis in foetal 
life [72]. However, whether the foetal Leydig cell and adult Leydig cell share a common stem 
cell ontogeny is still debated. The processes of post-natal regression of the foetal Leydig cell 
population and replacement with the developing adult Leydig cell populations have 
previously been debated, with evidence available for both the atrophy and regression of the 
foetal Leydig cell population [73, 74] and for the retention of a small sub-population of the 
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foetal Leydig cell in the adult testis [75-78]. However, the latter is now widely accepted to be 
the case.  
The adult Leydig cell population begins to develop around puberty from stem Leydig cells 
present in the postnatal testis. Studies utilising Leydig cell ablation/regeneration with ethane 
dimethanesulfonate (EDS) have indicated that stem Leydig cells; morphologically spindle 
shaped cells, can be located close to outer surface of the seminiferous tubules and the 
vasculature [79-81], Though they do not produce androgens and don’t express Leydig cell 
lineage markers (such as the steroidogenic enzymes and LH/chorionic gonadotrophin 
receptor (LHCGR)) as demonstrated by Ge et al (2006) [72], Kilcoyne et al (2014) has also 
shown that these stem Leydig cell express AR and can be impacted by reduced AR signalling 
in foetal life (subsequently impacting the final number of adult Leydig cell ) [82]. Ge et al 
(2006) also revealed that proliferation of this cell type ex vivo was stimulated by the growth 
factors; leukaemia inhibitory factor (LIF), PDGF and stem cell factor, all factors typically 
associated with stem cell renewal in other systems [72, 83]. 
Differentiation of the stem Leydig cells into progenitor Leydig cells during puberty is 
dependent upon LH, IGF-1 and Thyroid hormone signalling. Treatment with exogenous LH 
resulted in an increase in progenitor Leydig cell in both WT animals and in IGF-1 knock out 
mice (which have a decreased number of Leydig cell [84] due to impacted progenitor Leydig 
cell development [85]) , though full recovery of progenitor Leydig cell numbers was still 
reduced in these animals [86]. Indeed, signalling of LH and its receptor; LHCGR, is critical for 
the development of the of the adult Leydig cell population, with LHCGR knock out animals 
exhibiting a dramatic reduction in final adult Leydig cell numbers and in the expression of 
fundamental genes for endocrine function [87-90]. 
Daily administration of thyroid hormones in rats led to an advancement in the formation of 
Leydig cell progenitors and as a result an increase in final Leydig cell numbers in the testis. 
On the contrary, induced hypothyroidism results in eventual decreased numbers of Leydig 
cells as a result of a delay but not a complete arrest in the development of the adult Leydig 
cell population [80, 91, 92].  
1.1.1.2.1.3 Progenitor Leydig Cells 
The commitment of the stem cells into progenitor Leydig cells at around pnd10-14 in the 
rodent coinciding with the expression of Leydig cell lineage markers such as HSD3β and 
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LHCGR. As a result, they are now capable of producing androgens, albeit at relatively low 
levels due to steroidogenic enzyme expression levels also being lower than at later 
developmental stages [76, 93-95]. Along with LH, the intense proliferation of these cells (with 
a significant increase in interstitial cells being observed during this time point [76, 96, 97]) is 
dependent on Sf-1, and upon Sertoli cell produced factors such as TGF-β as supported by 
Sertoli cell ablation models demonstrating reduction in Leydig cell numbers following Sertoli 
cell ablation at pnd2 and pnd18 – key stages of stem Leydig cell differentiation and progenitor 
Leydig cell proliferation in the pre-pubertal testis [5, 98-100]. A key role of Sertoli cell AR has 
also been implicated in this proliferation, with SC-ARKO testis having significant reductions 
in Leydig cell number in adulthood as well as significant reductions in transcript expression 
of growth factors known to be implicated in progenitor Leydig cell proliferation [101].  The 
constitutive activity of FSHR has also been suggested to have a role in the development of 
final Leydig cell number [102]. This was demonstrated with a reduction in Leydig cell number 
being observed in mice deficient of FSHR but not in mice deficient of it ligand; FSHβ. This 
would suggest that, both FSHR and LH (but not FSH) are required for proper attainment of 
Leydig cell number in the developing testis.   
1.1.1.2.1.4 Immature Leydig Cells 
The proliferation and transition of progenitor Leydig cell to immature Leydig cell occurs at 
around pnd21 in the rodent and, in Mullerian inhibiting substance (MIS) or AMH knock out 
mice, Leydig cell number is increased, but Leydig cell are phenotypically and functionally 
immature, suggesting a role of MIS/AMH in this transition from progenitor to immature 
Leydig cells [11, 103-105]. At this age point, Amh expression in Sertoli cells is reducing, further 
suggesting an influence of Sertoli cell maturation on Leydig cell development. The 
transcription factor COUP-TFII is crucial for the transition of progenitor Leydig cell to 
immature Leydig cell. Coup-tfII ablation at puberty resulted in retention of spindle shaped 
Leydig cell in the interstitial compartment of the testis comparable to the progenitor Leydig 
cell seen in the pre-pubertal testis [106], confirming the importance of Coup-tfII in this 
progenitor to immature Leydig cell differentiation.  
Morphologically, the transition of progenitor to immature Leydig cell signifies the loss of this 
spindle shaped characteristic seen in stem and progenitor Leydig cell. The immature Leydig 
cells become more oval with a large nuclei containing condensed chromatin. A typical feature 
of immature Leydig cells in the rodent is the presence of numerous large lipid droplets, 
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indicative of the increasing capacity for steroidogenesis as production gradually shifts from 
that of androstanediol (in immature Leydig cell due to the presence of testosterone 
metabolising enzymes) to testosterone in the adult Leydig cell [96, 107].   
The proliferative activity of immature Leydig cell is significantly less of that than the 
progenitor Leydig cell highlighted by a reduction in proliferative markers such as PCNA and 
cyclin D3 [97]. In fact, immature Leydig cells have been shown to divide only once before 
finally maturing to adult Leydig cells [107]. Though limited, this proliferation cycle is 
important as it is effectively a final doubling of the immature Leydig cell population. 
Consequently, interference of this proliferation cycle in testis with knock out of IGF-1 has 
been shown to significantly reduce final adult Leydig cell numbers, evidently demonstrating 
the importance of IGF-1 in this final proliferation step (as well as for the proliferation of the 
progenitor Leydig cell) [85, 86].  
AR has been demonstrated to be crucial for the maturation of immature Leydig cell [108]. In 
model in which AR is ablated in Leydig cell from foetal life, Leydig cell maturation and 
regulation of steroidogenic enzymes was disrupted, revealing that autocrine roles of AR in 
Leydig cell. In this model, differences in Leydig cells are noted in adulthood, with AR negative 
Leydig cell expressing immature Leydig cell markers such as Insl3 and HSD3β1, confirming 
that Leydig cell maturation was indeed being impacted confirming suggestions from earlier 
studies [109].  
1.1.1.2.1.5 Adult Leydig Cells 
By pnd50, the adult Leydig cells populate the interstitial compartment of the rodent testis 
and are capable of producing testosterone from cholesterol synthesised de novo [110, 111]. 
The proliferative activity of adult Leydig cell is low under normal conditions, though it can be 
stimulated following ablation of the Leydig cell population with EDS. This indicates that the 
adult Leydig cell population does retain the potential to proliferate, but only upon 
stimulation from autocrine and paracrine factors such as DHH and PDGF-A [112-116] as a 
result of stem Leydig cell survival within the adult testis.  
Functioning and retention of the adult Leydig cells has also been shown to be dependent 
upon paracrine signalling from other testicular cell populations. For example, in adult Sertoli 
cell ablated testis, Leydig cell number was significantly reduced suggesting a crucial 
role/factor secreted by Sertoli cells for Leydig cell retention, though whether this is a direct 
Chapter 1 Introduction 
11 
 
effect or an indirect one signalling through peritubular myoid cells is not yet certain given the 
impact of adult Sertoli cell ablation on peritubular myoid cell function also observed in this 
study [7]. Lack of Sertoli cell proliferation seen in this model also suggests that the signalling 
required for Leydig cell regeneration, as seen in pre-pubertal Leydig cell development and in 
EDS models of Leydig cell ablation, may originate from the Sertoli cells, peritubular myoid 
cells and resident macrophages found in the adult testis, an idea that is supported by other 
studies [116, 117].  
One of these Sertoli cell expressed factors may be Dhh, known to be essential for proper 
development of adult Leydig cells (who express its receptor Patched 1 (Ptch1)), it is reduced 
in EDS models of Leydig cell ablation, and is thought to be involved in the commitment of 
stem Leydig cell to progenitor Leydig cell [113, 116, 118]. Another could be PDGFA and LIF, 
given the transient increase in expression of both through the regeneration of Leydig cell in 
EDS models of ablation [116]. 
1.1.1.3 Peritubular Myoid Cells 
1.1.1.3.1 Peritubular Myoid Cell Function 
The peritubular myoid cells are located in the outer periphery basal lamina of the 
seminiferous tubules (Figure 1.1) and are smooth muscle-like cells known to be involved in 
tubule contractility as first noted by Clement (1958) [119]. Along with the Sertoli cells, 
peritubular myoid cells are also responsible for contributing to the basement membrane of 
the seminiferous tubules through the production of extracellular matrix components such as 
fibronectin, laminin and collagens [120, 121].  Depending on the species, the organisation of 
the peritubular myoid cells can differ. In larger mammals such as humans, the peritubular 
myoid cells are arranged around the seminiferous tubules in more than one layer, whereas 
in rodents such as rats and mice, there is only one layer of peritubular myoid cells 
surrounding the seminiferous tubules [122].   
Interestingly, multilayering of the peritubular myoid cells in the mouse testis has been 
observed following ubiquitous loss of AR but not in peritubular myoid cell specific (PTM-
ARKO) and SC-ARKO testis [48, 52], though the reason for this and whether it is associated 
directly with the loss of AR in a cell type or as a by-product of the intra-abdominal location 
of the ARKO testis is not yet clear.  
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The peritubular myoid cells are the first to display expression of AR protein in the testis in 
foetal life and knock out of AR from these cells results in a reduction in germ cells and 
subsequent impact on fertility [123].  This was suggested to be a consequence of the 
androgen mediated influence of peritubular myoid cells on Sertoli cell function being 
disrupted, confirming the importance of cell to cell interactions within the testis for its 
function. Alongside interacting with the Sertoli cell in the adult testis, the same authors also 
described the impacts of disrupted peritubular myoid AR signalling on the regulation of 
normal Leydig cell development, structure and function, with a population of immature 
Leydig cell being identified in the PTM-ARKO testis that persists into adulthood [124].  
1.1.1.3.1.1 Contraction of Seminiferous Tubules 
The smooth muscle like morphology of the peritubular myoid cells is suggestive of their 
contractile functions in the adult testis with peritubular myoid cells expressing markers such 
as smooth muscle actin (SMA), myosin and desmin [125].  The purpose of this contractile 
ability is to aid the transport of spermatozoa in the tubular lumen into the rete testis and 
subsequently out to the epididymis. The contraction of the peritubular myoid cells has been 
shown to be stimulated to a number of triggers including prostaglandins, cyclic guanosine 
monophosphate (cGMP), testosterone, transforming growth factor beta (TGF-β), 
Angiotensin II and endothelin [126-129].  
1.1.1.3.1.2 Support of Spermatogonial Stem Cell Population 
The spermatogonial stem cell and spermatogonia population are located within the 
seminiferous tubules of the adult testis; on the basal lamina of the seminiferous tubules, in 
direct contact with the Sertoli cell and with peritubular myoid cells underlying the basal 
lamina.  Therefore, peritubular myoid cells may play an important role in maintaining and 
supporting the spermatogonial stem cell population and niche in the testis.  
This is further supported with the loss of germ cells at all stages of the spermatogenic cycle 
in the adult PTM-ARKO testis suggesting an impact early in the cycle [52].  
Transgenic knockouts of components implicated in GDNF signalling result in phenotypically 
infertile males as a result of disruptions early in spermatogenesis [130-133]. Though 
previously thought to originate from Sertoli cells, the increased expression of GDNF from 
peritubular myoid cells at key stages of the spermatogenic cycle indicate that it is peritubular 
myoid cell derived GDNF that is implicated in spermatogonial stem cell maintenance. 
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Furthermore, in cultured peritubular myoid cells, GDNF expression was found to be 
stimulated in the presence of testosterone, providing further support to the observations 
seen in the PTM-ARKO testis [63, 134].  
A cytokine involved in spermatogonial stem cell renewal; colony stimulating factor 1 (CSF1), 
has also been found to be produced by peritubular myoid cells, along with Leydig cells [135] 
and testicular macrophages. De Falco et al  have implicated peritubular myoid cells in 
contributing to CSF1 signalling with its receptor on spermatogonial stem cells , further 
supporting the notion that peritubular myoid cell communication within the testis is crucial 
for testicular function [136]. 
Finally, a study  into the inhibition of tyrosine kinases PDGFR and c-Kit in the postnatal testis 
resulted in a decrease in proliferating peritubular myoid cells in postnatally testis [137] and 
a reduction in the pool of spermatogonial stem cells [138]. This implies that there may be a 
role for the peritubular myoid cells in the early establishment of the spermatogonial stem 
cell pool in the postnatal testis. 
 
1.1.1.4 Germ cells 
Arrival of the primordial germ cells within the genital ridges of a 10dpc embryo and the 
embryonic Sertoli cells at 12.5dpc permits association of these two testicular cell types and 
eventual formation of the seminiferous cords which will go on to form the seminiferous 
tubules. It is within the cords that the primordial germ cells first undergo a period of mitotic 
proliferation before entering a quiescent period until birth, a step that is regulated by 
transforming growth factor beta (TGF-β) [139] . It is through factors secreted by Sertoli cells 
that germ cells are prevented from entering meiosis until adulthood. In the embryonic female 
gonad, primordial germ cells enter meiosis at 13.5dpc through the stimulation of Stra8 
activation as a result of retinoic acid (the biologically active form of vitamin A/retinol) 
expression [140]. In the male, the retinoic acid is metabolised following secretion of CYP26B1 
from Sertoli cells, preventing expression of Stra8 and subsequently germ cell entry into 
meiosis at 13.5dpc in the developing testis [140]. This inhibition of Stra8 is maintained in the 
days following through Nanos2 signalling. Nanos2-null testis revealed an upregulation of 
Stra8 expression, blocking male germ cell entry into meiosis after 13.5dpc [141]. Induction of 
Stra8 expression through retinoid acid signalling is required in the male during puberty for 
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the meiotic entry of the germ cells initiating the first wave of spermatogenesis at around 
pnd40-45 in the rodent, though it is not required for future meiotic divisions of germ cells 
[142-146].  Another factor implicated in the regulation of male germ cell development in both 
mouse and human foetal testis is FGF9, with a number of studies demonstrating its 
expression in the foetal testis, its role in meiosis suppression and promotion of male germ 
cell fate [140, 147-149] 
The first wave of spermatogenesis is highly regulated process that differs greatly from 
subsequent waves of spermatogenesis occurring in the testis and is known to be dependent 
on FSH and LH mediated stimulation of testosterone production. For instance, during the first 
wave of spermatogenesis there is an increase in apoptosis specifically in the pachytene 
spermatocytes as a result in an increase in apoptosis-promoting BAX protein in the germinal 
cells [150]. The expression of BAX protein at this time point is believed to maintain the proper 
Sertoli cell: germ cell ratio in the seminiferous tubules and perturbation of this protein and 
the subsequent wave of apoptosis results in marked alterations of spermatogenesis later in 
life [151]. In mice treated with a GnRH antagonist, there was a significant increase in 
apoptotic cells associated with a reduction in FSH levels during this time period, suggesting 
that FSH may be limiting or regulating the levels of spermatocyte apoptosis [152].  
FSH signalling, however, is not required in adulthood for the completion of quantitative 
spermatogenesis [153]. This has been demonstrated using hpg animals expressing transgenic 
FSH with and without testosterone treatment. Researchers demonstrated that transgenic 
expression of FSH stimulated maturation and proliferation of Sertoli cell and established a 
normal Sertoli: germ cell ratio. However, numbers of post meiotic haploid cell, though absent 
in hpg mouse (minus transgenic FSH expression), were limited. Testosterone treatment in 
hpg mouse had no impact on the proliferation of spermatogonia in the postnatal testis, but 
that progression into meiosis was greatly enhanced. Combination of transgenic FSH 
expression and testosterone treatment in the hpg mouse revealed both an additive and 
synergistic effect on the establishment of normal meiotic Sertoli cell : germ cell ratio and on 
the total number of spermatids in the testis [154].   
FSH can induce Leydig cell function indirectly through stimulation of Sertoli cells [155]. 
Therefore, some observations on spermatogenesis seen in hpg mice treated with FSH may 
also be due to stimulation from Leydig cells presumably through AR. O’Shaughnessy et al 
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utilised hpg mice with loss of AR in either Sertoli cells alone (hpg.SC-ARKO) or ubiquitously 
(hpg.ARKO) to determine the direct effects of FSH action on spermatogenesis. Treatment 
with recombinant FSH was found to increase spermatogonial number and entry into meiosis 
but had no effect on the completion of meiosis [6]. Taking the results of both studies together 
this would imply that androgens are required for the completion of meiosis during 
spermatogenesis and that FSH, along with its influences on Sertoli cell number, can support 
the entry of spermatogonia into meiosis and increase proliferation of spermatogonia.   
1.1.1.4.1 Stages of Spermatogenesis 
Spermatogenesis is the process in which diploid germ cells develop into haploid spermatozoa 
in the seminiferous tubules of the adult testis. The process is continuous throughout 
adulthood following initiation after puberty and takes place in three stages; mitosis, meiosis 
and cytodifferentiation.  
1.1.1.4.1.1 Mitosis 
As discussed previously, the spermatogonial stem cells reside in the basal lamina of the 
seminiferous tubules in the adult testis. The spermatogonial stem cells are a sub-type of 
spermatogonia, capable of both self-renewal and of developing into differentiating 
spermatogonia [156].  Huckins (1971) and Oakberg (1971) were first to describe this 
population of early spermatogonia and subsequently proposed a model of spermatogonial 
self-renewal, proliferation and differentiation in the rat and mouse respectively [157-159] 
(Figure 1.2).  In this model these early spermatogonia or undifferentiated spermatogonia can 
be grouped into different stages; single spermatogonia (Asingle or As), pairs of spermatogonia 
(Apaired or Apr), and chains of four, eight and 16 cells (Aaligned or Aal). The ‘spermatogonial stem 
cells’ in this model are the As stage of the model and following the mitotic division of the As 
spermatogonium, the two arising daughter cells can either migrate away from one another 
to become two new spermatogonial stem cells or As, or, as a result of incomplete cytoplasmic 
division, can remain connected, constituting the first step of differentiation to the Apr stage 
[157, 160]. Further mitotic divisions of these Apr then results in differentiation to the Aai in 
which the chain four, eight or 16 clones will emerge. These chain of Aai spermatogonia will 
then undergo a limited number of mitotic divisions (depending on species) and each stage is 
denoted A1 (the Aai spermatogonia), A2, A3 and A4 after the first three mitoses, intermediate 
spermatogonia   after the fourth and final type B spermatogonia after the final division. Each 
of these type B spermatogonia then divide to form resting primary spermatocytes [156-159]. 
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Alternative strategies have been later suggested for the maintenance of the spermatogonial 
stem cell pool. One model known as the “fragmentation model” describes the ability of the 
Apr and Aai chains to fragment into smaller clones from which more clones will be generated 
through mitotic divisions (Figure 1.2). In this model, As spermatogonia rarely produce two 
new As daughter cells and are more likely to form pairs [161, 162]. More recently, the 
‘hierarchical’ model has described the heterogeneity of the As population, suggesting that 
20% of As spermatogonia express high levels of the protein Inhibitor of DNA binding 4 (ID4), 
a protein reported to be involved in the self-renewal of spermatogonial stem cells  [163, 164]. 
In the hierarchical model, the ID4 bright As spermatogonia are postulated to be the ‘ultimate’ 
spermatogonial stem cells and the As spermatogonia expressing lower levels of ID4 were 
described as transitory spermatogonial stem cells, with a reduced capacity for self-renewal 
(Figure 1.2).  
As discussed in 1.1.1.3.1.2, the proliferation and differentiation of the spermatogonia is 
dependent on direct or indirect support from the Sertoli cells, peritubular myoid cells and 
macrophages through the secretion of factors such as GDNF and CSF1. Other Sertoli cell 
secreted factors that may be implicated in this support are fibroblast growth factor 2 (FGF2) 
and wingless-type MMTV integration site family member 5A (WNT5A) which has recently 
been shown to be negatively regulated by LH via testosterone secretion and interaction with 
Sertoli cells, suggesting a role of the Leydig cells in the regulation of the spermatogonial stem 
cell niche [64].  
1.1.1.4.1.2 Meiosis 
The proliferation of spermatogonia described in 1.1.1.4.1.1 takes place in the basal lamina of 
the seminiferous tubules, outside of the BTB. The resting primary spermatocytes formed 
must then cross the BTB to reach the adluminal compartment; a process which requires 
disassembly of existing junctional proteins and the simultaneous assembly of new junctions 
behind the entering spermatocyte. This ensures the integrity of the immune privilege in the 
adluminal compartment whilst permitting the continuous progression of spermatogenesis.  
The expression of AR in Sertoli cells is cyclical and has been linked to specific stages of the 
spermatogenic cycle, with a particular increase in expression at stages VI-VII, stages at which 
there is a presence of resting primary spermatocytes [165, 166]. The close relationship of 
Sertoli cells and germ cells and the phenotype seen in models with disrupted Sertoli cell AR 
signalling; a halt of spermatogenesis at meiosis [48], downregulation of Claudin 3 [31] (a 
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protein associated with the formation of new tight junctions in the BRB) and an influx of 
immune cells in the testis [167], suggests a clear role for androgens in the restructuring of 
the BTB following primary spermatocyte entry into the adluminal compartment . This 
association of androgens and the regulation of Claudin 3 expression was also further 
supported with a reduction in expression in hpg mice that was rescued following treatment 
with dihydrotestosterone (DHT) [26] (Figure 1.2). 
Once within the adluminal compartment; benefitting from the immune privilege provided by 
the BTB, the resting primary spermatocytes can now enter meiosis, involving two sequential 
divisions (Meiosis I and Meiosis II), each divided into four stages; prophase, metaphase, 
anaphase and telophase. Prior to Meiosis 1, during premeiotic interphase, the centrioles and 
chromosomes of the spermatocyte are duplicated. The first meiotic prophase is extended, 
during which homologous chromosomes condense, pair and DNA exchange occurs, resulting 
in chromosome crossover. In metaphase and anaphase, the homologous chromosome pairs 
align along the equator of the spindle before migrating in opposite directions. In telophase, 
cytokinesis occurs, yielding two daughter cells each with half the number of chromosomes 
with each chromosomes consisting of two unique chromatids. In the second phase of meiosis 
(which has no premeiotic interphase), the chromatids are separated to yield four, genetically 
unique haploid round spermatids from each spermatocyte entering the process.  
As discussed earlier in 1.1.1.4, entry of the spermatocytes into this process is reliant 
expression of Stra8, stimulated by the presence of retinoic acid.  
1.1.1.4.1.3 Spermiogenesis & Spermiation 
The haploid round spermatids must then undergo major morphological changes to 
differentiate into a mature spermatozoon. During this last stage of spermatogenesis, there 
are no further cycles of cell division and the round spermatids begin to undergo complex 
cytodifferentiation. This process takes places in three stages; i) the development of the 
acrosome, ii) the development of a flagella from an axoneme and iii) the elongation and 
condensation of the nucleus to form the characteristic and species dependant head of the 
elongated spermatid. During this the histones present in the chromatin of the early round 
spermatids are eventually replaced by protamines through an intermediate replacement 
with transition proteins (TP) to protect the DNA during this re-organisation [168]. In mice 
lacking the FSH receptor there was a significant decrease in the numbers of elongated 
spermatids [169]. This was reported to be a result of reduced nuclear compaction during 
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spermiogenesis suggesting that FSH signalling through it receptor may be important for the 
completion of qualitative spermatogenesis. This observation could also be relevant to the 
increased apoptosis seen in association with reduced levels of FSH as discussed earlier in 
section 1.1.1.4. 
As the spermatid is undergoing elongation, unique intercellular junctions with the supporting 
Sertoli cells are formed. Suppression of intratesticular testosterone has been shown to 
impact this attachment  due to the premature release of round spermatids from the Sertoli 
cells [170]. Following complete spermiogenesis the elongated spermatids are translocated to 
the luminal edge of the Sertoli cell, facilitated by the Sertoli cell cytoskeleton, undergo their 
final remodelling and are released into the seminiferous epithelium supported by the 
seminiferous tubule fluid, secreted by Sertoli cell as a result of androgen signalling.  
 
Figure 1.2 Models of Spermatogonial Stem Cell Renewal and Spermatogenesis. Proposed models of 
spermatogonial stem cell renewal and differentiation; (A) the As model, (B) the Fragmentation model 
and (C) the Hierarchal model. (Modified from de Rooij (2017) [156] (D) The mitotically dividing 
spermatogonia (orange) will then move from the basal lamina through the BTB (red) into the adluminal 
compartment begin meiosis become spermatocytes (blue) before developing into spermatids (yellow).  
Chapter 1 Introduction 
19 
 
1.1.1.5 The Hypothalamic-Pituitary-Gonadal Axis 
Both spermatogenesis and steroidogenesis are dependent on an intact hypothalamic-
pituitary-gonadal (HPG) axis through a system of negative feedback mechanisms. An 
overview of the negative feedback mechanisms involved in the HPG axis can be found in 
(Figure 1.3). Starting at the hypothalamus, Gonadotrophin Releasing Hormone (GnRH) 
secretion binds to GnRH receptors located on pituitary gonadotrophs (found in the anterior 
pituitary). The production of GnRH from the hypothalamus has recently been shown to be 
regulated by kispeptins, signalling through the kispeptin receptor (GPR54) [171-173]. 
Upon GnRH binding, the pituitary gonadotrophs synthesis and secrete FSH and LH. These 
gonadotrophins subsequently bind to their respective receptors found on specific somatic 
cells in the testis; FSH to FSHR on Sertoli cells and LH to LHR on Leydig cells. Binding of the 
gonadotrophins to their receptors in the testis has a number of impacts on both the 
spermatogenic and steroidogenic functions of the testis, as described earlier (in sections 
1.1.1.2.2 and 1.1.2.2).  
Production of testosterone and Inhibin from the Sertoli cells and Leydig cells (in response to 
gonadotrophin receptor activity) respectively act to negatively regulate the synthesis and 
production of the gonadotrophins by supressing production at both the level of the 
hypothalamus and the pituitary.  
 




Figure 1.3 The Hypothalamic-Pituitary-Gonadal (HPG) Axis.  Steroidogenesis and Spermatogenesis 
are under the control of the HPG axis. GnRH signalling from the hypothalamus and stimulated the 
production of LH and FSH from the anterior pituitary. On binding to their receptors on the Leydig cells 
(LH) and Sertoli cells (FSH), steroidogenesis and spermatogenesis is stimulated. Secretion of 
testosterone (from Leydig cells) and inhibin (from Sertoli cells) feeds back to the hypothalamus and 
pituitary to negatively regulate the production of GnRH. Green lines represent stimulation, red lines 
represent inhibition of the feedback loop.  
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1.1.1.6 Testosterone Biosynthesis 
The main role of the adult Leydig cells is to produce testosterone through the process of 
steroidogenesis. As a result of LHCGR signalling, testosterone is synthesised from cholesterol 
through a number of transformative and enzymatic interactions (Figure 1.4).  
1.1.1.6.1 Luteinising Hormone Receptor Activity  
On binding of LH to LHCGR; a G protein coupled receptor, protein kinases A (PKA) and C (PKC) 
are activated through an increase in intracellular cyclic adenosine monophosphate (cAMP). 
This increase in cAMP signalling and activation of PKA and PKC results in the binding of 
transcription factors such as cAMP-responsive element binding protein (CREB), GATA-4 and 
Sf-1 [174-177]. The binding of the transcription factors then initiates the activation of key 
target genes, resulting in expression of steroidogenic enzymes [178]. Interaction of LH with 
its receptor, expressed by Leydig cells, is essential for the subsequent production of 
testosterone. Natural inactivating mutations in LHCGR have resulted in partial or complete 
loss of receptor function leading to patients presenting with Leydig cell hypoplasia as a result 
of failure of Leydig cell differentiation [179].  This is mirrored in mouse models in which 
LHCGR is knocked out, in which postnatal development of the steroid producing Leydig cell 
is impaired with downregulation of Leydig cell markers HSD3β6 and HSD17β3. Consequently, 
serum testosterone levels were also reduced and LH significantly increased [88]. Exogenous 
testosterone delivery was sufficient to stimulate spermatogenesis but not rescue of adult 
Leydig cell and subsequent steroidogenesis in the LHCGR knockouts, implying that it may be 
androgen independent actions of LHCGR mediating Leydig cell differentiation postnatally.  
1.1.1.6.2 Cholesterol Synthesis & Trafficking 
All steroid hormones derive from the enzymatic metabolism of cholesterol. Cholesterol is 
first synthesised de novo from acetyl coenzyme A (acetyl-CoA) via the mevalonate pathway 
via the enzyme Hydroxymethylglutaryl-CoA Reductase 1 (HMGCR1) [180]. The resultant 
cholesterol is shuttled from the outer to the inner of Leydig cell mitochondrial membrane by 
steroidogenic acute regulatory protein (StAR), a rate limiting step of steroidogenesis [181, 
182]. Knock out of StAR resulted in accumulation of lipid droplets in the Leydig cell and low, 
but detectable plasma testosterone, presumably through less efficient StAR independent 
steroidogenesis [183, 184]. 




Once located in the mitochondria, active cholesterol is then converted into Pregnenolone 
through the action of cholesterol side chain cleavage P450 (P450cc), encoded by the gene 
Cytochrome P450 11A1 (CYP11A1). Pregnenolone is a common precursor of all steroid 
hormones including mineralocorticoids, glucocorticoids and sex hormones. Male CYP11A1 
null mice are feminised with a reduction in anogenital distance and un-descended testis 
[185]. This was echoed in 46,XY patients with frame shift causing CYP11A1 mutations [186-
188]. The subsequent enzymatic processes converting pregnenolone to testosterone can 
occur through either the Δ4 or Δ5 pathways, depending on enzyme preferences and 
substrate affinity and these processes occurs in the smooth endoplasmic reticulum. In the Δ4 
pathway, HSD3β acts to convert pregnenolone to progesterone. Progesterone is then 
converted to 17α-hydroxyprogesterone and then androstenedione through the actions of 
CYP17a1. Androstenedione is then finally converted to testosterone via HSD17β3. In the Δ5 
conversion of pregnenolone to testosterone, pregnenolone is converted to 17α-
hydroxypregnenolone and subsequently to dehydroepiandrosterone (DHEA) by the enzyme 
cytochrome P450 17Aa (CYP17A1) in both instances. DHEA can then be converted to 
testosterone through androstanediol or androstenedione, depending on whether HSD3β or 
HSD17β3 respectively are first to act. Studies have suggested that the dominance of a 
particular pathway is dependent on the species of the animal; with the Δ4 pathway (via 
progesterone) being dominant in rodents and the Δ5 pathway being preferential in humans 
[189, 190]. Earlier studies suggested that this may be the case in the neonatal testis but also 
provided evidence for changes in preferential pathways through development, with an 
increase in Δ5 metabolites detected in the adult testis when compared to the neonate and 
pubertal testis, indicating a shift from Δ4 in the neonate to Δ5 in the adult testis [191]. It was 
suggested that this may be due to the differences in Leydig cell populations and their 
differential capacities for testosterone production. 
Testosterone can be further metabolised into dihydrotestosterone (DHT) or estradiol 
through the actions of the enzymes 5α-reductase and aromatase (cytochrome 19A1 – 
CYP19A1) respectively. Conversion of testosterone to DHT usually occurs in the peripheral 
tissues where concentrations of testosterone may be much lower than that at the testis, due 
to the increased affinity of DHT for AR compared to testosterone.  




Figure 1.4 The Steroidogenic Pathway.  Schematic of the production of testosterone from cholesterol 
through the Δ5 and Δ4 pathways.  
 
1.1.1.7 Androgen Receptor 
Following synthesis and migration to target tissue/cell types, androgens mediate their 
functions through binding to their receptor; AR. AR (also referred to as nuclear receptor 
subfamily 3 group c member 4 – NR3C4), is a type of steroid/nuclear receptor found within 
the cytoplasm when without ligand.  
AR is a DNA binding transcription factor located on the X chromosome and is known to be 
expressed by a number of different tissues and cell types. AR –KO and deficiency models have 
reported impacts on a number of these systems including the cardiovascular system [192-
194], the haematopoietic and immune system [195-197], in bone [198-202], the reproductive 
system [6, 23-25, 44, 48, 52, 60, 101, 108, 109, 124, 203, 204], in muscle [205, 206], the brain 
[207-209] and in adipose system (influencing metabolic pathways) [210-212]. This supports 
the notion that androgens have a number of different function roles in the body.  
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AR, like other steroid/nuclear receptors is comprised of an N terminal domain (NTD); which 
is the transcriptional regulatory region of the protein, a highly conserved DNA binding 
domain (DBD), a small hinge region and a ligand binding domain (LBD) [213]. These four 
functionally distinct regions of AR protein are encoded by 8 exons spanning around 90kb of 
DNA on the X chromosome [213].  
The NTD domain of AR is a less conserved region in comparison to the DBD, with homology 
of only 15% with other steroid hormone receptors [214]. This region of AR, also known as AF-
1, is considered the main activation domain of AR, with two transcription activation units 
having been identified; Transcription activation unit (Tau)-1 and Tau-5 [215],  which can bind 
co-regulator proteins to increase or decrease transcription of downstream genes. The Tau-5 
fragment of the NTD is capable of retaining the action potential in absence of the LBD – 
allowing ligand independent AR activity.  
The DBD, recognises and binds to androgen responsive gene promoter and enhancer regions. 
This region of the nuclear receptor is highly conserved for a number of steroid receptors and 
is organised into two zinc finger motifs, the first makes nucleotide specific contacts and is 
therefore responsible for recognition of the target DNA sequence and the second functions 
as a DBD to DBD binding site on dimerization of nuclear receptors [216, 217].   
Between the DBD and the LBD is the small hinge region, which as a characteristic globular 
fold made up of two perpendicular α-helices. Previously believed to just function as a flexible 
linker, the hinge region is now known to be involved in nuclear translocation, DNA selectivity 
and affinity and in the transactivational potential of the AR [218].  
The LBD (containing a second transcription region; AF-2) is located at the carboxyl terminus 
of the AR and facilitates the binding of ligands such as testosterone and DHT as well as 
contributing to the dimerization interface of AR. AF-2 is also the target for several co-
regulators, all of which contain a conserved leucine rich motif with the sequence; LXXLL 
(where L is leucine and X denotes any amino acid) and are dependent upon ligand binding 
for their interaction [219, 220]. The interaction of AF-2 with these co-regulators are essential 
for androgen responsive gene regulation, whether that be activation or repression of the 
androgen responsive gene. The LBD is also the site of heat shock protein (hsp) (specifically 
hsp90) association and binding of ligand to the LBD results in dissociation of AR from hsp90; 
allowing translocation of AR to the nucleus [215, 221, 222].  
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In the absence of a ligand, AR is bound to heat shock proteins (such as hsp90) and cofactors 
and is located within the cytoplasm [213]. The binding of a ligand to AR initiates a 
conformational change in the LBD, releasing the heat shock proteins and enabling AR to 
interact with co-regulators, such as importin-α, facilitating nuclear targeting of AR and 
consequent dimerization at the nucleus, permitting the binding of AR to genomic androgen 
response elements [223, 224]. This is commonly referred to as classical AR signalling, 
regulating gene transcriptional processes via AR nuclear translocation, binding to response 
elements and recruitment of transcription factors. AR also functions in a non-classical 
manner, in which following ligand binding at the membrane or within the cytoplasm, the 
intracellular release of calcium in the cytoplasm triggers the activation of protein kinase 
pathways such as the extracellular kinase (ERK), mitogen-activated protein kinase (MAPK) 
and RAC-alpha serine/threonine-protein kinase (Akt) pathways [225-227] (Figure 1.5).  
 
Figure 1.5 Classical and Non-Classical AR Signalling.  Schematic depicting binding of testosterone or 
DHT to AR and the subsequent classical and non-classical pathways downstream. AR – Androgen 
Receptor, T/DHT – Testosterone/DHT, HSP – Heat Shock Proteins, ARE – Androgen Responsive 
Element, Ca2+ - Calcium, PI3K - Phosphoinositide 3-kinase, PKA - Protein Kinase A, Akt - 
serine/threonine-protein kinase (also known as Protein Kinase B), Ras – a GTP binding switch protein, 
Raf1 – Rapidly Accelerated Fibrosarcoma (a serine/threonine-specific protein kinase), MAPK - 
mitogen-activated protein kinases, ERK - extracellular signal-regulated kinases, TF – Transcription 
Factors. 
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1.1.2 Androgens, Male Health & Wellbeing 
1.1.2.1 Androgen Signalling in the Healthy Male 
Androgens are essential for the development and functioning of the testis as well as the 
masculinisation of the male during foetal and pubertal development. However, they are also 
crucial for male health throughout adulthood, with a number of tissues expressing AR (as 
described in section 1.1.1.7). Disruptions in androgen production and signalling in men is 
associated with a number of clinically prevalent conditions including male infertility and an 
impaired reproductive physiology, increased risk of cardiovascular and metabolic diseases 
[228-230] and earlier mortality [231, 232]. 
For example, the influence of androgens of body fat composition and muscle mass in the 
male is well described whereby a high incidence of metabolic syndrome has been associated 
with lower testosterone levels alongside an inverse association between men with low 
testosterone and men with an increase in waist circumference and obesity [233-235]. 
Therefore, the relationship between low testosterone and the increased risks for developing 
metabolic syndrome are evident. However, the causality of these factors is not clear (i.e. 
whether the low testosterone is responsible for the increased risk factors (such as obesity) 
associated with the development of metabolic syndrome or vice versa). 
The inverse relationship of testosterone with body fat in men can be attributed to an increase 
in the aromatisation of testosterone to estradiol as result of increase aromatase enzyme 
(CYP19A1) found in adipose tissue [236]  Furthermore, testosterone has also been shown to 
inhibit lipid uptake and stimulate lipolysis, particularly in visceral adipose tissue [237]. This 
can create a feedback loop which could promote a worsening condition in hypogonadal men 
(i.e. generating a situation in which low testosterone results in a reduction of lipolysis and 
increase in lipid uptake, resulting in an increase in adipose tissue capable of aromatising 
circulating testosterone and thus lowering testosterone further).  
1.1.2.2 Causes & Consequences of Disrupted Androgen Signalling 
in the Male 
1.1.2.2.1 Genetic Disorders 
The causes of impaired male reproductive physiology are heterogeneous [4], but a genetic 
component is suspected in many cases [238, 239]. Yet despite the testis being the most 
specialized of human organs (by number of enriched genes expressed; indeed far more 
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complex even than the brain http://www.proteinatlas.org/humanproteome/testis), only 
karyotyping, analysis of AZF microdeletions and CFTR gene mutations are routinely used in 
genetic diagnostic work-up of infertile men [240]; our wider understanding of the genetics 
underpinning male fertility is sporadic at best. Despite this, significant inroads in 
understanding have consistently been made, primarily from the study of transgenic mouse 
models on an ad hoc basis. More recently, the development and roll-out of major 
phenotyping screens, e.g. ENU screens such as the MRC Harwell screen 
http://www.har.mrc.ac.uk/services/archiving-distribution/enu-dna-archive and the 
Reproductive Genomics screen completed at the Jackson Laboratory 
https://www.jax.org/research-and-faculty/tools/reproductive-genomics-resource and more 
recently the IMPC (http://www.mousephenotype.org), have exponentially increased the 
number of genes known to support male reproductive physiology [241]. However, whether 
this is relevant in men often remains unclear. 
Historically, this is in part due to the ‘outbred’ gene-pool and multifactorial nature of 
reproductive pathophysiology in men. Mutations with severe effects cannot be traced in 
pedigrees, and are predicted to be rare and mostly sporadic, whereas moderate genetic risk 
variants exhibit variable level of penetrance and interaction with non-genic variants [238]. 
Until very recently, the field has essentially been working in two near-mutually exclusive 
silos: sporadic patient cases with no known functional mechanism, and mouse models for 
which no patient information has been identified. Limited mechanistic knowledge 
underpinning the influence of genetics hinders clinical management. 
Mutations to the AR gene have been well described in the literature and can lead to partial 
or complete loss of AR function. AR mutations are found in most subjects with complete 
androgen insensitivity syndrome (AIS) (previously known as testicular feminisation syndrome 
[242]) which is the most common cause of 46,XY disorders of sexual development. Similar 
sex reversal phenotypes and reduced masculinisation is also reported in patients with 
disorders of testosterone biosynthesis; usually as a result in steroidogenic enzyme 
deficiencies.  
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1.1.2.2.2 Age Related Disruptions in Androgen Signalling 
Alongside obesity, another risk factor associated with low testosterone is aging [243, 244]. 
As men age, they are likely to experience decreased muscle mass, reduced sexual function,  
decrease in bone mineral density and increase fat mass; all indicators  that have been 
associated with low circulating testosterone [245-249]. A number of longitudinal studies 
have investigated the age related changes in serum testosterone, who reported aberrations 
in the HPG axis as men age, regardless of ethnicity and geographical location [243, 244, 250, 
251]. Though a number of studies described a moderate reduction in total testosterone as 
men age, the reductions in free or bioavailable testosterone are more striking, coinciding 
with increases in sex hormone binding globulin (SHBG; the protein that binds to circulating 
testosterone), suggesting that there is a reduction in testosterone that is available to target 
androgen responsive tissues [243, 244, 250, 251]. Recently Travison et al (2017) generated a 
reference range of total testosterone levels in men which was found to range from 264-
916ng/dL in healthy non-obese men aged 19 to 39 years [252]. Also noted in this study was 
the lack of age related trend seen in total testosterone levels, contrary to previously 
published cross-sectional studies [253]. Wu et al also described a similar lack of difference in 
total testosterone between young and aged men [243]. Whether this is a true representation 
of circulating testosterone levels in aging men or whether there may be a cohort effect is yet 
to be fully elucidated. Though Wu et al was unable to establish any differences between the 
total circulating testosterone levels in young and aged men, a significant increase in 
circulating LH levels was detected in older men [243]. This increase in LH hormone is 
indicative of dysfunction at the level of the Leydig cell, suggesting that the Leydig cell 
population is requiring increasing levels of LH to stimulate the generation of ‘normal’ levels 
of testosterone. This age related decline in the steroidogenic function of Leydig cell has also 
been cited in the literature, attributing this to alteration to a number of factors including 
defects in the HPG axis, changes in levels of cytokines crucial for the maintenance of LH 
receptor and steroidogenic enzymes and increases in the levels of reactive oxygen species in 
Leydig cells resulting in disrupted mitochondrial function and StAR gene expression; the rate 
limiting factor of steroidogenesis [254-257].  
1.1.2.2.3 Androgen Replacement Therapy 
In men suffering from a reduced number of Leydig cell or from a reduced capacity of the 
Leydig cell to synthesise androgens; as a consequence of genetic mutations or from aging 
[258], a strategy to maintain a healthy androgen profile is a highly desirable one.  Currently, 
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the most common treatment to address androgen deficiency in the male, is androgen 
replacement therapy (ART) with prescriptions for testosterone increasing globally between 
2000 and 2011 [259, 260]. Indeed, treatment with exogenous testosterone has been 
reported to be beneficial for some hypogonadal patients, depending on extent of 
comorbidities, with some improvements in symptoms associated with both aging and low 
testosterone [261-263] 
However, a number of studies have been published indicating the potential adverse effects 
of ART on the cardiovascular system, with the risk of mortality and morbidity yet to be 
defined, particularly for individuals with pre-existing cardiovascular complications [264-268].  
 
1.2 Gene Editing, Vector Delivery and their Uses in the 
Testis 
The literature reviewed in section 1.2 has previously been summarised and published in the 
literature in 2017 by myself under the guidance of Professor Lee Smith [269] (PMID: 
29191697). As author of this publication, the rights are retained to reuse within a thesis or 
dissertation. Therefore, the following section is a duplicate of this review with the addition 
of studies published after the date of submission. 
1.2.1 History of Modifying Genes 
1.2.1.1 Global Gene Modification 
The concept of modifying genes has long been explored, with the first example of gene 
modification being demonstrated by the transformation of bacteria in the 1970s [270]. This 
was quickly followed by the successful transfer of genes into a number of other organisms 
including mammals, the first of which being a mouse in 1974 in an experiment which 
demonstrated the integration and persistence of simian virus 40 DNA in healthy adult mouse 
DNA following microinjection into the blastocyst cavity [271]. The introduction of gene 
modifying technology such as gene knock out by homologous recombination in Embryonic 
Stem (ES) cells, and more recently development and exploitation of the Cre/Lox system [272-
274] has permitted the experimental investigation of the function of thousands of genes. 
These approaches have allowed researchers to manipulate genes in a multitude of different 
ways, in specific or multiple organ systems, and across the whole lifespan of the organisms. 
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For the understanding of mammalian systems, the species of choice has primarily been the 
mouse due to their genetic and genomic similarities to humans; allowing the modelling of 
human disease.  
 
1.2.1.2 Modification of Genes in the Testis 
Use of gene knockouts, and other genetic manipulations (e.g. ENU screens) in the mouse has 
identified many genes involved in testis function and male fertility. At the time of writing 
(June 2018), 87 knockout mouse lines are listed on the International Mouse Phenotyping 
Consortium (IMPC) as showing male infertility (www.impc.org). As information such as this 
grows and functional details emerge as to the roles of these genes, we have the opportunity 
to match this to patient data to define cause to instances of male infertility and testicular 
dysfunction. This is a golden time in the field, as the coincident development of cheap, high 
throughput sequencing technologies means we are now able to identify likely causal 
mutations in patients, and marry this information to functional studies in model species to 
understand the issues in play, and moving forward, to develop bespoke gene therapy systems 
to directly correct these aberrant genes to restore fertility to these men. 
 
1.2.2 Gene Delivery Systems & their use Globally and in the 
Testis 
A number of systems have been developed for the delivery of gene therapy and their success 
rates vary depending on many factors, not least the organ system being targeted and species 
being studied. These gene delivery and transfection technologies can be divided into two 
broad categories depending on the carrier or vector being used; (i) Viral and (ii) Non-viral 
vectors, each of which have different benefits and drawbacks, some of which have been 
highlighted in Table 1.1. 
Theoretically, the ideal system to be used for gene therapy delivery in the testis would: (i) be 
easy to deliver, (ii) have a high efficacy/be robust enough to illicit an impact on a deficient 
system, (iii) have low immunogenicity so as to reduce the likelihood of initiating an immune 
response, (iv) be long lasting so as not to require repeated treatments (due to the increased 
chances of an immune response being raised on recurrent treatments), (v) be cell specific; to 
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only impact the target cell type (this is particularly important when targeting testicular cell 
types for human gene therapy in order to avoid impacting the spermatogonial stem cell 
population and thus preventing the generation of ‘transgenic human offspring’) and (vi) have 
minimal off target effects/toxicity to prevent a negative impact on the surrounding cell 
populations, both inside and outside of the testis. Consideration must also be given when 
determining the most appropriate delivery system, to the size of the genetic material to be 
transferred, the longevity of transgene expression required and the purpose for targeting the 
testis. For example, in some instances such as in an agricultural or in a research setting, 
targeting the germ cell population in the testis may be beneficial for generation of genetically 
modified offspring whereas for use in human gene therapy, permanently altering the germ 
cell population would be undesirable thus limiting the targeting capacity of the vector to 
either the somatic cells in the testis or to target the germ cells population temporarily using 
a transiently expressed transgene. Therefore, the success of a number of the current and 
previous applications of the gene delivery systems is/was dependent on the desired output 
or purpose of the study 
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Table 1.1 Table outlining the characteristics of each of the gene therapy delivery systems described.  




1.2.2.1 Non-Viral Vectors for Gene Delivery 
1.2.2.1.1 Naked/Plasmid DNA 
Considered one of the simpler systems for gene modification/therapy, naked DNA was first 
used in vivo in 1990 , where the direct transfer of both RNA and DNA into mouse skeletal 
muscle was demonstrated [275]. This was quickly followed by several other studies 
demonstrating gene expression following injection of naked DNA in a number of tissues, 
including heart, thyroid, and liver [276]. Whilst seemingly basic in terms of sophistication, 
this is now one of the most prevalent methods used in gene therapy clinical trials; 17.2% of 
such clinical trials worldwide in 2016 used naked/plasmid DNA for genetic vaccines (in which 
DNA that codes for specific proteins/antigens for a pathogen are introduced into the body 
where the native cells synthesize these foreign proteins which then trigger an immune 
response), and a number of other genetic conditions, such as Duchenne muscular dystrophy  
(http://www.wiley.com/legacy/wileychi/genmed/clinical/).   
Introduction of naked DNA and RNA into the target cell has proven difficult due to the 
hydrophilic nature of the DNA and the negative charge of both the DNA and the cell and 
nucleus membranes. To overcome this, physical methods, such as needle injection 
(mechanical force) [276-279], gene gun (use of pressure) [280-282], hydrodynamic gene 
injections [283, 284] and electroporation (application of an electrical field to cells in order to 
increase the permeability of the cell membrane) [285] have been developed to ‘force’ the 
molecules through the membrane and thus introduce them in to the cell’s cytoplasm (Figure 
1.6).  
Hydrodynamic injection can be described as a large volume and high velocity injection (up to 
2ml over a period of three to five seconds) of saline containing the plasmid DNA (pDNA) 
causing an increased local pressure resulting in an improved uptake of genetic material. This 
method of DNA delivery has been successful used in studies focused on gene therapy in the 
liver [286, 287] and in skin [288]. Following delivery of DNA using hydrodynamic injection, 
transgene expression has been detected in a number of major internal organs including the 
lung, heart, kidney, spleen and particularly in the liver [283]. Studies have also shown that by 
directing the delivery of the hydrodynamic injection in to the vasculature supplying the target 
organ, a higher transgene expression can be reached, for example by injecting into the renal 
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vein, higher transgene expression was reported in the kidney [289, 290]. However there have 
been a number of studies indicating a link between an increase in testicular pressure and 
spermatogenic damage in the seminiferous tubules suggesting that hydrodynamic injection 
of naked DNA in the testis vasculature may result in a damaged testis as opposed to a 
repaired one [291-293]. 
Efficient transfection of plasmid DNA using electroporation was first demonstrated in vivo in 
1996 in both the rat liver; in which genes transferred encoding luciferase were detectable in 
up to 40% of liver cells 48h post transfer and up to 5% of this level at least 21 days following 
electroporation [294] and rat brain tumours; in which human monocyte chemoattractant 
protein-1 cDNA was transferred and even deemed functional (as evident from an increase in 
the presence of monocytes in the tumour tissue) three weeks post gene transfer [295]. 
Electroporation has since been used to aid chemotherapy treatments by increasing the 
permeability and thus the susceptibility of cells to the toxicity of lipophilic drugs and 
facilitating entry of plasmids expressing cytokines such as interleukin [296, 297]. More 
recently, this technique has been used for gene transfection in vivo in the mouse testis [298, 
299] and in rat testis [300] with the goal of integration of DNA into the germ cells and 
transmission to progeny in which researchers were able to demonstrate successful 
generation of transgenic offspring in both mice; with an average of 57-62% of progeny being 
transgenic, and rats; which resulted in an average of 33.08% of transgenic progeny (following 
mating of treated males with wild type females). However, electroporation of the testis is 
reported to be less reliable/suitable for large animal transgenesis in the testis due to 
variations in testis size and scrotal thickness [301]. Attempts at optimising this system of gene 
transfer in goat testis were relatively unsuccessful. Using an isolated testis ex vivo, a GFP 
expressing plasmid was injected into the interstitial compartment then electroporated 
before the seminiferous tubules were separated and then cultured for up to four weeks. 
Despite expression of GFP being achieved in the transfected tubules, expression was 
unexpectedly short lived potentially due to lack of integration of the plasmid as a result of its 
use in circular form as opposed to linear and it is also not known whether it was germ cells 
or the Sertoli cells that were expressing GFP within the seminiferous tubules.  
With the majority of current gene transfer research in the testes focusing on transfer to germ 
cells and the generation of transgenic animals, little is also known about the potential 
impacts of using electroporation on the supporting somatic cells of the testis and the effects 
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it could have both on spermatogenesis and steroidogenesis. One study has demonstrated 
disordered tubules, impacted spermatogenesis and an initial increase in apoptosis within 
testis following injection of gene/vehicle with electroporation and electroporation alone 
[302], indicating the requirement for further investigation into the impacts this technique 
could have on testis function before considering its use for gene therapy in men with already 
existing reproductive disorders.  
 Another consideration must also be that, by using this technique, regardless of injection site, 
the naked or plasmid DNA can be delivered to the germ cells of the testis. Whether this be 
intentional or accidental, human germline modification is currently banned in 29 countries 
[303], making the use of the technique for human gene therapy in the testis both an unethical 
and impractical one.  
Additionally, one major disadvantage of using naked DNA molecules for gene therapy is their 
susceptibility to degradation via nucleases on entry into bloodstream and into the cell, 
reducing the targeting efficiency of the naked DNA and pDNA. To overcome this, a number 
of ‘carriers’ or vectors have been developed and modified to facilitate gene transfer to the 
target cells reducing nuclease mediated degradation [304, 305].  
 
1.2.2.1.2 Liposomes 
Nanoparticles, such as liposomes are commonly used non-viral vectors that can aid the 
delivery exogenous genetic material (whether this be DNA, RNA interference (RNAi), small 
interfering RNA (siRNA)) into the target cell of interest and to subsequently modify the 
signalling pathways of this cell. Nanoparticle gene delivery systems are known to have a low 
immunogenicity, high loading capacities and are relatively easy to produce.  
First described in 1964, liposomes are membranous lipid vesicles which enclose an aqueous 
volume [306]. Generated by the formation of a complex between plasmid DNA and a lipid 
solution, DNA can be transferred into cells via the fusion of the liposome with a cell 
membrane. On fusion with the cell membrane, the genetic material is introduced into the 
cytoplasm and the nucleus of the cell where it is then transiently expressed (Figure 1.6). The 
idea of utilising liposomes for a therapeutic use was first proposed in 1971 by Gregoriadis 
and colleagues [307] for enzyme replacement treatment of genetic disorders impacting 
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enzyme production and function. This was later successfully demonstrated by Weissman et 
al in 1976 in which they were able to introduce enzymes via immunoglobulin-coated 
liposomes into lysosomes of deficient Mustelus canis phagocytes, demonstrating their 
potential as a mechanism for delivery of drugs and genes in vivo [308].  Just over a decade 
later the first protocol for the use of liposomes for DNA transfection was published [309]. 
Today there are a number of different modified liposome vectors including cationic 
liposomes [309-311], solid lipid nanoparticles (SLN) [312, 313] and reconstituted high density 
lipoproteins (rHDL) [314, 315]. Attempts to improve the targeting specificity of liposomes 
have been made by combining these lipid nanoparticles with antibodies directed to a 
receptor expressed by the target cell/tissue of interest. For example, Kuo & Wang (2016) 
were able to increase the efficiency of delivery of chemotherapeutic drugs across the blood-
brain-barrier using antibody and tamoxifen conjugated nanoparticles [316]. Studies have 
utilised liposomes for the delivery of transgenes to the testis [317, 318]. These studies were 
carried out with the purpose of creating transgenic offspring via the transfection of the 
spermatogonial stem cells in the testis. Unfortunately, neither of these studies demonstrated 
a high integration of the exogenous DNA into the genome of the injected animals. Both 
studies confirmed expression of the plasmid (though in circular form in) in between 28% and 
40% of the F1 generation and 0%-37% in the subsequent F2 generations from F1 matings 
[300]. Though successful, both studies demonstrate the reduced efficiency of liposomal 
transfection in vivo and the potential for lack of integration into the genome of the germ cells 
of the fathering males. For the purpose of generating transgenic offspring, non-integration is 
not ideal, however, for a gene therapy situation, a system that produces fertile offspring that 
are not transgenic could be a desirable one.  In such a situation, it would be anticipated that 
function would only be temporarily restored and repeat treatments may be required. 
1.2.2.2 Viral Vectors for Gene delivery 
In addition to the use of liposomes, viruses that are able to naturally and specifically target 
different cell types, or that have been engineered to do so have been widely exploited in 
gene therapy. A number of different viral vector systems have been developed and utilised 
for gene therapy applications, and in 2016, over 67% of gene therapy clinical trials used viral 
vectors (http://www.wiley.com/legacy/wileychi/genmed/clinical/) highlighting the utility 
that these systems have for gene delivery.   





First isolated in 1953, adenovirus are non-enveloped viruses with an icosahedral protein shell 
surrounding an inner core enclosing a double stranded DNA genome [319]. Due to their large 
genome size and overall stability, members of the Adenoviridae family have been utilised in 
the development of viral vectors. Of the six species and over 50 infective serotypes, viruses 
Ad2 and Ad5 of species C have been exploited the most for creating viral vectors for use in 
gene therapy applications [320]. On entering the host cell via receptors such as the coxsackie 
adenovirus receptor (CAR) and integrins, the adenoviral vector then loses its protein coat 
before introducing the DNA cargo into the host nucleus where it can then be transcribed 
(Figure 1.6). However, as adenoviruses are not able to integrate the viral DNA into the host 
cell’s genome, the DNA remains episomal in the nucleus of the host cell before eventually 
being lost as the cell progresses through the cell cycle. If the host cell is terminally 
differentiated, duration of transgene expression is still limited due to immune responses 
elicited by the viral transduction, resulting in clearance of the infected cells [321].  
In most tissues treated with an adenoviral gene therapy vector, the transgene expression is 
transient. For the treatment of permanent genetic disorders this may not be a suitable, 
however, for treatment of conditions such as cancer and cardiac dysfunction and in principle 
for the treatment of dysfunctional germ cells, transient expression may be more appropriate. 
For example; one group, using adenovirus delivered shRNA, were able to reduce 
inflammatory responses and improve cardiac remodelling when examined seven days after 
delivery in a model of myocardial infarction in rats [322]. Modifications to adenoviral vectors 
have been shown to prolong the expression of the introduced transgene with one study 
demonstrating expression of a transgene for between two to ten months in mice following 
the initial injection depending on the vector modification, transgene being delivered and the 
tissue being targeted [323, 324] 
Any expression, including transient expression, of the transgene in tissues other than the 
target tissue may produce unwanted side effects and thus safety issues. In a study evaluating 
the biodistribution of adenovirus following catheter mediated transfer to the aorta in the 
rabbit, a number of non-target tissues, such as the liver and the testis, were found to express 
the transgene as a result of leakage of the vector into the systemic circulation [325]. Some 
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investigation into the potential for modifying adenoviral vectors has resulted in a successful 
targeted approach for the in vivo delivery of tumour antigens to dendritic cells [326]. This 
demonstrates that specific targeting is possible and that further refinement of viral specificity 
to target tissues and subsequent analysis of distribution to other tissues would be beneficial 
for both therapeutic and research applications.  
Despite mouse germ cells expressing CAR, to date there have been no reports of germ line 
transmission by adenovirus mediated gene transfer to mouse testis [327-329]. On the 
contrary, intratesticular and intratubular injection of adenovirus vector has been shown to 
result in a strong expression of the transgene in both Leydig and Sertoli cells respectively 
[330]. In terms of producing transgenic mouse lines this may be a drawback to using 
adenoviral vectors, however, with regards to gene therapy delivery to the testis, this can be 
considered a positive factor indicating that this method could be exploited, following some 
optimisation, for the treatment of male reproductive disorders as a consequence of somatic 
cell dysfunction. Delivery of genes to testicular somatic cells using adenovirus has already 
been demonstrated, ex vivo [331], in vitro (for the study of testicular germ cell cancer) [332, 
333] and in vivo [175, 334, 335]. However, one study investigating the use of adenoviral 
vectors in the testis in vivo noted disturbances within the seminiferous epithelium and 
suggested that this may be due to a disturbance in the tight junctions that form part of the 
BTB as a result of the adenoviral vector binding to the coxsackie/adenovirus receptor [336]. 
Contrastingly, when delivered to the interstitial compartment of the testis, adenoviral 
vectors were able to successfully target Leydig cell and deliver both exogenous GFP and CRE 
recombinase transgenes. Due to the transient nature and increased immunogenicity of 
adenoviral vectors, reporter expression began to diminish 12 days post injection. However, 
as the investigators delivered CRE recombinase with the adenoviral vectors, which altered 
host DNA within 3 days of adenoviral injection, longevity of transgene expression was not 
required.  
It has been suggested that the transduction efficiency of adenoviral vectors in vivo could be 
impacted by lipid levels and lipoproteins in the host system. Using mice maintained on a high 
fat diet, Kivelä et al [337], demonstrated a reduced transduction efficiency in mice. This was 
attributed to specific lipoproteins competing with the viral vector uptake via lipoprotein 
receptors indicating that adenoviral gene therapy may be less efficient in patients with high 
cholesterol levels. The implications this could have for adenoviral treatment in the testis, in 
Chapter 1 Introduction 
39 
 
which both lipoproteins and cholesterol are essential for steroidogenesis, are yet to be 
defined.  
Due to the high exposure of humans to adenoviruses in the form of common colds, 
respiratory illnesses such as pneumonia, gastroenteritis and conjunctivitis, the majority of 
adults have already generated antibodies against the virus which may also limit the 
effectiveness of adenoviral vector mediated gene therapy, particularly in treatments which 
may require a second dose. Additional studies investigating the possibility for engineering 
adenovirus serotypes by chemically modifying the viral capsid, generation of chimeric 
adenoviral serotypes and genome modification could allow the generation of tailored 
adenoviral vectors with distinct features specific to their intended purpose, whether that be 
for gene therapy or for DNA vaccines [338-340] 
 
1.2.2.2.2 Adeno-Associated Virus 
First believed to be a contaminant in adenoviral preparations, Adeno-associated viruses 
(AAV) were first utilised as DNA cloning vectors in 1984 in which the viral capsid genes were 
substituted for a neomycin resistance gene before being used to transduce this foreign DNA 
into human and murine tissue culture cells [341]. By binding to heparin or other primary 
receptors on the host cell surface and subsequently to co-receptors such as integrin and 
human fibroblast growth factor receptors, AAV is then internalised by endocytosis, gaining 
entry into the host cell (Figure 1.6). Due to low pathogenicity and replication defectiveness, 
AAV have been gaining popularity for use as gene therapy delivery systems.  
Wild type AAV retains the ability to integrate into the host cell DNA, making AAV a more 
permanent strategy for combating genetic disorders. In the past decade, human clinical trials 
using AAV delivered gene therapy have shown promise with some improvement noted in 
each of the treated patients diagnosed with inherited loss of vision [342]. More recently, 
researchers were able to rescue bisretinoid accumulation and photoreceptor degeneration 
for one year following subretinal injections of AAV expressing the gene for a complement 
negative-regulatory protein in a mouse model of Stargardt macular degeneration [343]. The 
integration of the viral DNA into the host genome was able to rescue the phenotype via 
modulation of the complement system, potentially giving clues for treatment strategy for 
pathologies associated with complement dysregulation and for developing combination gene 
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therapies in cases where replacement gene therapy may require additional treatment to 
prevent further degeneration.  
In the testis, AAV has been utilised in the investigation of testicular autoimmunity. In this 
study, AAV encoding human IL-10 was delivered via intra-muscular injection to mice 
immunised by unilateral testicular injury. This suppressed the incidence of orchitis and 
disturbance of spermatogenesis by regulating the cell-mediated immunity in the testis [344]. 
Expression levels of the human IL-10 peaked 3 weeks following the injection to fourfold the 
initial expression level.  
As with the previous vectors, attempts have been made to target the germ line using AAV 
with conflicting results. In one study, despite detection of the AAV delivered transgene in the 
gonads of some injected animals, PCR of isolated sperm DNA and investigation of the progeny 
of these animals revealed no germ line transmission of the transgene [345]. In contrast, a 
later study using mouse germ cells harvested from donor testis, transduced with AAV vectors 
carrying a GFP transgene and then reintroduced to a germ cell depleted recipient testis, 
resulted in the transmission of the GFP to the germ cells. It is reported that this group 
favoured transduction of the germ cells in vitro due to the uptake of the virus by Sertoli cells 
when introduced to the testis in vivo, as reported in studies using retroviral and adenoviral 
vectors. This study resulted in the transgene being detected in 10% of the F1 offspring of the 
recipient mouse and 33% detection of the transgene in the resultant F2 offspring (when two 
heterozygous transgenic F1 offspring were mated together). This percentage of offspring is 
relatively low compared with the expected rates of transgene transmission from 
heterozygous parents and this was attributed to the potential episomal location of the 
transgene in a proportion of the transgenic F1 pups [346].  
More recently, a study has suggested the potential for different adeno-associated viral 
serotypes to target Leydig cells [347]. It was found that at higher concentrations (5x1012 
TU/ml), adeno-associated serotypes 1 and 9 could infect Leydig cells as well as Sertoli cells, 
peritubular myoid cells and spermatogonia – though when spermatogonia were targeted, 
the AAV vectors did not stably integrate into the spermatogonial genome. The same group 
were also able to demonstrate rescue of an infertility phenotype and lack of germ line 
transmission to the resultant offspring, providing a promising argument for the use of AAV 
as a vector for gene therapy [348] 
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One disadvantage of using AAV is the limitation of the transgene size they are able to 
accommodate. One way in which researchers are attempting to overcome this is to use a 
number of AAV vectors expressing overlapping gene fragments with the hope of 
reconstitution upon transduction of the host cell [349]. Despite being successful, it is 
unknown whether this approach may be as efficient in other tissue and to deliver other 
genes. Indeed, a recent review concluded that the use of dual vector systems may not be a 
“one-fits-all system” and that the tissue being targeted could drastically impact the success 
of their use [350]. 
 
1.2.2.2.3 Retrovirus 
Retroviruses are a family of enveloped viruses that encode a single stranded RNA alongside 
a gene for reverse transcriptase and thus are able to transcribe their own viral genetic 
material into double stranded DNA upon infection of a host cell via membrane fusion through 
viral attachment proteins binding to their receptors; resulting in irreversible binding of the 
virus to the host cell. Following delivery of the viral genome into the host cell, viral DNA is 
then incorporated into the host DNA, allowing the host cell machinery to produce any 
necessary viral component for replication [321] (Figure 1.6). As a result of this stable 
integration in to the host cell DNA, any modifications made by the retroviral DNA will thus 
be present in any daughter cells upon cell division. Members of this family include a number 
of pathogens such as HIV-1, murine leukaemia (MLV) and some cancer causing viruses for 
example Rous sarcoma virus.  
Despite the association with these pathological conditions, the use of retroviral vectors has 
been key to the development of gene delivery techniques for therapeutic use in the past 
three decades. In fact, it was this family of vectors that were utilised in the first ex vivo gene 
therapy trial [351, 352]. For this trial, a subset of T cells were removed from a patient 
suffering from adenosine deaminase severe combined immunodeficiency (ADA SCID). These 
cells were then treated with a gammaretrovirus expressing the ADA gene before being 
reintroduced into the patient’s circulation. This procedure was a relative success as the 
treated T cells were able to reconstitute the patient’s immune system up to 4 years later 
however, production of ADA did not increase [351, 352]. This clinical trial involved two 
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patients and results varied in each of the subjects. This is potentially due to transfection rate 
of the retroviral vector being considerably lower in one of the patients T cells.  
Gammaretroviral vectors, as demonstrated in this first clinical trial, are able to stably 
integrate into the genome of the host cell, which results in a long term expression of the 
transgene. However, a consequence of this integration is an increased risk of insertional 
mutagenesis. Insertional mutagenesis is caused by the insertion of additional DNA bases into 
the host cells genome that disrupts local gene function near the site of integration. In the 
most severe cases, this can accelerate tumour development due to the insertion of the 
transgene close to endogenous oncogenes, resulting in activation and/or overexpression of 
the oncogene. This was first realised following clinical trials carried out in France [353-356] 
and the UK [357] in X linked severe compromised immune deficiency (SCID) patients 
following treatments with retroviral gene therapy. Almost three years post-completion of the 
study, four out of nine patients presented with T cell leukaemia following treatment with the 
retroviral vector. Retrospectively, it is now known that gammaretroviral vectors are more 
likely to integrate in undesirable places within the host cell DNA and this results in a high 
probability of negative insertional mutagenesis outcomes, such as leukaemia. One potential 
strategy researchers are investigating is the use of chromatin insulators which may able to 
block the interaction between an integrating vector and the target cell genome, however, 
more research is needed to determine the impacts of this approach on viral titre and 
transductions efficiencies and indeed, its impact on genotoxicity, before this could be utilised 
in clinical trials [358, 359].  
Initial studies of retroviral vector transduction in the testis detected expression of the virus 
in Leydig cells following intraperitoneal inoculation with murine leukaemia virus at birth 
[360]. Retroviral vectors have also been utilised in the testis with the objective of creating 
transgenic offspring. This was first demonstrated in 2003 by Nagano and colleagues [361], 
who achieved successful transduction of spermatogonial stem cells in vitro before injecting 
these transduced cells into recipient testis (that were depleted of germ cells via 
cryptorchidism or with busulfan) [361]. However, no mating experiments were carried out 
during this study. Similar results have later been achieved in the mouse using both in vitro 
[362] and in vivo [363] methods. In these experiments, descendants of the recipient/injected 
male expressed the inserted transgene demonstrating integration of the transgene by 
retroviral transduction. However, efficiency of the targeting in the in vivo experiments was 
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low; producing an average of just 2.8% of subsequent offspring carrying the transgene. 
Studies using larger mammals, such as sheep, have demonstrated a very low transduction 
rate of germ cells and a higher transduction rate of somatic cells when injecting retroviral 
vectors into foetal sheep in-utero indicating a risk of transducing germ cells in foetal gene 
therapy treatments [364]. Later studies have demonstrated, however, that this risk is 
reduced when treatment is performed later in gestation [365]. 
  
1.2.2.2.4 Lentivirus 
Lentiviral gene therapy vectors have been developed from lentiviruses; a member of the 
family Retroviridae. First utilised as a vector in 1996, where the envelope of a HIV virus was 
replaced with the envelope glycoprotein of vesicular stomatitis virus (VSV), resulting in a 
stable, high titre virus with the ability to infect and integrate into a wide range of cellular 
targets [366]. Consequently, lentiviral vectors are a particularly attractive gene delivery 
system to both increase knowledge and understanding of biological systems and for gene 
therapeutics in a clinical setting. The utility of this system was initially demonstrated by stable 
in vivo gene transfer into terminally differentiated neurons in the rat brain [367].  
To minimise the risk of generating lentiviral vectors capable of replication in the host cells, 
second, third and fourth generation lentiviral vectors have been engineered. The 
development of these subsequent generations involved the removal of accessory genes not 
required for integration (to reduce the likelihood of a replication competent lentivirus), 
elimination of the transactivator gene, splitting the viral plasmid into three to further reduce 
recombination potential and finally splitting the genes necessary for transgene expression 
over the separate plasmids to further prevent replication upon viral generation [368]. The 
design of such replication incompetent lentiviral vectors has subsequently allowed for an 
increase in the size of the carried transgene (up to 10kb) in comparison to limitations of 
transgene size with gammaretroviral and AAV vectors (up to 5kb).   
As with gammaretroviral vectors, another concern with the use of lentiviral vectors as a 
vector for gene therapy is the risk of insertional mutagenesis due to its ability to integrate 
into the host cell DNA. However, unlike other retroviral vectors, which have been shown to 
preferentially integrate in or around the promoter region of a gene, lentiviral vectors 
integrate further along the transcribed region of the gene resulting in a lower chance of 
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stimulating the promoter via enhancer effects and as a consequence, reducing the oncogenic 
potential caused by insertional mutagenesis [369]. 
A number of modifications have been made to both retroviral and lentiviral vectors to 
enhance the expression of the delivered transgene one of which being the addition of 
elements known to increase gene expression post transcriptionally, one of the first being the 
posttranscriptional regulatory element (PRE) present in hepatitis B virus (HPRE) [370]. The 
posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (a close relative 
of HPRE) into the 3’ untranslated region of coding sequences in both gammaretroviral and 
lentiviral vectors was found to be a more active element than HPRE and thus has been used 
to even further enhance the efficiency of retroviral and lentiviral vectors [371, 372]. 
However, a caveat of introducing this element comes with an increased oncogenic risk due 
to the presence of a promoter for the woodchuck hepatitis virus X protein and the sequence 
for the first 60 amino acids of this X protein within the WPRE fragment that has been 
incorporated into both retroviral and lentiviral vectors [373].  This X protein, particularly the 
truncated form, has been linked to increases in cellular proliferation in human hepatocellular 
cancers in which there is a high frequency of hepatitis B virus sequences and has also been 
shown to act as a co-factor for oncogenesis [374-376]. Though speculative, this raises 
concerns as to the safety of the use of unmodified PREs in gene therapy vectors. To overcome 
this, PRE mutants have been generated that lack the X protein open reading frames without 
significant loss of lentivirus titre and transgene expression (as demonstrated in a number of 
studies [45, 377-380]) thus minimising the potential harmful effects of the PRE [381] 
The first ex vivo clinical trial to utilise lentiviral vectors failed to detect any adverse events 
eight years post treatment in 65 patients treated with lentiviral transduced CD4 T cells with 
the purpose of providing viral load control on HIV-2 positive subjects [382, 383]. More 
recently, another clinical trial investigating a dose escalation of Prosavin; a potential lentiviral 
vector based in vivo gene therapy for Parkinson’s disease, was found safe and well tolerated 
by patients alongside a significant improvement in motor behaviour symptoms usually 
experienced by patients with Parkinson’s disease [384]. However, despite the seemingly 
lower risk/benefit of lentiviral vectors, the potential for insertional mutagenesis is still 
present, therefore genome wide analysis of integration frequency and pattern of lentiviral 
vector systems (among other integrating vector systems) is still required following their use.  
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One way in which researchers are attempting to further prevent insertional mutagenesis is 
with the generation of integrase deficient lentiviral vectors. These lentiviral vectors have an 
inserted mutation in the lentiviral integrase gene resulting in the integration of the viral DNA 
being driven by transient double strand sites in the host genome [385-388]. Consequently 
there is a lower frequency of random integration of the viral vector DNA reducing chances of 
any negative off-target effects such as oncogenesis. However, whether these vectors are 
capable of sustaining vector DNA expression in the host genome, like their integrase 
competent counterparts, is yet to be fully determined, with studies indicating that their use 
may be more suited for transduction in non-dividing cells due to the transient expression 
observed in cells undergoing division and proliferation [385-388].  
Attempts have also been made to target the germline using lentiviral vectors. Hamra and 
colleagues were the first to demonstrate transduction of rat germ cells ex vivo with a 
lentiviral vector [389]. Following transfer of the transduced germ cells into a recipient wild-
type testis and mating with a wild type female, pups expressing the lentiviral transgene were 
produced, with this transgene being transferred to the next generation indicating a stable, 
integrated expression. Similar results have also been found in mice [390] and in larger 
mammals, for example, in pig and bovine testicular gonocytes [391-393]. This technique, 
though promising for the production of transgenic animals with the purpose of research, or 
possibly agriculture, would be more difficult to transfer to a clinical setting, for the ethical 
reasons mentioned earlier.  
Transduction of germ cells using lentivirus has also been attempted in vivo with varying 
degrees of success. The first study describing the delivery of lentiviral vectors into the testis 
in vivo suggested transduction of spermatogenic as well as Sertoli and Leydig cells. Following 
this, similar results were also demonstrated resulting in the production of transgenic 
offspring after injection of lentiviral vectors into either the interstitial or the tubular 
compartments of the testis; thus targeting the spermatogonial stem cells in vivo [394-396]. 
However, the expression of the transgene in offspring seems to vary depending on the 
promoter driving lentiviral vector gene expression. This was addressed in a study in which 
the ability of lentiviruses expressing GFP driven by two different promoters to target 
spermatogonial stem cells (and thus potentially generate transgenic offspring) were 
compared [394, 395]. Lentiviral delivered GFP expression under the CMV (cytomegalovirus) 
promoter to the testis has resulted in production of GFP expressing offspring visible under 
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fluorescent lamp and this was further confirmed with both immunohistochemistry and 
genotyping results. When injected with lentivirus with EF1 (human elongation factor 1) 
promoter driving eGFP expression, despite eGFP being present in offspring genomic DNA, 
transgene expression was not detectable by fluorescent microscopy or by RT-PCR due to the 
silencing of the transgene via DNA methylation [394, 395]. Using either promoter, using 
lentiviral injections into the testis for the production of transgenic offspring resulted in 
overall success rates of over 60% in both studies [394, 395]. In contrast, earlier study found 
that, following injection of lentivirus expressing PICK1 into the testis, overall transgenic 
efficiency of 1.3% but also that using this method had a high preference to generate testis 
specific transgenic mice [396].  
 There are also a number of studies, conducted with the aim of targeting the somatic cells in 
the testis for gene therapy, that claim there is no risk of germ line transduction using in vivo 
injection of lentiviral vectors. In an early study by Ikawa and colleagues, spermatogenesis of 
infertile mice was restored by injection of a lentiviral vector expressing the transmembrane 
form of the c-kit ligand, targeting the Sertoli cells [397]. Though demonstrating the potential 
of lentiviral vectors for the treatment of male reproductive disorders impacting fertility, this 
study initiated the investigation of germ line transmission of lentiviral vector DNA just days 
following lentiviral vector injection and, therefore, neglecting to investigate the transduction 
of the spermatogonial stem cells present in the testis at the time of injection. Transduction 
of these cells would potentially result in transduced, mature spermatozoa after one round of 
spermatogenesis (approximately 35 days in the mouse), indicating that germ line 
transmission could be possible using this technique. 
Recently, a study utilising a doxycycline inducible short hairpin RNA system expressed by 
lentiviral vectors was utilised to demonstrate the novel target; urokinase-type plasminogen 
activator (uPA) for the regulation of infertility [398]. Using this system researchers were able 
to reduce pregnancy rate by approximately 40%. This would suggest that targeting of the 
lentiviral vector was not highly efficient, though researchers did not provide information on 
cell type being targeted and efficiency of targeting. Interestingly, the researchers were able 
to demonstrate recovery of infertility following withdrawal of doxycycline. The further 
refinement of this inducible lentiviral delivered technology could prove beneficial for the 
study of genes essential for male fertility as well as for methods of male contraception. 
Chapter 1 Introduction 
47 
 
Evidence of targeting Sertoli cells using lentiviral vectors has recently been demonstrated 
both ex vivo [399] and in vivo [45]. These studies were both able to demonstrate, following 
delivery directly to the seminiferous tubules, that stable expression of lentiviral vector DNA 
was specifically in the Sertoli cells (and not in the Germ cells) and the resultant tubule 
disruption as a consequence of disruption of essential genes in targeted cells. In conjunction 
with this, a study has also been able to demonstrate the transduction of Leydig cells in vivo 
using lentiviral vectors [400]. In this study, overexpression of 50 kDa protein activating 
transcription factor 6 in the Leydig cells using lentiviral vectors disrupted production of key 
steroidogenic enzymes in the testis. This indicates the potential of this technology for 
targeting gene therapy in the Sertoli and Leydig cells in vivo for use in both research and also 
for the treatment of male reproductive disorders in the clinic, following further due diligence 
investigation into their potential for transmission to the germ line.  
  





Figure 1.6 Schematic overview of the different methods of cell entry for each of the vector systems 
used for gene therapy delivery.  Naked/Plasmid DNA - due to the negative charge of both the DNA 
and the Cell membranes, physical methods such as electroporation have been developed to introduce 
the DNA to the target cells cytoplasm. Naked or Plasmid DNA can also enter by endocytosis and on 
reaching the nuclear membrane, can be transported into the nucleus (N) via the nuclear pore complex 
(NPC) where it is then transcribed. Liposome – Liposomes, following anchorage to the cell via 
proteoglycans, can also enter via endocytosis and also via fusion with the target cell membrane. On 
entry to the cell cytoplasm, the liposome breaks down and is able to release the DNA contents into 
the cell cytoplasm before being transported into the nucleus for transcription. Adenovirus – On 
binding of the viral fibres to the coxsackie adenovirus receptor (CAR) on the target cell surface, the 
Adenovirus is transported into the cell membrane via clathrin mediated endocytosis, during which the 
fibres disassociate from the viral capsid. Following release of the endosome contents into the cell 
cytoplasm, the adenovirus loses its protein coat before introducing the DNA into the host nucleus via 
docking at the NPC. Here the capsid can be completely disassembled and viral genome can be 
transported into the nucleus where it can then be transcribed. Adeno-Associated Virus (AAV) – 
Following binding of the AAV to heparin or other primary receptors, as well as co-receptors such as 
integrin on the target cell membrane, the AAV is internalised into the cytoplasm via endocytosis. 
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Following endosomal trafficking the AAV viral capsid escapes from the late endosome and is uncoated 
before translocation to the NPC. On entry into the nucleus, the viral genome is converted from a single 
stranded (ssDNA) to a double stranded (ds) genome and integrates into the host genome. Retrovirus 
& Lentivirus – Upon binding to binding and fusion receptors on the cell surface, the viral envelope 
fuses with the cell membrane. From here the viral capsid can enter the cell cytoplasm where it is 
uncoated, allowing the single strands of viral RNA to be converted into double stranded DNA by the 
viruses own reverse transcriptase enzyme. Following intracellular trafficking, the viral DNA is 
transported into the nucleus where it can then permanently integrate into the host cell DNA using an 
integrase enzyme, permitting the transcription of the viral genome. For retroviral vectors, this process 
can only occur in cells undergoing mitosis. However, lentiviral vectors have no dependence on the 
target cell being in cell cycle and can thus also infect non-dividing calls.  
 
1.2.2.3 Other Approaches 
The apparent challenges and risks associated with the use of viral vectors for gene therapy 
and the low targeting efficiency of non-viral vectors such as liposomes warrants the 
development of alternative vectors and gene delivery systems. Around 10% of gene therapy 
clinical trials in 2016 were undertaken using alternative methods of gene therapy delivery 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/). One of these alternative 
methods of gene delivery was the use of bacteria to deliver DNA to host cells, known as 
bactofection mediated gene therapy. Bactofection occurs, in the case of the most commonly 
used attenuated S. typhimurium, when the carrier bacteria invades the host cell, escapes the 
vacuole into the cytosol where it then lyses, releasing the carrier plasmid. The first indication 
that this would be possible was in 1980 with the delivery of cloned genes to mammalian cells 
in vitro [401] and has since been developed for use in DNA vaccines [402-404], gene therapy 
(in particular, for cancer treatment and targeting immune cells within cancerous tumours 
[405-407]) and for the production of therapeutic proteins (also known as alternative gene 
therapy) in which the host genome is not affected [408, 409].  
However, despite the use of bacteria for gene delivery having a number of advantages; one 
being the ability of the bacteria to transfer a large cargo to the host cell and another being 
the ability to trigger and stop the transference/expression of the bacterial delivered DNA 
using the appropriate antibiotics, thus increasing the safety for the use of this vector in a 
clinical setting, the use of bacteria in gene therapy clinical trials still remains relatively low. 
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This may be due to the lower transfection efficiency of the bacteria in vivo alongside the lack 
of knowledge regarding the differences in animal immunoresponse and the toxicity of these 
vectors, with a number of differences in results from studies focussed on rodent vs human 
tissues and cells. To our knowledge, this approach has not yet been used for successful gene 
delivery in the testis. 
Another way in which bacterial components have been applied to gene transference is the 
use of bacterial magnetic particles (BMP). BMPS are created by organelles called 
magnetosomes in magnetotactic bacteria believed to aid the bacteria in reaching regions of 
optimum oxygen concentration. When used in combination with other gene delivery 
techniques, they have also been shown to improve targeting efficiency of vectors upon 
application of a magnetic field. This technique has been utilised in the testis in which BMPs 
were combined with nanoparticle vectors and delivered to the testis in vivo with the goal of 
producing transgenic mice [410]. Results suggested an increased efficiency of the BMP 
delivered DNA for the production of transgenic mice in comparison to liposome only 
delivered DNA, indicating that a combination of the numerous vectors available may be 
beneficial for future application of DNA delivery techniques.  
1.2.2.4 Applications of Gene Editing Technology in Male 
Reproductive Health – Future for Gene Therapy in the Testis 
Alongside the development of a wide range of vectors for DNA delivery, there has also been 
a number of key developments in gene editing technology making the prospect of gene 
editing based therapies an increasingly likely concept.  The three most common nucleases 
used for gene editing are zinc finger nucleases (ZFN), transcription activator-like effector 
nucleases (TALEN) and clustered regularly interspaced short palindromic repeats (CRISPR) – 
associated nuclease Cas9 (CRISPR/Cas9), which all consist of engineered DNA binding 
domains and are capable of producing double stranded breaks (DSB) in the target/host DNA. 
ZFN utilise zinc finger modules (of around 30 amino acids in size) as DNA binding domains 
which recognise a specific 3bp sequence in the target DNA and, following module binding to 
the target DNA, the FokI nuclease mediates DNA cleavage. TALENs also use the FokI nuclease, 
however, the customisable DNA binding domain contains 34-35 amino acids (derived from 
transcription activator like effectors) per module and can relate to individual bases in the 
target DNA sequence. Unfortunately, both techniques require the complicated engineering 
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of a protein which is able to recognise the specific DNA sequence that is being targeted 
making the process complicated and relatively expensive.  
More recently, the development and exploitation of the CRISPR/Cas9 system has revived the 
gene editing prospects advancing the rate at which gene editing therapies could be 
developed for clinical use. The CRISPR/Cas9 system is a bacterial antiviral immune system 
modified for genome editing. Using small guide RNAs, which bind to a complementary 
sequence of the target DNA, a set of nucleases (Cas9) is guided to cleave the target DNA 
specifically at the target site. The system provides the rapid development of gene editing 
therapies due to the simplicity of the manufacturing process, and for this reason amongst 
others they are currently the most common gene editing tool in non-clinical development 
[411].  
Among the first studies using CRISPR/Cas9 technology to correct a genetic disorder in vivo 
were Wu and colleagues, who, by injecting Cas9 mRNA and guide RNA into zygotes of a 
mouse model of cataracts, were able to rescue the mutation in the affected gene, a 
correction which was also transmitted to the next generation through the germline [412]. 
Further studies also demonstrated the ability of the CRISPR/Cas9 system to both correct 
genetic mutations and introduce humanised mutations in adult organs in vivo, as well as for 
a number of different disease models including blood disorders, muscular dystrophy and liver 
disease [413-418].  
Gene editing nucleases have been used for gene editing experiments in spermatogonial stem 
cells, using ZFNs [419], TALENS [420] and CRISPR/Cas9 [420-422] nucleases, providing models 
for studying spermatogenesis, for generating targeted germ line mutations and potentially 
for the prevention of genetic disorders passed through the germ line. Due to the controversy 
of germ cell alteration in humans, whether, when combined with delivery vectors, these gene 
editing systems could be applicable to a clinical gene therapy needs to be further examined. 
To date, there has been no application of this technology for the manipulation of the somatic 
cells in the testis. The use of these technologies for the identification of factors impacting 
testis function and fertility is paramount for increasing understanding and thus affording the 
opportunity to apply this knowledge for the benefit of men impacted by male reproductive 
disorders including hypogonadism and infertility. 
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One of the risks of using any of these nucleases for gene editing is that, with a systemic gene 
therapy protocol, multiple organs could be targeted with the same gene editing technology. 
Using cell-specific delivery vectors, it is possible for gene editing nucleases and their 
components to be targeted to a specific cell type, or to be delivered separately to increase 
the safety of their use [423] (Figure 1.7). This technique has already been demonstrated with 
CRISPR/Cas9 in combination with AAV vectors. In one study, a modified Cas9 ortholog was 
delivered intramuscularly and shown to be capable of correcting disruptive mutations and 
partially recover functional deficiencies in a mouse model of Duchenne muscular dystrophy 
[424]. 
 Depending on the requirement of the gene editing by the patient, the delivery vector should 
be chosen giving particular attention to potential off target effects of multiple organ delivery 
of both the nuclease and the vector itself. Therefore, future applications of both gene editing 
technologies such as CRISPR/Cas9 and vector systems should tailor the strategy used to the 
application required paying particular attention to the potential for off-target toxicity from 
both of these powerful biotechnological tools.   
 




Figure 1.7 Schematic representation of the combinatory use of cell specific delivery vectors  - 
including lentiviral vectors, and gene editing nucleases. This would allow the targeted DSB and/or 
repair in a cell of interest or for use as a therapy in a diseased cell. 
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1.3 Hypothesis, Aims & Approach 
 
1.3.1 Hypothesis 
The overarching hypothesis of the experiments described is that the optimisation of viral 
vector delivery into the testis will permit targeting the adult testicular somatic cells in vivo, 
providing a tool from which (i) further insights into testicular function can be determined 
and (ii) the development of therapeutic techniques to treat male reproductive disorders 
could be established. 
 
1.3.2 Aims 
1. To establish and validate viral vector delivery and targeting of the adult testicular 
somatic cells. 
2. To generate a model of testicular dysfunction in which the potential of the optimised 
viral vector techniques could be determined and which could be also utilised to gain 
further insight into androgen signalling in the adult testis. 
3. To determine the potential of viral vectors to rescue the phenotype described in an 
adult model of testicular dysfunction. 
 
1.3.3 Approach 
To optimise and validate viral vector targeting in the adult testis, vehicle (PBS or serum free 
media), dye, adenoviral and lentiviral vectors were injected into the interstitial and tubular 
compartments of the testis using different volumes, locations and injection pressures 
dependant on the cell type being targeted. Testis were then collected and analysed at 
different time points post injection to determine the most appropriate methodology for 
future attempts at gene delivery/editing. 
Using Cre/loxP technology, novel models of double testicular somatic cell specific ARKOs 
were generated for repair with viral vector delivered transgenes. The adult testicular 
phenotype of the model was also characterised in the context of single testicular somatic cell 
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specific ARKOs to determine the synergistic and additive AR mediated relationships between 
the testicular somatic cells. 
To confirm the practical uses of viral vector delivery to the testis, lentiviral vectors carrying 
mouse AR were delivered to adult SC-ARKO testis in vivo. Rescue of AR expression and 
testicular function was analysed to establish the potential of lentiviral vectors to rescue a 
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2.1 Animals  
2.1.1 Welfare 
Mice were bred and maintained in the Biomedical Research Facility based at Little France, 
University of Edinburgh on a 12hr light/dark cycle with temperature and humidity maintained 
at between 20°C and 25°C and at 55% respectively. Mice were screened for pathogens and 
certified clean prior to their use in experiments. Soya-free chow and drinking water were 
continually available.  All procedures were carried out in accordance with UK Home Office 
regulations under project licences 60/4200 and 70/8804 held by Professor Lee B. Smith and 
were compliant with the with the Animals (Scientific Procedures) Act, 1986. Daily animal 
husbandry, technical assistance and timed matings were performed by Mr. Michael Dodds 
(Senior Animal Technician for the Central Biomedical Research Facility at the University of 
Edinburgh).  
2.1.2 Timed Matings 
When animals at specific embryonic ages were required, timed matings were set up in which 
one male and one female were paired in the afternoon. At 8am on the following morning, 
females were examined for the presence of a post copulatory vaginal plug with the 
expectation that mice mate in the middle of their dark period. As a result of this, presence of 
a post-copulatory vaginal plug would allow the calculation of the gestation stage with the 
first morning being designated embryonic day (e) 0.5. 
2.1.3 Transgenic Lines Used 
Transgenic animals used in this study were generated using the Cre-loxP system. This system 
utilises the Cre recombinase enzyme, a 38-kDa protein originally derived from the P1 
bacteriophage [273, 425].  The Cre protein is able to efficiently promote recombination at 
specific 34bp sites called loxP sites. On recognition of these loxP sites, the recombinase 
catalyses site specific recombination, leading to precise deletion of the DNA flanked by the 
loxP sites (said to be the ‘floxed’ region of DNA). As the mammalian genome is lacking in high 
affinity loxP sites, this has made Cre-loxP technology an invaluable source for gene editing, 
whether this be insertion, deletion or modification, in mammalian research.  
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To enable cell or tissue specific DNA modifications, the Cre recombinase enzyme must be 
expressed in the cell/tissue type of interest. To do so, the exogenous Cre recombinase gene 
must be placed downstream of a cell/tissue specific promoter, limiting gene expression and 
subsequent DNA modification to this cell type. Using the same methodology, the Cre 
recombinase enzyme can also be expressed at specific time points in a life span, depending 
on when the promoter is expressed; although it is important to note that upon a cells 
expression of the Cre recombinase gene, daughter cells deriving from the cell will also bear 
the consequential phenotype. 
2.1.3.1 Tomato Red Cre Reporter Mice 
Mice ubiquitously expressing a loxP flanked (floxed) stop cassette-controlled gene for red 
fluorescent protein (RFP) tdTomato (Gt(Rosa)26Sortm14(CAG-tdTomato)Hze) [426] were obtained 
from a colony maintained onsite by Professor Lee Smith (MRC Centre for Reproductive 
Health, University of Edinburgh) gratefully received from Professor Neil Henderson (MRC 
Centre for Inflammation Research, University of Edinburgh). Animals were genotyped as later 
described in section 2.2.  
2.1.3.2 Yellow Fluorescent Protein Reporter Mice 
Mice expressing a loxP flanked (floxed) stop cassette-controlled gene for yellow fluorescent 
protein (YFP) under the ubiquitously expressed ROSA26 locus were used for tracing Cre 
expression in the testis. These mice were obtained from a colony maintained onsite by 
Professor Lee Smith (MRC Centre for Reproductive Health, University of Edinburgh) [427]. 
Animals were genotyped as later described in section 2.2. 
2.1.3.3 Complete Androgen Receptor Knock Out Mice 
For ubiquitous ablation of Androgen Receptor (AR), female mice heterozygous for the X-
linked hypoxanthine phosphoribosyltransferase-Cre transgene were mated to male mice 
bearing a floxed AR allele to produce females carrying one deleted allele and one wild-type 
(WT) allele of the X-linked AR gene. These females were subsequently mated to produce 
ARKO males and control littermates [428]. Archived tissues were used in these studies. 
Breeding of these animals and collections were carried out by Dr Michelle Welsh (Centre for 
Reproductive Health, University of Edinburgh)  
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2.1.3.4 Conditional Androgen Receptor Knock Out Mice 
To selectively ablate expression of AR from single and/or multiple cell types in the testis, a 
number of different Cre expressing mouse lines were used. For each line, a Male mouse, 
expressing Cre recombinase in a specific cell type was mated with a female mouse 
homozygous for a floxed Androgen Receptor to ensure every male offspring produced from 
the cross will inherit an X chromosome bearing a floxed Androgen receptor allele (as 
androgen receptor is located on the X chromosome, male offspring only carry one copy of 
the androgen receptor allele).  
For ablation of AR expression in Sertoli cells, a mouse line in which Cre recombinase was 
expressed under the control of the Anti-Müllerian Hormone (Amh) promoter was used. This 
mouse line (Tg(AMH-Cre)1Flor was obtained from a colony maintained on site by Professor Lee 
Smith (MRC Centre for Reproductive Health, University of Edinburgh) [48, 429]. 
To generate mice with AR ablation in Sertoli and/or peritubular Myoid cells, male mice 
heterozygous for smMHC-eGFP-Cre were mated with female mice heterozygous for Tg(AMH-
Cre)1Flor to generate offspring that expressed Cre recombinase under both promoters. Male 
mice positive for both Cre recombinases were then mated to a female mouse homozygous 
for a floxed Androgen Receptor. These matings gave rise to double positive (expressing both 
Cre recombinases), Amh-Cre positive (and MH-Cre negative), MH-Cre positive (and Amh-Cre 
negative) and wild type (expressing no Cre recombinases) offspring. The offspring derived 
from these matings are the animals used for the analysis performed in these studies. 
Breeding of these animals and collection of tissue was carried out by Mr. Martin O’Neill 
(Centre for Reproductive Health, University of Edinburgh). 
For ablation of AR expression in Leydig cells, a mouse line in which Cre recombinase was 
expressed under the control of the Fatty acid binding protein 4 (Fabp4 or Ap2) promoter was 
used. This mouse line was obtained from a colony maintained on site by Professor Lee Smith 
(MRC Centre for Reproductive Health, University of Edinburgh) [108, 430]. Breeding of these 
animals and collection of tissue was carried out by Dr Laura O’Hara (Centre for Reproductive 
Health, University of Edinburgh). 
For ablation of AR expression in both Sertoli and Leydig cells, mice expressing Cre under the 
Cyp19/Aromatase promoter were used. This mouse line was obtained from Dr Sophie 
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Fouchécourt (INRA, UMR85 Physiologie de la Reproduction et des Comportements, F-37380, 
Nouzilly, France) [17]. 
All animals were genotyped as described in section 2.2. 
2.2 Genotyping of Animals 
To correctly identify animals inheriting genes for both the Cre and the floxed alleles, ear clips 
taken for identification at weaning (around d21) were retained for genomic DNA extraction 
and subsequent polymerase chain reaction (PCR) assays. All routine genotyping (unless 
stated otherwise) was carried out by the technical support available in the team of Professor 
Lee Smith. 
2.2.1 Genomic DNA Extraction 
For genomic DNA extraction, ear clips taken at weaning and/or tail tips taken at dissection 
were individually submerged and digested with 2 µl Proteinase K added to 25µl TE-Tween 
supplemented and incubated for one hour at 55°C on a TProfessional Thermocycler 
(Biometra GmbH, Germany). Samples were incubated for a further seven minutes at 97°C to 
denature any remaining Proteinase K in the solution and then cooled to 25°C. Samples were 
then vortexed and briefly centrifuged at low speed. The resulting supernatant was then 
diluted at 1:10 with sterile water for future downstream PCR assays.  
2.2.2 PCR & Determination of Genotype Using QIAxcel System 
PCR reactions were performed using either Biomix PCR reaction buffer (Bioline Reagents Ltd, 
UK) or Type-It Mutation Detect PCR kit (QIAGEN Ltd, UK) according to manufacturer’s 
instructions. Forward and reverse primer sequences, annealing temperatures and buffers 
used for specific assays are listed in Table 2.1. PCR cycles were executed on a TProfessional 
Thermocycler (Biometra GmbH, Germany) and resulting PCR products were analysed using 
the QIAxcel capillary electrophoresis system (QIAGEN Ltd, UK). Positive, negative and no 
template controls were included in each PCR reaction to confirm validity of results and to 
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Table 2.1 Details of Primers used for Genotyping Assays.  
































2.3 Surgery, Injections and Treatments 
2.3.1 Lentiviral Vectors 
2.3.1.1 Production of Lentiviral Vectors 
To ensure safety of lentiviral vectors and their production, individual components required 
for the production of the lentiviral structure were split across multiple plasmids. In brief, 
shuttle vectors were packaged with a third-generation lentiviral vector plasmid pseudotyped 
for VSV-G, produced at a viral titre of >1x109. Information regarding lentiviral vectors used in 
these studies, including details of viral titre and specific viral components can be found in 
Table 2.2. All Lentiviral vectors were produced by Dr Pamela Brown (Head of Biomolecular 




Table 2.2 Details of Viral Vectors used. 
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GFP under the CMV 
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GFP under the EF1α 
promoter
Biomolecular Core, 







and a scrambled miR 
under the CMV 
promoter
Biomolecular Core, 







GFP under the CMV 
promoter
Vector Biolabs, 








(separated with an 
IRES component) 
under the CMV 
promoter
Vector Biolabs, 







GFP downstream of 
the CMV promoter 
and a P2A cleavage 
site
Biomolecular Core, 








and a monomeric 
enhanced GFP 
downstream of the 
CMV promoter and 
separated with a P2A 
cleavage site
Biomolecular Core, 
SuRF, University of 
Edinburgh
5.1 x 109
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2.3.2 Surgical Procedure for Interstitial Injections 
Lentiviral and Adenoviral vectors (Vector Biolabs, USA) and vehicle controls were injected 
into the interstitial compartment of adult testis. The procedure was performed under 
anaesthesia by inhalation of isoflurane and under aseptic conditions. Testis were exposed 
through an incision in the scrotum before between 10ul and 20ul of Lenti/Adeno-virus + 0.4% 
Trypan Blue (ThermoFisher Scientific, United States) (for visualisation of viral injection) was 
injected just under the tunica albuginea into the interstitial compartment using a 0.3mL 25g 
insulin needle (BD Bioscience U.K Ltd, United Kingdom). In some cases, animals underwent 
orchidectomy to remove one uninjected testis. Exposed testis were then replaced back into 
the scrotal compartment before the abdominal incision was closed with sterile sutures. Mice 
were injected subcutaneously with Vetergesic (active ingredient: Buprenorphine) 0.05mg/kg 
(Ceva Animal Health Ltd, United Kingdom), whilst anaesthetised and allowed to recover 
whilst being monitored. Mice were then closely monitored over the next 24 hours for any 
welfare problems, and twice daily from then onwards. Initial lentiviral vector injections were 
performed by Dr. Cornelia Roesl (Centre for Reproductive Health, University of Edinburgh).  
 
2.3.3 Surgical Procedure for Rete Injections 
Lentiviral vectors (or vehicle controls) were introduced into the rete compartment of the 
adult testis. As with the interstitial injections, the procedure was performed under 
anaesthesia by inhalation of isoflurane and under aseptic conditions. Testis were exposed 
through an incision in the abdominal cavity. Adipose tissue was carefully removed from the 
areas surrounding the rete testis, efferent duct and vasculature before between 10ul and 
20ul of Lentivirus + 0.4% Trypan Blue (ThermoFisher Scientific, United States) (for 
visualisation of viral injection) was injected into the rete testis using a glass micropipette 
(outer diameter: 80µm (bevelled) (Biomedical Instruments, Germany) and a microinjector 
(Eppendorf FemtoJet; Eppendorf, Germany). Exposed testis were then replaced back into the 
scrotal compartment before the abdominal incision was closed with sterile sutures. Mice 
were injected subcutaneously with Vetergesic (active ingredient: Buprenorphine) 0.05mg/kg 
(Ceva Animal Health Ltd, United Kingdom), whilst anaesthetised and allowed to recover 
whilst being monitored. Mice were then closely monitored over the next 24 hours for any 
welfare problems, and twice daily from then onwards. 
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2.4 Tissue Collections & Imaging 
2.4.1 Culling of Animals 
Animals were sacrificed using as per conditions outlined in the Animals (Scientific 
Procedures) Act 1986; by exposure to carbon dioxide gas in a rising concentration. Foetal,  
larval and embryonic animals were decapitated following the sacrifice of the pregnant dam.  
2.4.2 Measurement of Gross Anatomy  
Following sacrifice and blood collection (detailed in 2.3.3), gross body weight of animals was 
measured using a digital balance. In some cases, anogenital distance was also recorded using 
digital callipers. Animals were observed for any gross abnormalities, in particular, presence 
of nipples and whether testis were located within the scrotum (for male animals).  
2.4.3 Blood Collection & Dissection 
Immediately following sacrifice, blood was collected via cardiac puncture using a 23G needle 
(BD Bioscience U.K Ltd, United Kingdom) and 1mL syringe (BD Bioscience U.K Ltd, United 
Kingdom) coated with heparin (LEO Laboratories Ltd., United Kingdom) prior to use. Blood 
samples were kept on ice before centrifugation at 17136g for 10 minutes at 4°C in order to 
harvest the plasma. Plasma was then stored at -80°C until required for analysis.  
Both testis, epidimides and seminal vesicles were removed, cleared of excess adipose tissue 
and weight recorded. In some circumstances, extra gonadal tissues were collected including 
the pituitary, brain, adrenal, kidney, liver and spleen. 
2.4.4 Imaging of Organs Post Dissection  
Following removal from the cadaver, organs to be imaged were placed on ice in cold 
phosphate buffered saline (PBS) (detailed in 2.9.2). Organs were imaged in cold PBS using a 
Leica MZ-FLIII fluorescence stereomicroscope (Leica Microsystems, Germany) prior to either 
fixation or snap freezing (both of which are detailed in 2.4.5).  
2.4.5 Tissue Processing  
For histological analysis of tissues, organs were fixed in Modified Bouins Solution (Clin-Tech 
Ltd, United Kingdom). Testis (and other organs collected to be fixed) were submerged in 
Bouins solution for around six hours (applying a rule of around one hour of fixation time per 
millimetre of tissue). After the first four hours of fixation, testis were cut in half along the 
transverse plane and re-submerged in the Bouins solution to allow adequate fixative 
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penetration into the centre of the testis. Following fixation, samples were transferred to 70% 
ethanol (EtOH) (VWR International Ltd, United States) until required for further processing 
and embedding. Samples for embedding underwent an automated tissue processing 
procedure using the Leica ASP300 S Tissue Processor (Leica Biosystems, Germany) in which 
the samples were dehydrated in a series of EtOH solutions of increasing concentration, 
cleared with xylene and then infiltrated with histological wax (Shandon™ Paraffin; Thermo 
Scientific, United Kingdom). Once infiltrated with the wax, the samples were embedded into 
molten wax to form blocks and stored at room temperature until required for sectioning. All 
tissue processing and embedding was performed by Mr Garry Menzies (Technical Officer for 
Shared University Research Facilities core (SuRF) at the University of Edinburgh).  
 
2.5 Analysis of Tissue Histology 
2.5.1 Tissue Sectioning 
Tissues embedded in paraffin blocks were cut into 5um sections using a Leica rotary 
microtome (Leica RM2125RT) and mounted onto positively charged microscope slides (Leica 
Biosystems, UK). Slides were then incubated in a drying oven, maintained at 55°C, overnight 
(for around 16 hours). Following dehydration, slides were stored at room temperature for 
use in downstream applications.  
2.5.2 Dewaxing and Rehydration 
In order to utilise tissues for downstream procedures detailed in sections 2.5.3 and 2.5.4, 
sections must be free of histological wax to allow penetration of aqueous solutions. To do so, 
slides were submerged in Xylene for the removal of the paraffin wax before being passed 
through a series of decreasing EtOH concentrations ending with tap water to both displace 
the Xylene solution and to rehydrate tissue sections. 
 
2.5.3 Haematoxylin & Eosin Staining 
To examine cellular components of tissue sections, haematoxylin and eosin stains were used 
to distinguish between nuclear and cytoplasmic structures. Following dewaxing and 
rehydration, slides were immersed in Harris’ Haematoxylin solution (Leica Biosystems, UK) 
to stain nuclei (negatively charged cellular components, e.g. nucleic acids found in the 
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nucleus) for up to 5 minutes. After washing any residual haematoxylin stain, slides were 
briefly placed in 1% acid-alcohol (Leica Biosystems, UK) to further remove excess stain from 
tissues and to define nucleic staining. To increase contrast of haematoxylin staining by 
converting staining colour from purple to blue, slides were then immersed in Scotts tap water 
solution (Cell Path, UK). For staining of cytoplasm (positively charged cellular components, 
e.g. amino groups in proteins within a cells cytoplasm),   slides were immersed in Eosin Y 
solution (Leica Biosystems, UK). Residual stain was washed from slides in tap water before 
being passed through a series of increasing EtOH concentrations to dehydrate tissue and 
cleared of residual alcohol with submersion in Xylene. Slides were then mounted with glass 
coverslips (Leica Biosystems, UK) using a non-aqueous mounting medium, Pertex (Cell Path, 
UK) and left to dry within a fume cupboard.  
2.5.4 Immunohistochemistry 
Immunohistochemistry (IHC) methods were applied to confirm and visualise both presence 
and localisation of specific proteins in fixed tissue samples. Depending on downstream 
experiments required from the tissue (for example, whether the stained sections were to be 
used for imaging or for stereology/cell counts), different methods of protein revelation were 
applied. For simple detection and for tissue/proteins requiring stereology, chromogenic IHC 
was used and for detecting more than one protein in the same section of tissue; fluorescent 
IHC was used. Details of antibodies, revelation, antigen retrieval and detection methods 
following optimisation can be found in Table 2.3. For all immunohistochemistry experiments, 
positive tissue and negative (in which primary antibody incubation was omitted) controls 
were included.  
2.5.4.1 Antigen retrieval 
During tissue fixing, antigenic sites on proteins are masked as a consequence of cross linking 
proteins. To reveal these antigenic sites and thus enable the detection of proteins, antigen 
retrieval is often a required step in IHC. For the majority of antibodies used in this thesis, heat 
induced epitope retrieval were used (unless stated otherwise in Table 2.3). This consisted of 
incubating slides (following dewaxing and dehydration) in either pH6 citrate buffer or pH9 
Tris-EDTA buffer within a pressure cooker (InstantPot, Canada) for 5 minutes before cooling 
in water.  
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2.5.4.2 Labelling of Samples with Antibodies 
A number of steps were included in the immunohistochemistry protocol to prevent non-
specific immunostaining of tissue sections. Slides were subjected to an incubation of 0.03% 
hydrogen peroxidase (Fisher Scientific, UK) in TBS for 30 minutes at room temperature to 
quench any activity of endogenous peroxidases. Following this, slides were rinsed with water 
and sections were incubated with normal serum blocking solution for 30 minutes in a 
humidity chamber at room temperature (species of serum was the same species in which the 
secondary antibody was raised). This prevented the binding of the primary antibody to any 
non-specific epitopes. 
Tissue sections were then incubated with the primary antibody (diluted in the normal serum 
blocking solution) in a humidity chamber at 4°C overnight. Following all subsequent 
incubations with antibodies and reagents slides were washed in TBS for three 5 minute 
incubations. 
2.5.4.3 Chromogenic detection 
After removal of the primary antibody with the TBS washes, either a biotin-conjugated 
secondary antibody (species dependant on primary antibody – see Table 2.3) diluted in 
normal serum blocking solution or with ImmPRESS™ peroxidase polymer detection reagent 
(one drop per section) (Vector Labs, USA) were then added to tissue sections for 30 minutes 
in a humidity chamber at room temperature. If the ImmPRESS™ peroxidase polymer 
detection reagent was not being used, tissue sections were then incubated with streptavidin-
peroxidase conjugate (SA-5004, Vector Labs, USA) diluted in TBS for a further 30 minutes in 
a humidity chamber at room temperature. The chromogen used for visualisation was 
ImmPACT DAB peroxidase substrate (Vector Labs, USA); a DAB (3, 3 -diaminobenzidine) horse 
radish peroxidase substrate, according to manufacturer’s instructions. Development of the 
dark brown colour reaction was monitored and timed on control slides and reaction time of 
experimental slides was based on these controls. Reaction and colour development was 
stopped by immersing slides in tap water. Slides were then rinsed again with tap water before 
counterstaining with Harris haematoxylin, dehydrated, cleared and mounted (as earlier in 
2.5.3, omitting staining with Eosin Y solution).  
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2.5.4.4 Fluorescent detection 
For fluorescent detection of proteins, primary antibody was removed as with chromogenic 
detection before the addition of the appropriate peroxidase conjugated secondary antibody 
(diluted in normal serum blocking solution) (Table 2.3) to tissue sections for 30 minutes in a 
humidity chamber at room temperature. Tor visualisation of proteins, tissue sections were 
then incubated with Tyramide Signal Amplification (TSA) working solution (PerkinElmer, UK) 
for five minutes in a humidity chamber at room temperature; as per manufacturer’s 
instructions.  
This system was also utilised to visualise multiple proteins in the same tissue section to aid 
investigation into co-localisation of proteins, for example. To do so, following detection of 
the first primary antibody, tissue sections were subjected to further antigen retrieval, 
blocking of endogenous peroxidases and non-specific epitopes to prevent background 
staining and overnight incubation with a different primary antibody as described in preceding 
sections (2.4.5.1 and 2.4.5.2). Detection of subsequent primary antibodies was performed 
using the TSA system, ensuring different fluorophores to those used for previous proteins 
were being used to distinguish detected proteins from one another.  
Following detection of all proteins, tissue sections were incubated with either SYTOX™ 
nucleic acid stain (Life Technologies, UK) or DAPI nucleic acid stain (Sigma-Aldrich, USA) 
diluted in TBS for 10 minutes in a humidity chamber at room temperature. Slides were then 
mounted with glass coverslips (Leica Biosystems, UK) using an aqueous mounting medium; 
Lab Vision™ PermaFluor™ (ThermoFisher Scientific, UK) and stored in the dark at 4°C until 
required for imaging and analysis.  
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Red Fluorescent Protein (RFP) None Evrogen, Russ ia AB233 1/1000
Biotinylated Goat Anti -Rabbit 
IgG
Vector Labs , USA BA-1000 1/500 DAB
Red Fluorescent Protein (RFP) None Evrogen, Russ ia AB233 1/4000 Goat Anti  Rabbit IgG-HRP Vector Labs , USA PI-1000 1/200 Tyramide
Citrate
pH6
BA-1000 1/500 DABSRY-Box 9 (Sox9) Merck Mi l l ipore, USA AB5535 1/500
Biotinylated Goat Anti -Rabbit 
IgG
Vector Labs , USA
Tyramide
Phosphoglycerate Kinase 1 and 2 (PGK1/2)
Santa  Cruz 
Biotechnology Inc, USA
sc-28784 1/300 ImmPRESSTM HRP Anti -Rabbit IgG Vector Labs , USA MP-7402 n/a DAB
1/500 DAB
Galectin-3/Mac2
Cedarlane Labs , 
Canada
CL8942AP 1/2000 ImmPRESSTM HRP Anti -Rabbit IgG Vector Labs , USA MP-7401 n/a
PI-1000 1/200 Tyramide
Insulin-like 3 (Insl3)
Santa  Cruz 
Biotechnology Inc, USA
s-134587 1/500
Biotinylated Goat Anti -Rabbit 
IgG
Vector Labs , USA BA-1000
Green Fluorescent Protein (monomeric enhanced) (moeGFP) Abcam, UK ab6556 1/3500 Goat Anti  Rabbit IgG-HRP Vector Labs , USA
Tyramide
Green Fluorescent Protein (enhanced) (eGFP) Abcam, UK ab6556 1/4000 Goat Anti  Rabbit IgG-HRP Vector Labs , USA PI-1000 1/200 Tyramide
1/200 Tyramide
Cytochrome P450 17A1 (Cyp17a1)
Santa  Cruz 
Biotechnology Inc, USA
sc-46081 1/1000 Chicken Anti - Goat IgG-HRP





Cel l  Signal l ing 
Technology (New 
England Biolabs),
9661S 1/500 Chicken Anti - Goat IgG-HRP
Santa  Cruz 
Biotechnology Inc, USA
sc-2961






M4070 1/400 ImmPRESSTM HRP Anti -Rabbit IgG Vector Labs , USA
Target Antigen Retrieval
Primary Antibody Secondary Antibody
Detection Method
3-Beta-Hydroxysteroid Dehydrogenase (HSD3β)
Santa  Cruz 
Biotechnology Inc, USA
sc30820 1/2000 Chicken Anti - Goat IgG-HRP
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2.5.5 Microscopy and Image Capture 
Imaging of Haematoxylin & Eosin and chromogenic (DAB) stained tissue sections was 
performed on an Olympus Provis AX70 microscope (Olympus, Japan) and/or an Axio Scan Z.1 
SlideScanner (Carl Zeiss Ltd, UK). Fluorescent stained sections were imaged using an LSM 710 
confocal microscope (Carl Zeiss Ltd, UK). All microscope/imaging systems were used with Zen 
imaging software (Carl Zeiss Ltd, UK).  
2.5.6 Stereological Analysis 
Cell counts and histological measurements were determined using Image-Pro Plus 7.0 
software (Media Cybernetics, UK) with a Zeiss Axio Imager A1 Microscope (Carl Zeiss, UK), 
Qimaging QICAM Fast 1394 digital camera (Qimaging, Canada) and a Prior ProScan 
automated stage (Prior Scientific Instruments Ltd, UK). For all measurements, a tiled image 
of the entire testis section was captured and from this an area of interest was manually 
highlighted. Within this area of interest, up to 200 random fields of view were generated for 
analysis at higher magnification.  
For cell counts, this magnification was at 60x resulting in a counting grid of 18x24 points being 
overlaid the random field of view. Using the ‘count’ function, the points within the nuclei and 
the cytoplasm of either HSDβ3 (for Leydig cell counts) and SOX9 (for Sertoli cell counts) were 
counted. From this the percentage of the random view recorded as cell nuclei over the total 
number of points counted was calculated using the following equation (noted as % Cell Nuclei 
for downstream calculations): 
 
% Cell Nuclei = �
Total Number of Nuclei Counted
Total Number of Points in Counting Grid (18x24)
� x 100 
 
These measurements, along with the testis weight noted at dissection, were then used to 
calculate the absolute volume of the cell within the testis using the following formula: 
 
Absolute Volume of Cell Nuclei (mg) =
(% Cell Nuclei) x Testis Weight (mg)
100
 




Within the same field, the mean nuclear volume of the cell type of interest was also 
measured using the ‘nucleator’ function included with the software. Here, the centre of the 
nucleus of the cell of interest is selected. This generates three random lines intersecting the 
centre of the nucleus. The points in which each of these lines cross the nuclear membrane 
were selected, generating measurements of the nuclei radius; this allowing the nuclear 
volume to be calculated.  
The total number of cells (either Leydig cells or Sertoli cells) within a testis was then 
calculated using the absolute volume of the cell nuclei and the mean nuclear volume of the 
cell type with the following formula: 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑇𝑇𝑜𝑜 𝐶𝐶𝑁𝑁𝑇𝑇𝑇𝑇𝐶𝐶 = �
𝐴𝐴𝑁𝑁𝐶𝐶𝑇𝑇𝑇𝑇𝑁𝑁𝑇𝑇𝑁𝑁 𝑉𝑉𝑇𝑇𝑇𝑇𝑁𝑁𝑁𝑁𝑁𝑁 𝑇𝑇𝑜𝑜 𝐶𝐶𝑁𝑁𝑇𝑇𝑇𝑇 𝑁𝑁𝑁𝑁𝑁𝑁𝑇𝑇𝑁𝑁𝑁𝑁 (𝑁𝑁𝑚𝑚)
𝑀𝑀𝑁𝑁𝑇𝑇𝑀𝑀 𝑁𝑁𝑁𝑁𝑁𝑁𝑇𝑇𝑁𝑁𝑇𝑇𝑁𝑁 𝑉𝑉𝑇𝑇𝑇𝑇𝑁𝑁𝑁𝑁𝑁𝑁 (µ𝑁𝑁³)
�𝑥𝑥100 
 
For seminiferous tubule and lumen diameters, analysis magnification was at 10x and the 
‘nucleator’ function was utilised in the same manner as with mean nuclear volume 
measurements (generating measurements from the centre of the tubules as opposed to the 
centre of the nuclei). Only whole, round, tubules visible in the random field of view were 
measured.  
For analysis of dye distribution following interstitial injection of Biomark Tissue Marker Dye 
(Biostain Ready Reagents Ltd, UK). Tissue Marker Dye injected testis sections were images 
using an Axio Scan Z.1 slide scanner (Carl Zeiss Ltd, UK) with Zen imaging software (Carl Zeiss 
Ltd, UK). Percentage of coverage by the Tissue Marker Dye was quantified using Image J 
software (National Institutes of Health, USA) using the instructions taken from Image J; 
“Quantifying Stained Liver Tissue” (https://imagej.nih.gov/ij/docs/examples/stained-
sections/index.html) and applied to the Tissue Marker Dye testis sections. In brief, images 
were split into red, green and blue channels and threshold was manually adjusted until Tissue 
Marker Dye was highlighted in red (threshold was adjusted according to the blue channel 
given that the blue channel exhibited the best separation of tissue from dye in testis 
sections). The whole section was then selected and termed the “area of interest” before 
measurements were set. The fraction of area with Tissue Marker Dye detected was then 
Chapter 2 Materials & Methods 
71 
 
calculated within the limit of the previously set threshold, producing a percentage of area 
occupied by Tissue Marker Dye. Uninjected testis were also included as negative controls. 
For analysis of testis injected at different pressures, haematoxylin and eosin stained sections 
of testis injected at a range of pressures (20hPA-50hPA) were analysed subjectively for the 
presence of vacuoles, distended tubules and sloughing of germ cells. Each of these features 
were graded separately on a scale as follows; 0=feature not observed in testis section, 
1=feature observe d on one occasion in testis section, 2= feature observed in a small number 
of tubules, 3= feature observed in an estimated quarter of tubules, 4= feature observed in 
estimated half of tubules, 5= all/majority of tubules in testis section have feature present. 
Grades were then added together to give a total score out of 15. Scores were averaged from 
each of the testis in each pressure group. 
2.6 Hormone Analysis 
Luteinising hormone (LH) quantification in mouse plasma was performed using the MILLIPLEX 
MAP Rat Pituitary Magnetic Bead Panel (RPTMAG-86K; Merk Millipore, USA) according to the 
manufacturer’s instructions. Assays were read on a Bio-Plex 200 suspension array system 
using Bio-Plex Manager software (Bio-Rad Laboratories Ltd, UK). Assays for LH and FSH were 
carried out by Dr Laura Milne at the University of Edinburgh.  
Quantification of testosterone in mouse plasma was carried out using a competitive Enzyme 
Linked Immunosorbent assay (ELISA). A competitive ELISA differs from a direct or sandwich 
ELISA as they involve a step which mixes the sample with another reagent prior to its addition 
to the ELISA plate. First 96 well ELISA plates were coated with Donkey Anti Rabbit serum at 
4°C overnight. 0.5% bovine serum albumin phosphate buffer (BSA PBS) was then added to 
prevent any non-specific binding of proteins to the ELISA plate. Samples (and standards) were 
then mixed with testosterone conjugated with Horse Radish Peroxidase (HRP) (at a dilution 
of 1 in 20,000) (Astra Biotech, Germany) in 0.1% BSA PBS and Assay buffer and added to the 
ELISA plate and mixed using a plate shaker. Anti-Rabbit Anti-Testosterone Antibody was then 
added at a dilution of 1 in 200,000 in 0.1% BSA PBS Assay Buffer. The reactions were then 
incubated for two hours at 28°C on a shaker. After removal of any remaining unbound 
antibody with washing steps, reactions were incubated with tetramethylbenzidine for 10 
minutes. Any wells containing testosterone bound HRP will boast a colour change from clear 
to blue due to the enzymatic action of HRP on tetramethylbenzidine. This reaction was 
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stopped with the addition of 1N sulphuric acid; changing the reaction colour from blue to 
yellow in the process. The wells were then read with a Multiskan EX plate reader (Thermo 
Scientific, US) with a filter of 450nm. Samples containing high levels of testosterone will 
contain less testosterone conjugated with HRP bound to the Donkey Anti Rabbit Serum 
coating the plate compared to samples with low levels of testosterone. Consequently, a 
reduction in the levels of HRP enzyme will result in a reduced conversion of the clear 
tetramethylbenzidine to a blue substrate. Therefore, testosterone concentration in samples 
was inversely related to the colour change measured with a Multiskan EX plate reader 
(Thermo Scientific, US). Testosterone assays were carried out by Dr Forbes Howie (Head of 
Specialised Assay Service, Shared University Research Facilities, University of Edinburgh).  
2.7 mRNA Expression Analysis 
2.7.1 RNA Extraction and Quantification 
Before extraction, up to 30mg of testis was collected and weighed from a whole snap frozen 
testis. To this, a proportionate amount of luciferase RNA (5ng/testis; Promega, UK) was 
added for use as an external reference gene before being homogenised with a ball bearing 
using a TissueLyser LT tissue disrupter (QIAGEN, UK). RNA was extracted and purified from 
the lysate using the RNeasy Mini Kit (QIAGEN Ltd, UK) following manufacturer’s instructions.  
The optional on column DNase treatment step was included to minimise genomic DNA 
contamination. Extracted RNA was analysed for both quality and quantity using a 
NanodropOne spectrophotometer (ThermoFisher Scientific, UK) with a 260:280 absorbance 
ratio of around 2.0 being considered as pure RNA. Extracted RNA was stored in RNase free 
tubes at -80°C until required for further downstream applications. 
2.7.2 cDNA Synthesis 
cDNA was reverse transcribed from up to 2µg of the extracted RNA described in 2.5.6.1 using 
the SuperScript® VILO™ cDNA synthesis kit (ThermoFisher Scientific, UK) according to 
manufacturer’s instructions. A reaction free of the reverse transcriptase enzyme was also 
included as a control (-RT control) to ensure reagents were free of nucleic acid 
contamination. All reactions were performed on a TProfessional Thermocycler (Biometra 
GmbH, Germany) and resulting cDNA was stored at -20°C. 
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2.7.3 Quantitative Real Time Polymerase Chain Reaction (qRT-
PCR) 
To analyse and quantify expression of specific mRNA within samples, qRT-PCR was performed 
using the Universal Probe Library (UPL; Roche Diagnostics Ltd, UK) on cDNA (2.5.6.2). The 
UPL is based on short hydrolysis probes labelled with fluorescein (FAM) at the 5’ end and 
with a dark quencher dye at the 3’ end. These probes are capable of detecting 8- and 9-mer 
motifs that prevalent in the relevant organism’s transcriptomes (for example, there are 90 
probes configured for the Mouse transcriptome).  Assays were designed using the 
ProbeFinder Assay Design Software (Roche Diagnostics Ltd, UK) in which the design software 
suggests a number of suitable PCR primers and UPL probes specific to the gene of interest. 
Where possible, primers spanning introns were chosen to avoid amplification of 
contaminating genomic DNA (as cDNA is synthesised from mRNA, it does not contain 
sequences derived from introns, unlike genomic DNA which consists of sequences from both 
introns and exons). 
During the qRT-PCR reaction, the short UPL probe sequence is complementary to the one of 
the strands of the amplicon. During each annealing stage of the PCR cycles, the probe binds 
to the amplicon and as the polymerase extends from primer to the amplicon, it displaces the 
fluorescein (at the 5’ end) from the quencher (at the 3’end), resulting in an increase in 
fluorescence emitted.  
Theoretically, PCR doubles the number of molecules or strands with each amplification cycle; 
amplifying DNA exponentially. The exponential phase of the PCR cycle, when reagents are in 
excess, the DNA polymerase is still highly efficient and when final DNA product is still 
relatively low so as not to compete with the primers annealing capability, is when the 
threshold cycle (Ct) is set. At this point, the fluorescent signal being emitted from the PCR 
reaction is distinguishable from background signal. As the Ct value is the point at which the 
fluorescent signal crosses the threshold from background to relevant and significant signal, 
the Ct value is inversely related to the amount of amplicon present in a reaction; the greater 
the expression of mRNA in the cDNA sample, the lower the Ct value.  
qRT-PCR reactions were set up in triplicate (technical replicates of each sample) using the 
Applied Biosytems Taqman Universal PCR Master Mix (Applied Biosystems, Life 
Technologies, UK) according to manufacturer’s instructions  and were run on the ABI 7900HT 
Chapter 2 Materials & Methods 
74 
 
Real-Time PCR system with SDS 2.4 software (Applied Biosystems, Life Technologies, UK). No 
template and reverse transcriptase negative controls were included to ensure reactions were 
free of contamination. The external Luciferase control gene was detected using a probe 
labelled with NED at the 5’ end (as opposed to FAM with the UPL probe).  
Details of assays used for this thesis, including primer sequences, UPL probe number and 
details of the Luciferase external control assay can be found in Table 2.4. 
Table 2.4 Details of primers and probes used in qRT-PCR assays. 
Gene Forward Primer Reverse Primer UPL Probe 
Aquaporin-8 (Aqp8) CCATTCTCCATTGGCTTCTC 
CAGGTCCAAAGGCACGA
G 50 






Endothelin-1 (ET-1) CTGCTGTTCGTGACTTTCCA 
AGCTCCGGTGCTGAGTT
C 50 
Smooth Muscle Actin (SMA) ACTCTCTTCCAGCCATCTTTCA 
ATAGGTGGTTTCGTGGA
TGC 58 
HMG-CoA reductase (HMGCR1) TGCGTAAGCGCAGTTCCT 
TTGTAGCCTCACAGTCCT
TGG 19 
Steroidogenic Acute Regulatory 
Protein (StAR) 
TTGGGCATACTCAACA
ACCA ACTTCGTCCCCGTTCTCC 11 
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2.7.3.1 qRT-PCR Assay Optimisation and Validation 
With the assumption that a 100% efficient PCR reaction is doubling the amplicon with each 
cycle, assays were tested for efficiency to ensure Ct values were suitable for quantitative 
analysis. 
For these studies, assays with an efficiency between 90 and 110% were considered 
acceptable. Assays were validated for efficiency using a standard curve in which a serial 
dilution of cDNA (from tissue known to express the gene of interest) was added to reactions 
and resulting Ct values were plotted against the log dilution factor. The efficiency of the 
reaction was then calculated using the equation of the linear regression line (produced from 
the plotted Ct values) using the following formulas: 
Exponential Amplification(E) = 10
−1
(Coefficient of X)  
Efficency of Reaction(%) = (E − 1) x 100 
For each gene of interest, a number of assays were designed and tested for efficiency before 
the most efficient was utilised for experimental tissues.  
2.7.3.2 Analysis of qRT-PCR Assays 
Real time PCR data was analysed using the comparative Ct method to give a quantification of 
mRNA expression relative to expression of a control mRNA. This method is also known as the 
2-∆∆Ct method [431].  
Using this method, the Ct values of the experimental samples (for example androgen receptor 
knock out testis) are compared to control samples (for example, wild type testis tissue). 
These Ct values are first normalised to the external control gene by subtracting the Ct value 
of the gene of interest from that of the external control gene (∆Ct) and then corrected to 
control groups to give the ∆∆Ct value. The fold change of the of mRNA expression relative to 
control mRNA expression was calculated with the following formula: 
mRNA Expression Fold Change =  2−∆∆Ct 
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2.8 Statistical Analysis 
Statistical analysis of data was carried out using GraphPad Prism 7.02 (GraphPad Software 
Inc., USA). Data sets were tested for normality (assuming the data approximates a Gaussian 
distribution) using the D’Agnostino & Pearson Normality Test. A p value of ≥ 0.05 indicates 
derivation from the Gaussian distribution is no more that would be seen with chance alone 
(i.e. the data is normally distributed) and a p value of ≤ 0.05 indicates that the data set was 
not sampled from a Gaussian distribution. 
If data was considered ‘normally distributed’; it was determined to be acceptable to use 
parametric tests to compare data sets. For comparison of two data sets alone, an unpaired, 
two tailed t-test was performed. For analysis of differences of means between three or more 
groups, a one-way ANOVA was performed and when groups were subjected to two 
experimental factors, a two-way ANOVA was performed. Multiple comparisons of means 
were performed using post-hoc analyses; Dunnet’s or Turkeys depending on whether means 
were compared to every other mean or to a control mean respectively. 
If data was not ‘normally distributed, data was either log transformed to enforce Gaussian 
distribution before performing parametric tests or, in cases where this was not possible, non-
parametric tests were used for comparison. For comparison of two data sets alone, a Mann-
Whitney U Test was used. For comparison of three or more groups, a Kruskal-Wallis test was 
applied with means of groups being compared using a Dunn’s post hoc analysis.  
For these studies, a p value of ≤ 0.05 was considered statistically significant for both 
parametric and non-parametric analyses. 
2.9 Commonly Used Buffers and Solutions 
2.9.1 Tris Buffered Saline 
For one litre of a 20x stock of Tris buffered saline (TBS) (0.4M Tris, 3M NaCl, pH7.6) 48g Tris 
HCl, 11.2g Tris base and 176g NaCl were dissolved in 900mL of deionised water. Once at room 
temperature, the pH was then adjusted to pH7.6 (pH was then adjusted to 6.0 with 
Hydrochloric Acid (to decrease pH) or sodium hydroxide (to increase pH) and final volume 
adjusted to one litre using distilled water. 20x stock was kept at 4°C until required. For a 
working stock of TBS solution (20mM Tris, 150mM NaCl, pH7.6), 500mL of 20x TBS was added 
9.5L of deionised water and then stored at room temperature. 
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2.9.2 Phosphate Buffered Saline 
For one litre of 1x Phosphate buffered saline (PBS)(10mM Phosphate Buffer, 137mM NaCl, 
2.7mM KCl, pH7.4), 5 PBS tablets (Sigma-Aldrich, UK) were dissolved in one litre of deionised 
water. The solution was stored at room temperature.  
2.9.3 Genomic DNA Extraction 
2.9.3.1 Tris Stock Solution 
For one litre of Tris (1M Tris, pH8.0), 121.14g Tris base (Sigma Aldrich, UK) was dissolved in 
800mL deionised water. pH was adjusted to pH8.0 with Hydrochloric Acid (to decrease pH) 
or sodium hydroxide (to increase pH) and final volume adjusted to one litre using distilled 
water. The solution was stored at room temperature. 
2.9.3.2 Ethylenediaminetetraacetic Acid (EDTA) 
For one litre of EDTA stock (0.5M EDTA, pH8.0), 185g EDTA (Sigma-Aldrich, UK) was dissolved 
in 800mL deionised water. pH was then adjusted to pH8.0 and volume adjusted to one litre 
with deionised water. The solution was stored at room temperature.  
2.9.3.3 Tris-EDTA-Tween 
For 50mL of Tris-EDTA-Tween, 100µl 0.5M EDTA (pH8.0) and 250µl TWEEN® 20  were added 
to 2.5mL of 1M Tris (pH8.0) before adjusting  the volume to 50mL with deionised water. The 
solution was the filter sterilised through a 0.2µm tube top filter disc (Merk Millipore, USA) 
into a fresh sterile falcon tube. The solution was stored at room temperature. 
2.9.4 Immunohistochemistry 
2.9.4.1 Citrate Buffer for Heat Induced Citrate Retrieval 
For one litre of 10x stock of 0.1M Citrate Buffer, 21.01g Citric Acid monohydrate was added 
to 875mL deionised water. Concentrated Sodium Hydroxide was then added until the pH 
reached pH5.5. Final volume was then adjusted to one litre with deionised water and pH 
adjusted to 6.0 with Hydrochloric Acid (to decrease pH) or sodium hydroxide (to increase pH). 
The solution was then stored at room temperature 
2.9.4.2 Tris-EDTA for Heat Induced Citrate Retrieval 
To make a 20x stock of Tris-EDTA buffer (0.2M Tris Base, 20mM EDTA solution, pH9), 1.21g 
of Tris and 0.37g of EDTA was added to 50mL of deionised water and mixed to dissolve. For 
Chapter 2 Materials & Methods 
78 
 
a working 1x stock of Tris-EDTA buffer (10mM Tris Base, 1mM EDTA solution, 0.05% TWEEN® 
20, pH9), 50mL of the 20x stock and 0.5mL of TWEEN® 20  (Sigma-Aldrich, UK) was added to 
one litre of deionised water before mixing well. The solution was then stored at room 
temperature for up to three months or at 4°C for longer periods of time.  
 
2.9.4.3 Normal Sera & Blocking Solutions 
2.9.4.3.1 Normal Sera 
Normal sera (Biosera, UK) was obtained through the SuRF histology facility. For the 
immunohistochemistry experiments used in these studies, Normal Goat (NGS), Chicken 
(NChS), Horse (NHS) or Donkey (NDS) were used. 
2.9.4.3.2 Blocking Solutions 
For 200mL of blocking solution, 2g bovine serum albumin (BSA; Sigma-Aldrich, UK) was 
dissolved in 140mL of TBS (2.5.8.1), 20mL of normal serum (2.5.8.4.3.1) was added before 
the final volume was made up to 200mL with TBS. The solution was then filtered through a 
0.22µm syringe filter unit (Merk Millipore, USA) before being dispensed into aliquots of up 





Chapter 3 Optimisation and Validation of 
Targeting the Testicular Somatic 
Cells Using Viral Vectors 
3.1 Introduction 
The somatic cells of the testis are essential for maintaining both the endocrine and the 
reproductive functions of the adult testis. In particular, the Sertoli cells have been noted to 
be master regulators of both of these testicular functions with studies demonstrating their 
requirement for spermatogenesis and to maintain the Leydig cells numbers and 
steroidogenic function [7-9].  
It is believed that a number of male infertility cases are as a result of genetic mutations and 
that these genetic mutations can result in Sertoli and Leydig cell dysfunction [238, 239, 432]. 
However, understanding of the genetic mechanisms in both testis function and dysfunction 
is currently incomplete. This is, in part due to routine genetic testing of men presenting with 
reproductive disorders being limited to karyotyping, specific microdeletions and gene 
mutations (Azoospermia factor (AZF) microdeletions and Cystic fibrosis transmembrane 
conductance regulator (CFTR) mutations) which have already been identified as issues [433]. 
As a result of this, the causes for the majority of cases of male reproductive disorders remain 
idiopathic.  
Currently, treatments available to men presenting with infertility or hypogonadism are 
limited to treating the symptoms as opposed to the underlying causes of disorders; using in 
vitro fertilisation and/or ICSI and hormone replacement therapy respectively. A number of 
studies have been published disputing the potential adverse effects of using androgen 
replacement therapy (ART) to treat the symptoms of hypogonadism as a result of the 
potential adverse effects on the cardiovascular system [264, 266, 434, 435].  Alongside this, 
there is some debate regarding the increased likelihood of producing offspring bearing a 
congenital defect such as anencephaly and limb abnormalities in pregnancies resulting from 
assisted reproductive technology in comparison to ‘natural pregnancies’ [436-438]. This may 
be due to the assisted reproductive technology techniques bypassing the normal checkpoints 
reached by fertilisation that prevent abnormal genetic replication, essentially allowing 
genetic abnormalities to ‘slip through the net’ [8]. However, the introduction of pre-





implantation genetic diagnosis has resulted in a steady decline in the incidence of these 
congenital abnormalities [439].  
The diagnosis and treatment of both male infertility and hypogonadism could be improved 
by targeting the causative mutations underlying the condition. There are currently over 2500 
gene therapy clinical trials worldwide (http://www.abedia.com/wiley/countries.php) 
highlighting the accelerating advancement in gene targeting technologies. Recent 
technological advances in both gene modification and their delivery systems are making the 
idea of both increasing the understanding of and subsequently the treatment of male 
reproductive conditions a reality. 
Targeting the testicular somatic cells in vivo with gene modification has been approached in 
a number of ways; using both non-viral and viral vectors. Non-viral methods such as 
electroporation with naked DNA and using liposomes carrying naked DNA have proven to 
result in a low efficiency of targeting and, due to a lack of integration of the DNA into the 
host/target cell DNA, relatively short lived targeting [317, 318, 440]. The majority of studies 
using these methods were carried out with the purpose of targeting of the germ cell lineage 
as opposed to targeting the somatic cells of the testis, though expression of the plasmid in 
the offspring was in circular form. Further studies have demonstrated that the use of 
electroporation (a technique in which an electrical pulse is applied in order to increase the 
permeability of membranes, commonly used with naked and liposome DNA delivery) on the 
testis can negatively impact spermatogenesis, making it incompatible for the application of 
gene therapy and/or repair [302].  
The use of viral vectors have been used more extensively in the testis to target both somatic 
cells and the germ cell population. Studies suggesting successful targeting of germ cells with 
viral vectors are controversial with a number of publications reporting low targeting 
efficiencies and episomal location of the inherited transgene [346, 363, 396]. Greater success 
has been found with using viral vectors to target somatic cells, with studies demonstrating 
viral vector targeting of both Leydig [175, 330, 334, 364] and Sertoli cells [45, 330, 336, 347, 
397, 399, 441-443]. Using this method, viral vectors have been used to generate cell ablation 
through the knockout of essential genes (through Cre expressing adenoviral injections [175]), 
to generate an acute adult knockout of Androgen receptor (using lentiviral vectors expressing 





Cre recombinase) [45]) and to repair mouse models of infertility through reintroduction of 
genes with viral delivery [396, 397].  However, some studies have reported some negative 
side effects as a result of injecting viral vectors into the testis indicating that the use of viral 
vectors for gene delivery may not be a ‘one fits all system’ and further refinement is required 
depending on the purpose of viral vector delivery [336].  
 
3.2 Hypothesis & Aims 
3.2.1 Hypothesis 
It is hypothesised that delivery of viral vectors (Lentiviral and Adenoviral) to the testis will 
target the somatic cells. Specifically the Leydig or Sertoli cells of the testis will be targeted 
and upon refinement of the delivery technique, that this will be suitable for the repair of 
dysfunctional testis in that there will be little or no side effects as a result of the introduction 
of viral vectors.  
3.2.2 Aims 
The overarching aim of the experiments described in this chapter was to determine the best 
methods/protocols for targeting these two somatic cell types utilising methods and protocols 
published previously and modifying these protocols for the purpose of gene therapy/repair 
of testis (inducing as little impact to testicular histology and function as possible). Specifically, 
the following aims were established: 
Aim 1: To establish a protocol for injection of vectors into the testis that would result in a 
wide coverage of the interstitial compartment with the goal of targeting the Leydig cells. 
Aim 2: To confirm whether injection of a viral vector into the interstitial compartment of the 
testis would result in the production of transgenic offspring through viral targeting of the 
germ cells. 
Aim 3:  To determine the efficiency of lentiviral targeting of Leydig cells using interstitial 
injections. 
Aim 4: To determine the efficiency of adenoviral targeting of Leydig cells using interstitial 
injections. 





Aim 5: To establish a protocol for injection of vectors into the rete compartment of the testis, 
with the overarching aim of targeting the Sertoli cells with a reduction in the impact on 
testicular histology. 
3.2.3 Approach 
To achieve these aims, vehicle (PBS or serum free media), dye, adenoviral and lentiviral 
vectors were injected into the interstitial and tubular compartments of the testis using 
different volumes, locations and injection pressures dependant on the cell type being 
targeted. Testis were then collected and analysed at different time points post injection to 
determine the most appropriate methodology for future attempts at gene delivery/editing. 
 
3.3 Results 
3.3.1 Using Interstitial Injections to target Leydig cells in the 
Adult Testis 
3.3.1.1 Optimising Injection Volume and Site 
With the aim of targeting cells in the interstitium, first the optimal injection volume and site 
for interstitial injections had to be determined. Injection sites chosen for investigation were 
around the area close to the rete testis and the area furthest away from the rete testis; 
allowing consistent positioning of injections (due to the ease of location of the rete testis) 
(Figure 3.1A). To determine the optimal volume (defined as being the volume resulting in the 
widest distribution of injected solution through the testis), testis were injected with either 
10µl or 20 µl of Tissue Marker Dye (a dye capable of withstanding tissue processing and 
histological procedures) at either of two injection sites (close to or away from the rete testis) 
and collected 30 minutes post injection.  Injection procedures were performed as described 
in section 2.3.2. At the time of collection, distribution of the Tissue Marker Dye was clearly 
visible particularly in regions close to the injection site (Figure 3.1B). Cross sections through 
the testis gave further insight into the distribution of the dye through the testis with those 
injected with 20µl of dye appearing to have a wider distribution of dye compared to those 
injected with 10 µl of dye (Figure 3.1B). The percentage of cross section surface area with 
dye present was then calculated for comparisons (as described in 2.5.4.6). Uninjected testis 
were included in order to set a negative baseline for the analysis. Analysis confirmed that 





injections of 20µl of dye localised at the rete testis resulted in a significantly greater 
proportion of testis section positive for the dye in comparison to testis injected with 10µl of 
dye (Figure 3.1C). For testis injected in the area furthest away from the rete, there was no 
difference between injection volumes (Figure 3.1C). Given the wider distribution of the dye 
at higher volumes and the lower variation of values, 20µl volume injections localised close to 
the rete were regarded as the most suitable for future interstitial injections. Closer inspection 
of H&E stained, vehicle injected testis sections also indicated that there were no significant 
impacts on testicular histology following injection with either volume (Figure 3.1D), further 
confirming the suitability of using a higher volume for injections, echoing methods used and 
published by Kojima et al (2003) and Penny et al (2017) [175, 330]. 
 








Figure 3.1 Optimisation of Interstitial Injection Volume and Site.  (A) Schematic of mouse testis 
demonstrating locations of interstitial injections being investigated; Close to the rete testis and Away 
from the rete testis. (B) Representative images of freshly dissected testis injected with different 
volumes of Tissue Marker Dye at the two different locations (Not to Scale) and corresponding whole 
cross sections of H&E stained testis directly below. (Not to Scale) (C) Analysis of Tissue Marker Dye 
coverage within interstitial injected testis sections (One way ANOVA; * significant at p<0.05, ** 
significant at <0.005, *** significant at p<0.001). Bars represent average ± SEM. n number = 3 for each 
experimental group and n=4 for non-injected controls.  (D) Representative images H&E stained testis 
injected with either 10µl or 20µl of vehicle, illustrating that there were no significant impacts on 
testicular histology following interstitial injection with either volume. Scale bars = 100µm. 
 
 





3.3.1.2 Using Interstitial Injections to target Leydig cells in the Adult 
Testis  
To date, targeting of Leydig cells in the interstitial compartment of the testis has been 
successfully demonstrated using adenoviral [175, 330], gamma-retroviral vectors [364] and, 
in brief, lentiviral vectors [400]in the mouse and sheep respectively. Having confirmed the 
optimal technique for injection into the interstitial compartment, preliminary studies using 
testis injected interstitially with lentivirus, (including archived tissue sections injected by Dr 
Cornelia Roesl) into the interstitial compartment were performed.  
3.3.1.2.1 Ensuring Germ cells are not being targeted by Lentiviral vectors 
Two published studies have reported targeting of the germ cell population following viral 
vector injection into the interstitial compartment of the testis [394, 395, 444]. Given that 
human germline modification is currently banned in 29 countries [445], and the overarching 
aim of this study to investigate a technique which could ultimately be applicable to human 
male reproductive disorders, we then sought to confirm whether lentiviral vectors were 
indeed capable of transducing the germ cell population. Sehgal et al (2011) successfully 
utilised a lentiviral vector containing human elongation factor-1 (EF-1) promoter driven eGFP 
to generate transgenic offspring, following previous reports suggesting lentiviral vectors 
expressing cytomegalovirus (CMV) promoter driven GFP were unsuccessful [394, 444]. A 
follow up study by Qin et al (2015) confirmed successful generation of transgenic offspring 
using both the EF-1 and the CMV promoter but found that the delivered transgene was 
silenced in offspring derived from males injected with the lentiviral vector containing the EF-
1 promoter [395]. This was attributed to the delivered transgene being suppressed by DNA 
methylation. With a number of studies attempting to target the germ cell population and 
with many of these studies contradicting each other, we then recapitulated the protocol as 
published by Seghal [394] (Figure 3.2A) and analysed offspring produced for GFP expression 
following interstitial injection with lentiviral vectors expressing GFP under either the CMV or 
EF1α promoters . GFP expression in offspring would indicate targeting of the spermatogonial 
stem cell population in the testis suggesting that this technique may not be suitable for the 
treatment of men with reproductive disorders.  
Collected embryos were imaged under BF and GFP fluorescent filters adjacent to negative 
control tissue (Figure 3.2B) before being frozen for analysis of genomic DNA (Figure 3.2C). 





Both imaging and genotyping of a total of 263 embryos (Figure 3.2D&E) derived from ten 
lentivirus injected males (n=5 for each promoter) confirmed that there was no transmission 
of GFP to offspring indicating that the lentiviral vectors were not targeting the 
spermatogonial stem cell population in the injected testis.  











Figure 3.2 Ensuring Germ cells are not being targeted by Lentiviral vectors.  (A) Schematics of the 
Lentiviral vectors expressing GFP under either the CMV or EF1α promoter. (B) Schematic of the 
experimental procedure; wild type male mice (at 28 days postpartum) were injected with either of the 
lentiviral vectors into the interstitial compartment of the testis. The contralateral testis was removed. 
35 days post procedure, the males were mated with wild type females and any resultant embryos 
were collected for analysis. (C) Images of freshly dissected embryos (and negative control tissue – 
located on the left of the image) derived from males injected with lentiviral vectors. Images were taken 
under brightfield and GFP fluorescent lamps. (Brightfield images taken at 0.5 seconds of exposure, GFP 
fluorescent images taken at 5.5 seconds of exposure) (D) PCR analysis of genomic DNA isolated from 
embryos derived from males injected with lentiviral vectors. GFP positive, negative and water controls 
were included. Primers for a positive control gene; Interleukin 2 were also included to ensure 
successful amplification of DNA. (Interleukin2; 330bp, GFP; 264bp). (E) Occurrence of GFP positive or 
GFP negative results in 263 embryos derived from males injected with either LV-CMV-emGFP or LV-
EF1α-EGFP. 
 
3.3.1.2.2 Injection of Lentiviral Vectors into the Interstitial Compartment 
Results in Targeting of 9.3% of the Adult Leydig Cell Population 
To determine the cell type targeted by lentiviral particles in the interstitial compartment. 
Lentiviral vectors carrying a GFP reporter were injected into the interstitial compartment of 
the testis and collected seven days post injection for analysis. Immunostaining for GFP and 
Leydig cell expressed protein HSD3β confirmed targeting of Leydig cells by the injected 
lentiviral vectors with co-localisation of GFP and 3βHSD observed in the interstitial 
compartment (Figure 3.3A). Estimates of targeting efficiency (from counts of GFP+HSD3β 
positive cells) suggested that up to 9.3% of Leydig cells were being transduced by the 
lentiviral particles (with a maximum volume delivered) (Figure 3.3B) 7 days post injection 
(dpi) (allowing time for both integration of the viral particles and sufficient expression of the 
delivered transgene) with numbers of cells being targeted increasing with increasing 
injection volume. 






Figure 3.3 Investigating targeting in testis injected interstitially with Lentiviral vectors carrying GFP. 
(A) GFP and 3bHSD expression in testis 7 days post interstitial injection with LV-CMV-emGFP 
demonstrating targeting of Leydig cells with the lentiviral vector (B) Percentage of GFP positive HSD3β 
positive cells in the testis injected with 7.5µl (n=4), 10µl (n=1) or 20µl (n=2) of lentiviral vectors carrying 
GFP. 
3.3.1.2.3 Longevity of delivered gene expression 
It is well documented that lentiviral vectors have the ability to integrate into the host cell 
DNA, allowing potentially permanent expression of a delivered transgene [366]. To assess 
the longevity of gene expression in adult Leydig cells transduced with lentivirus in vivo, testis 
were collected 3.5, 7 and 10 days post injection (dpi) of GFP expressing lentiviral particles 
and analysed for GFP expression using immunohistochemistry. At 3dpi and 7dpi , GFP 
expression is visible in the interstitial compartment of the injected testis, however at 10dpi 
there were no GFP positive cells present in the injected testis suggesting that targeted cells 





had either stopped expressing/silenced the transgene or the that the cells expressing the 
delivered transgene had been cleared from the testis (Figure 3.4). Immunohistochemistry for 
cleaved caspase 3 (a marker of apoptosis) revealed that GFP positive cells were co-expressing 
this marker (Figure 3.4) and, therefore, cells targeted by the lentiviral particles were 




Figure 3.4 Investigating the longevity of lentiviral delivered gene expression in Leydig cells.  GFP and 
Cleaved caspase 3 expression in testis collected 3.5 days (n= 4), 7 days (n= 3) and 10 days (n=5) post 
interstitial injection with LV-CMV-emGFP demonstrating targeting of Leydig cells with the lentiviral 
vector and resultant cleaved caspase expression exclusively in cells targeted by the lentiviral vector. 
Consequently, targeted cells were cleared from the interstitial compartment by 10 days post injection 
(dpi). 
 





3.3.1.3 Injecting Adenoviral vectors into the interstitial compartment 
3.3.1.3.1 Cell Type being targeted and Longevity of delivered gene & 
Efficiency of targeting 
With lentiviral vector targeted Leydig cells undergoing apoptosis, an alternative vector to 
target these cells would be required. Following completion of experiments determining the 
targeting efficiency of lentiviral vectors in the interstitium, a study was published 
demonstrating successful targeting of Leydig cells with an Adenoviral vector, with the 
purpose of probing Gata4 function [175]. To confirm targeting of Leydig cells with adenoviral 
vectors and to determine whether expression of transgene would persist for longer than 
those delivered by lentiviral vectors, wildtype and RFP reporter testis were injected with 
either a GFP expressing adenoviral vector (Ad-eGFP) or a Cre-GFP expressing adenoviral 
vectors (Ad-Cre-eGFP) into the interstitial compartment and collected at 3dpi and 10dpi 
(Figure 3.5A). 
Post collection, testis were imaged under brightfield, GFP and RFP fluorescent filters (Figure 
3.5B). From these images it was clear, at both 3 and 10dpi that targeted cells were still 
expressing the delivered transgene and that targeted cells appeared to be located in the 
interstitial compartment, as expected. It was also evident that, following injection of Ad-Cre-
eGFP into RFP (Tomato Red) reporter mice; that the GFP transgene was not as highly 
expressed as the CRE transgene; a typical artefact of using a vector expression multiple 
transgenes separated with an IRES component [446]. On closer inspection, and using the 
Leydig cell marker Cyp17a1, we confirmed that the cell type being targeted in the interstitium 
was the Leydig cells (Figure 3.5C). When quantified, the number of Leydig cells being 
targeted was 15.39% at 3dpi and 19.31% at 10dpi (mean ±SEM). There was also no 
differences in the mean number of Leydig cells targeted after 10dpi when compared with 
testis collected 3dpi, namely due to the large variance in targeted Leydig cells counted 
between each injected testis (Figure 3.5D). The expression of the delivered transgene was 
unexpected at 10dpi, given the results shown by Penny et al (2017) who report a loss of 
reporter gene expression at 12dpi. 



















Figure 3.5 Injecting Adenoviral vectors into the interstitial compartment of Adult Mouse Testis. (A) 
Schematic diagrams of adenoviral constructs used. (B) Representative images of freshly dissected wild 
types and tomato red reporter testis under brightfield and GFP fluorescent lamps at 3 and 10 days 
post injection with either GFP or Cre-GFP expressing adenoviral vectors. (Brightfield images taken at 
0.5 seconds of exposure, GFP fluorescent images taken after 5.5 seconds of exposure). 5 mice were 
included in each of the injected groups. (C) GFP, tRFP and Cyp17a1 expression in wildtype (WT) and 
tomato red reporter (TR) testis 3 and 10 days post injection (dpi) with GFP or Cre-GFP expressing 
adenoviral particles. Representative images clearly demonstrate uptake of adenoviral particles by 
Cyp17a1 expressing cells (Leydig cells) in the interstitial compartment of the testis. Scale bar = 20µm 
(D) Counts of cells co-expressing red fluorescent protein (RFP) and Leydig cell marker; HSD3β in tomato 
red reporter testis injected with Cre-GFP expressing adenovirus give an estimation as to the number 
of Leydig cells being targeted at both 3dpi (n= 5) and 10dpi (n=3). (Unpaired t-test; p=0.6479). Bars 
represent average ±SEM.  
 
3.3.1.3.2 Immune Response to introduction of Adenoviral vectors into 
the interstitial compartment of the testis 
Given the apoptosis observed previously in lentiviral targeted Leydig cells, 
immunohistochemistry was used to stain testis sections with cleaved caspase 3 (a marker of 
apoptosis) to determine whether adenoviral targeted Leydig cells also underwent cell death. 
At both 3dpi and 10dpi, in both WT and RFP reporter testis, there were no cleaved caspase 3 
positive cells in the interstitial compartment, confirming that adenoviral infection did not 
induce Leydig cell death (Figure 3.6A). 





As adenoviral vectors have an increased immunogenicity compared to other viral vectors, 
the immune response of testis post adenoviral injection was investigated. To give an idea of 
the impact of the injection alone, non-injected and vehicle-injected testis sections were 
analysed for the presence of macrophages using a Mac2 antibody; a general macrophage 
marker recognising mouse peritoneal exudate macrophages as well as tissue resident 
macrophages (Figure 3.6B). This confirmed presence of macrophages within the interstitial 
compartment regardless of treatment and time post procedure, suggesting that the 
procedure and introduction of solution into the interstitial compartment alone does not 
induce a dramatic response from testicular macrophages. Wild type testis injected with Ad-
eGFP and RFP reporter testis injected with either Ad-eGFP or Ad-Cre-eGFP and collected 3dpi 
and 10dpi were immuno-stained for macrophage marker Mac2 (Figure 3.6C). There appeared 
to be no differences in Mac2 staining between the testis of different genotypes and testis 
injected with different viruses, though further quantification of Mac2 positive cells would 
confirm this. In testis collected 10dpi (regardless of viral construct injected), some targeted 
cells in the interstitium appear to be being encompassed and surrounded by Mac2 positive 
cells (Figure 3.6C, inset), suggest a response of the testicular immune cells to the introduction 
of adenoviral particles. This is similar to the immune delayed immune response observed in 
Penny et al (2017), who noted a delayed influx of T lymphocytes at 12dpi coinciding with a 
loss of reporter transgene expression. Whether this is a response to the delivered transgene 
or the virus itself it yet to be confirmed.  
















Figure 3.6 Immune Response to introduction of Adenoviral vectors into the interstitial compartment 
of the testis. (A) GFP/tRFP and Cleaved Caspase 3 expression in wildtype (WT) and tomato red reporter 
(TR) testis 3 and 10 days post injection (dpi) with eGFP or Cre-eGFP expressing adenoviral particles. 
Representative images indicate that there is no apoptosis occurring as a result of adenoviral targeted. 
Inset = positive cleaved caspase 3 staining as a result of blood testis barrier disruption serving as an 
internal positive control. (B) Mac2 expression in WT testis 3 and 10 days post procedure consisting of 
either no injection or injection with vehicle. Images reveal the presence of Mac2 positive cells in 
control testis. (C) GFP/tRFP and Mac2 expression in wildtype (WT) and tomato red reporter (TR) testis 
3 and 10 days post injection (dpi) with GFP or Cre-GFP expressing adenoviral particles. Representative 
images reveal some interaction between targeted cells and Mac2 positive macrophages at 10dpi 
(highlighted with yellow arrows and inset zoomed in image). 5 animals were used in each of the 
injection groups. 
 
3.3.2 Seminiferous Tubule Injections to target Sertoli cells in 
the Testis 
3.3.2.1 Determining the best pressure to use for injection into the 
rete compartment 
Previously, lentiviral vectors have been delivered via the efferent ducts of the testis to target 
the Sertoli cells. Though this method can occasionally be effective (as described in Willems 
et al 2015 [45]), this delivery technique often resulted in distended seminiferous tubules, 
presumably as a result of blockage or damage to the fragile efferent duct (Figure 3.7A). To 
circumvent this, we first moved the injection site to the rete compartment of the testis, 
bypassing the need for over handling and dissection of the efferent duct during the injection 
procedure yet still providing good access to the seminiferous tubules [293] (Figure 3.7B). 
Blanchard and Boekelheide [441] observed that mechanical disruption of the rete resulted in 
seepage of the injected solution into the interstitial compartment, giving suggestion as to the 
delicate structure of the rete compartment. Therefore, injection pressure was then 
optimised using a microinjector (Eppendorf Femtojet; Eppendorf, Germany) to introduce 
vehicle into the seminiferous tubules at pressures ranging from 20hPA to 50hPA, the latter 
being the pressure previously used with efferent duct injections. H&E staining of testis 
sections indicated that a lower injection pressure resulted in a reduced likelihood of negative 
features such as vacuolisation and tubule distension being present (Figure 3.7C). 





Quantification (using the methodology described in 2.5.4.6) confirmed that lower injection 
pressures resulted in a reduction in the likelihood of artefacts being present in the testis 
(Figure 3.7D), with a low score indicating fewer artefacts observed and a high scores 
indicated an increase in the negative impact in a testis section. However, it was noted during 
injection procedures that the time taken to complete the injection would increase as 
injection pressure was lowered. Because of this, an injection pressure of 25hPA was chosen 
for all future injections in order to both reduce the likelihood of negative impacts on the 
testis and to complete the injection in a timely manner (for animal welfare considerations). 
Figure 3.7E demonstrates the specific targeting of lentiviral vectors with presence of Sertoli 
cells expressing the lentiviral delivered tRFP transgene 50dpi and that testicular histology is 
maintained following injection at the lower pressure of 25hPa as opposed to that seen in the 
testis injected at 50hPA. Injection procedures were performed as described in section 2.3.3. 
 













Figure 3.7 Determining the best pressure to use for injection into the rete compartment.  (A) 
Injections via the efferent duct performed previously in the group have resulted in damage to 
testicular histology with presence of vacuoles at 7dpi and 100dpi (open arrows) and shrunken tubules 
100dpi as evident from the representative images (closed arrowheads).[Injection performed by Dr C 
Roesl, Images taken by Mr N Jeffery] (B) Schematic illustrating injection into the rete compartment of 
the testis.  (C) Representative images of H&E stained testis sections following either a sham injection 
or injection of vehicle at the following pressures; 20hPA, 25hPA, 30hPA, 40hPA and 50hPA. (D) Average 
scores of testis following either sham injection of injection of vehicle at the varying pressures. Scores 
are out of 15 and were determined following observation of vacuoles, germ cell sloughing and 
distended tubules, scoring on both presence and incidence of the histological factor. A higher score 
would indicate presence and higher incidence of negative testicular factors indicating an increase in 
the potential for testicular damage. Bars represent average score ±SEM (E) mKate2 (RFP) expression 
in testis injected with a lentiviral vector carrying mKate2 (LV-CMV-mKate2-negmiR) at 50hPA and 
25hPA demonstrating the impacts of reducing rete injection pressure. (Scale Bars = 50µm). Between 











As yet, only a handful of published studies have focussed on targeting the somatic cells of 
the testis, with some success using viral vectors as a delivery mechanism [45, 175, 330, 334, 
336, 347, 397, 399, 441-443]. Few of these studies have attempted targeting of Leydig cells 
using viral vectors; with studies utilising adenoviral, lentiviral and adeno-associated viral 
vectors to target these cell types [175, 330, 334, 347, 400]. With little previous insight into 
the most appropriate methodology for delivery of substances to the interstitial compartment 
of the testis, an injection protocol was first optimised in order to cover a wide range of this 
compartment whilst inducing as little disruption to the testis architecture as possible. Results 
indicated that injections of a higher volume, specifically at the rete compartment of the testis 
resulted in an increased proportion of testis section surface area being infiltrated with the 
dye and at this location, injections were more consistent. H&E stained sections of testis 
injected with either 10µl or 20µl of vehicle also confirmed that there appeared to be no 
severe phenotypes arising as a result of the introduction of substances into the interstitial 
compartment of the testis. In the literature, any studies describing injection of substances 
into the interstitial compartment of the testis have set their volume at 20µl, further 
confirming the observations described here [394, 395, 444] but have not described optimal 
location of testicular injections. As a result, all future injections were performed according to 
these standards to both increase targeting efficiencies and reduce negative impacts of 
injections.         
Studies utilising lentiviral vector injections into the interstitial compartment have so far done 
so with the purpose of generate transgenic offspring in vivo, with conflicting results [394, 
395, 444]. To establish whether lentiviral vectors were indeed capable of transducing the 
spermatogonial stem cell population (as described in the literature), we mated wildtype 
males 50dpi with lentiviral vectors carrying plasmids expressing GFP under either the EF1α 
or CMV promoters with wild type females. Both fluorescent imaging and genotyping of all 
offspring produced revealed that no offspring were positive for the GFP transgene, regardless 
of the promoter driving transgene expression. Sehgal et al (2011) [394, 444], described 
successful generation of transgenic offspring using the EF1α promoter but not the CMV 
promoter with Qin et al (2015) describing the contrary attributing lack of transgene 
expression in lentivirus carrying EF1α promoter driven GFP derived offspring to gene 





silencing through DNA methylation. This may also be the case in the present study and could 
be confirmed by determining the presence or absence of proviral DNA in the DNA of the 
offspring. Retroviral delivered transgene silencing in stem cells has been well described in 
the literature [447, 448], however whether lentiviral delivered transgenes are also silenced 
is still subject to debate [449-451]. It has been suggested that transgene silencing is 
particularly prevalent in stem cell populations as a result of intrinsic defence mechanisms 
against exogenous DNA [451, 452], further evidence as to why the experiments performed 
in this study (and that of Sehgal et al (2011) and Li et al (2015)) fail to consistently produce 
transgenic offspring through in vivo targeting of the spermatogonial stem cell population. 
One way this may be circumvented is by incorporating a ubiquitous chromatin opening 
element into the lentiviral vector backbone, helping to establish stable transgene expression 
in the transfected cells [453]; potentially permitting the generation of transgenic offspring. 
However, in terms of somatic cell modification using lentiviral vectors with the purpose of 
therapeutic development, the difficulties presented with targeting the adult stem cell 
populations is advantageous, given that germline modification in humans is currently banned 
in 29 countries [445] 
Having confirmed that interstitial injection of lentiviral vectors does not result in the 
production of transgenic offspring, testis injected interstitially with lentiviral vectors were 
analysed to determine the cell type(s) being targeted. Testes were analysed at three, seven 
and ten days post lentiviral injection into the interstitial compartment. Presence of the 
lentiviral reporter gene (GFP) was found in up to 9.3% of Leydig cells at 3dpi and 7dpi, but 
was absent from injected testis after 10 days as a result of targeted cells undergoing 
apoptosis. Increased apoptosis of cells exposed by lentivirus has also recently been reported 
in human hematopoietic stem and progenitor cells as a result of lentiviral vectors triggering 
signalling through Tumour Protein 53 (p53), a protein encoded by a tumour suppression 
gene, known to have a role in stem cell maintenance and in the initiation of apoptosis [454], 
though whether this is the mechanism through which lentiviral targeted Leydig cells and 
undergoing apoptosis is yet to be confirmed.  
One type of viral vector that has shown some promise for the targeting of Leydig cells is 
adenovirus. In a recent study by Penny et al (2017) GFP and/or Cre expression adenoviral 
vectors were injected into the testicular interstitial compartment of mice carrying floxed 





Gata2 and Gata4 alleles [175].  As a result, testes injected with GFP expressing adenoviral 
vectors demonstrated GFP positive Leydig cells and those injected with adenoviral vectors 
expressing Cre resulted in ablation of the Leydig cells as a result of the excision of the Gata2 
and Gata4 alleles in the targeted cells. The study also noted that transgene expression 
persisted for up to 12 days before reporter expression was lost from the targeted cells and, 
to coincide with this, a delayed influx of immune cells into the testis at the same time point. 
To characterise adenoviral targeting of Leydig cells further, testes injected with these same 
adenoviral vectors were analysed at three and ten days post interstitial injection and we 
found that around 20% of Leydig cells. Though targeting efficiency of adenoviral vectors 
appeared to be greater than when using lentiviral vectors, variability was high with some 
injected testis exhibiting as low as 8.8% and as high as 36.6% of cells targeted, a 4 fold 
difference in targeting efficiency. This may be due to some technical issues related to the 
injection procedure as opposed to ability of the viral vector to target the Leydig cells. Another 
avenue which could be investigated would be to inject juvenile reporter testis with Cre 
expressing adenoviral vector in an attempt to target the proliferating cell populations of the 
Leydig cells found in juvenile testis. This would result in delivered transgene (Cre) expression 
in daughter cells deriving from the targeted juvenile cells, affording potential to increasing 
the final number of cells targeted. Transgene expression was still detectable at ten days post 
injection, though at this time point, targeted cells were interacting with Mac2+ macrophages, 
reflecting the delayed immune response reported by Penny et al (2017) and indicating a 
possible clearance of adenoviral targeted cells from the testis soon after ten days post 
injection. Collections at later time points post injection would also provide further 
information as to the longevity of the adenoviral vector delivered transgene expression with 
previous studies suggesting a loss of delivered transgene expression between ten and thirty 
days post injection in Leydig cells, though this may be dependent on host species with 
Blanchard et al investigating the use of adenoviral vectors in rat testis [175, 441]. 
The Sertoli cells are key regulators of both the endocrine and the spermatogenic functions of 
the testis [7-9]. As with both the germ cell and the Leydig cell populations, attempts to target 
the Sertoli cell population using viral vectors have been made [45, 330, 336, 347, 396, 397, 
441, 443], the first being Blanchard and Boekelheide [441] who targeted rat Sertoli cells in 
vivo by introducing adenovirus into the tubular compartment via the rete testis with similar 
experiments in the mouse being performed. There has been some success using adenoviral 





vectors for gene delivery; with evidence of partial restoration of spermatogenesis following 
adenovirus mediated gene delivery in Steel/Steel(dickie) mutant mouse testis (a mouse 
model that is otherwise infertile) [443]. However, a number of studies have reported an 
immune response as a result of adenovirus injection with some demonstrating cells 
undergoing apoptosis within the targeted seminiferous tubules. These observations were 
validated in a later study confirming that adenoviral vectors are unsuitable as vehicles for 
gene delivery to Sertoli cells [330, 336, 397, 441].  
Using lentiviral vectors to target Sertoli cells has proven more suitable with no reports of 
testicular disturbances following introduction of lentiviral particles into the seminiferous 
tubules [45, 396, 397, 399]. The majority of published viral targeting of Sertoli cell studies 
have delivered viral particles to the seminiferous tubules via the efferent duct, the exception 
being Blanchard and Boekelheide [441] in the rat testis. In the study conducted by Li et al 
(2013), out of 24 males injected with lentivirus into the efferent duct, only 21 were fertile. 
This is not discussed at length nor attributed to a particular cause throughout the paper and 
no histological images of ‘infertile’ testes are provided following lentiviral injection. However, 
previous unpublished experiments from our group have suggested that efferent duct 
injections may result in negative testicular phenotypes such are distended tubules and 
vacuolisation presumably as a result of damage or blockage to the delicate efferent duct 
structures. By injecting directly into the rete compartment at low pressures, impacts on 
testicular histology have been circumvented and this has also been confirmed with the 
observation of both an uninterrupted testicular histology alongside lentiviral delivered 
transgene expression following delivery using low pressure injection. This improvement in 
delivery to the seminiferous tubules will assist in future experiments, ensuring that any 
testicular phenotypes present are a direct result of the delivered transgene expression as 
opposed to the injection itself.  
The results obtained from the experiments described in this chapter have established a 
protocol for the injection of vectors into the interstitial compartment of the testis allowing 
the targeting of Leydig cells using either Lenti- or Adeno- viral vectors. Following this, results 
have demonstrated the lack of germline transmission following injection of Lentiviral vectors 
into the interstitial compartment, disputing previous studies suggesting that by using this 
technique, spermatogonial stem cells could be transduced. Injection of lentiviral vectors into 





the interstitial compartment resulted in targeting of the adult Leydig cell population, 
however, the cells targeted by the lentiviral vector underwent apoptosis soon after injection. 
This was not the case for Leydig cells targeted with Adenoviral vectors, however, due to the 
increased immunogenicity and the transient expression of transgenes with these vector 
types, further investigation into the longevity of Adenoviral vector delivered transgenes 
would be beneficial.  
Delivery of Lentiviral particles to Sertoli cells has previously been reported in the literature 
to be more appropriate than using Adenoviral vectors. Here, an improved methodology for 
the delivery of Lentiviral vectors has been described allowing delivery of lentiviral vectors 
with minimal side effects. 
To determine the practical uses of using this methodology coupled with the delivery of 
lentiviral vectors, the subsequent chapters will describe the generation of a model for use as 





Chapter 4 Identifying a model for Testicular 
Repair and Determining the Effects 
of Single and Double Somatic Cell 
Androgen Receptor Knock-Out 
Models  
4.1 Introduction 
Having established a technique to deliver viral vectors to the somatic cells of the testis, the 
key interest was to determine whether and how existing knowledge could be applied to 
exploit this technology to identify its potential for use for gene therapy or repair. To address 
this, a model of male infertility or hypogonadism would be required. An ideal model for proof 
of principle of gene repair or replacement would consist of a gene whose function within the 
testis has been well defined in the literature and whose impacts on testis function can be 
easily analysed; for example, presence or absence of ongoing spermatogenesis.  
The effects of androgens through androgen receptor (AR) signalling are known to be essential 
for both the steroidogenic and spermatogenic functions of the testis as described [6, 45, 48-
50, 52, 101, 102, 108, 109, 124, 455-460].  AR, a steroid nuclear hormone receptor, is 
expressed by a number of cell types in a wide range of tissues including in a number of the 
somatic cells located within the testis in the male. Genetically modified mouse models in 
which Androgen receptor has been completely knocked out (ARKO) have previously been 
generated.  This resulted in overall feminisation, with reductions in body weight and impacts 
on testicular descent, development and function; with a decrease in spermatogenesis and 
testosterone production being observed in ARKO models [60, 101, 456]. 
Despite androgen signalling being crucial for spermatogenesis, germ cells themselves do not 
express AR; indicating that the regulation of spermatogenesis through androgens must be 
mediated through other testicular cell types within a more complex signalling network [39, 
40, 461]. To dissect this androgen signalling network, testicular cell specific knock outs of 
androgen receptor have been well characterised, each with differing impacts on both the 
endocrine and reproductive functions of the testis. 
Sertoli cell (SC) AR knock out (SC-ARKO) models have suggested that a loss of Sertoli cell AR 
may impact the development and proper function of Leydig cells (LC) as well as reduce the 
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capacity of Sertoli cells to support germ cells past the meiotic stages of spermatogenesis [6, 
48, 49, 101, 457, 458]. Sertoli cell function was also found to be compromised in a peritubular 
myoid cell specific ARKO (PTM-ARKO) with a decrease in the expression of Sertoli cell specific 
androgen dependent genes and disruption in the orientation of Sertoli cells resulting in PTM-
ARKO males being infertile [52]. Alongside this, some Leydig cells within the PTM-ARKO testis 
were also found to be unable to fully differentiate into adult Leydig cells further illustrating 
the importance of paracrine signalling in somatic cell function [124]. A Leydig cell AR knock 
out (LC-ARKO) revealed that AR was dispensable for the attainment of normal Leydig cell 
numbers but is vital for the functional maturation of the adult Leydig cell population. Unlike 
other testicular cell specific ARKO models, the LC-ARKO males were still fertile in early 
adulthood (post-natal day 80), however, when left to age further, wide spread loss of germ 
cells became increasingly apparent, suggesting that Leydig cell AR activity may (whether it be 
directly or indirectly) have a protective role throughout the cycle of spermatogenesis within 
the seminiferous tubules [108].  
These testicular cell specific androgen receptor knock models were all generated using 
Cre/Lox P technology. In each of the models, the promoter driving Cre expression was active 
early in testicular development, allowing the investigation of the roles of AR throughout 
development. However, this made investigating the role of AR in the adulthood difficult as it 
was impossible to determine whether impacts are a result of perturbed testicular 
development or due to disrupted AR signalling specifically in adulthood. To circumvent this, 
one study introduced Cre expressing lentiviral vectors into the seminiferous tubules of AR 
floxed mice to generate an adult SC-ARKO model. In doing so, it became possible to dissect 
the roles of AR specifically in adult Sertoli cells and, due to the evident germ cell arrest during 
meiosis following injection of Cre expressing lentiviral particle, concluded that Sertoli cell AR 
is essential for complete spermatogenesis in the adult testis [45]. 
The number of studies investigating testicular cell specific androgen receptor roles clearly 
indicate that the testicular somatic cells work in concert to maintain steroidogenesis and 
spermatogenesis. However, the interactions between these cell types and the role that AR 
plays in these relationships appears to be complicated and is yet to be fully described as to 
whether these cell types complement or overlap each other’s specific functions and whether 
a loss of AR from more than one cell type would generate an additive phenotypic effect. 
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4.2 Hypothesis & Aims 
4.2.1 Hypothesis 
Given the previously published findings on the roles of somatic cell AR expression in testicular 
function, it is hypothesised that loss of AR from both the Sertoli and Leydig cells will have a 
significant impact on adult testis function. Furthermore, the generation of this model will 
allow a comparison to both single and double somatic cell ARKOs to give further insight into 
the roles of AR on these specific cell types. Finally, analysis of this model, in context with the 
other cell specific ARKO models available will help to gain a wider perspective of AR signalling 
in the testis and allow the most suitable ARKO model for gene rescue to be identified. 
4.2.2 Aims 
From this hypothesis, a number of aims were established: 
Aim 1: To establish the expression pattern of a recently published Aromatase-iCre using a 
fluorescent reporter mouse. 
Aim 2: To generate and validate a Sertoli and Leydig cell AR knock out using the Aromatase-
iCre for both the study of AR signalling in the testis and in context with previously generated 
single and double somatic cell AR knock outs. 
Aim 3: To identify the most suitable cell specific ARKO model to determine the potential for 
lentiviral transgene delivery in the adult testis.   
4.2.3 Approach 
To achieve the aims described, single and double testicular somatic cell specific AR knock 
outs were generated as described in section 2.1.3.3. Tissue was collected at adulthood 
between pnd80-100 and compared to the wild type littermate controls of each respective 
cell-specific ARKO model.  
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4.3.1 Androgen Receptor Expression in the Adult Testis 
Immunostaining for AR shown in Figure 4.1 illustrates the expression of AR by Sertoli cells, 
Peritubular Myoid cells and Leydig cells (and lack thereof in the germ cell populations) in the 
adult testis. 
 
Figure 4.1 Expression of AR in a wild type Testis. Immunostaining for Androgen Receptor (AR) in a 
wild type testis reveals expression of AR in Sertoli cells (closed arrows), peritubular Myoid Cells (open 
arrows) and Leydig cells (open arrow heads). A Blood vessel (BV) in the interstitial compartment can 
also be seen to express AR. Scale Bar = 50µm. 
4.3.2 Generation of Conditional YFP Reporter Line using the 
Aromatase Cre 
The suitability of the Aromatase-Cre for targeting Sertoli and Leydig cells was first 
established. 
4.3.2.1 Characterisation of Aromatase Cre Expression using the 
Reporter 
To characterise the expression of Cre recombinase driven by the human CYP19/Aromatase 
promoter, mice positive for the Aromatase-iCre were mated to yellow fluorescent protein 
(YFP) reporter mice (described in 2.1.3.2) and offspring was collected at differing age points 
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through development and into adulthood. The constructs used to generate the Aromatase-
Cre   mice used in these studies [17]  contained two response elements, a steroidogenic factor 
1- (SF1)- site and a CRE-like sequence binding CREB protein, critical for cyclic AMP induction 
of the human CYP19/Aromatase promoter known to be active in the testis and ovary; 
specifically within the somatic cells [462]. Double fluorescent immunostaining for YFP and 
HSD3β reveal Cre-mediated YFP expression in the Sertoli cells from postnatal day 0 and 
within the Leydig cells from postnatal day 18 (Figure 4.2A). YFP expression appeared to be in 
the majority of Sertoli cells at pnd100, though this was not confirmed with stereological 
methods. Quantification of YFP and HSD3β double positive cells in the testis at these different 
age points reveal that YFP expression continued to increase throughout testis development 
in 24.78% of the total Leydig cell population at postnatal d100 (Figure 4.2B). This suggests 
that the CYP19/Aromatase promoter activity may be activated early in Leydig cell 
development in progenitor Leydig cells (from postnatal day 10) and expression of YFP is 
subsequently being inherited following Leydig cell proliferation during the pubertal period, 
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Figure 4.2 Analysis of Aromatase-iCre expression using a YFP reporter.  (A) Immunostaining for yellow 
fluorescent protein (YFP; green) and hydroxysteroid dehydrogenase 3-beta (HSD3β; red) illustrate 
expression of Aromatase-iCre at different stages of testicular development. Blue open arrowheads 
identify areas of co-localisation, signifying expression of Aromatase-iCre in Leydig cells. YFP expression 
was also detected in the majority of Sertoli cells within the tubules. Scale Bars: 50µm. (B) 
Quantification of YFP+ HSD3β+ cells revealed an increase in cells positive for YFP as animals aged to 
pnd100. Kruskal-Wallis one-way ANOVAs were performed followed by a Dunn’s multiple comparison 
testis to determine differences between groups (** denotes p=<0.01). Bars represent mean ±SEM. 
(pnd0: n=3, pnd18: n=2, pnd35: n=4, pnd50: n=3, pnd100: n=4).  
4.3.3 Androgen Receptor Knock out in the Somatic cells of the 
Testis 
Single and double testicular somatic cell specific AR knock out models were generated to 
explore the roles of AR expressed by the different testicular somatic cell types in adulthood 
and for the identification of suitable cell specific ARKO model for repair/rescue. To do so, 
adult males collected at around 3 months of age (pnd 80 - 100) were used from each of the 
ARKO models for analysis. 
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4.3.3.1 Generation of double and single cell AR knock out models 
using smMHC-eGFP/Amh-Cre and Aromatase-Cre 
Single and double testicular somatic cell specific AR knock outs were generated as described 
in section 2.1.3.3. Using the Aromatase-iCre (of which the expression in the testis was 
characterised in 4.3.2.1), a double somatic cell knock out in both Sertoli (from pnd 0, though 
AR is not present in mouse Sertoli cells until around pnd 4 [464]) and Leydig cells (from as 
early as pnd 18) was generated (Figure 4.4A). PCR amplification of genomic DNA isolated 
from ear clips of these animals demonstrate the inheritance of the iCre (390bp band) 
alongside the internal positive control gene interleukin 2 (324bp band) (Figure 4.4B). This 
ARKO model will be referred to as the SC-LC-ARKO model from this point onwards. 
Littermates negative for iCre will also be referred to as either WT or WT littermates 
depending on the models being included in the analysis. 
 Animals deriving from the breedings using a smMHC-eGFP-Amh-Cre (illustrated in Figure 
4.4C) generated offspring with AR knocked out in Sertoli cells (SC-ARKO), peritubular myoid 
cells (PTM-ARKO) or both Sertoli and peritubular myoid cells (SC-PTM-ARKO), thus generating 
both single and double testicular somatic cell AR knock outs as well as Cre negative (WT) 
littermates within one generation of offspring. The smMHC-eGFP/Amh-Cre is a combination 
of the smMHC-eGFP-Cre and the Amh-Cre, both of which have been characterised and 
utilised previously and published in the literature [48, 52, 60, 124, 429, 465]. Genotyping of 
these offspring confirmed Cre inheritance with PCR amplification of a 239bp product in SC-
ARKOs, a 264bp product in PTM-ARKOs and both a 239bp and a 264bp product in SC-PTM-
ARKO animals (Figure 4.4D). All lanes (except that of the water/no template control) also 
revealed the 324bp band representative of the internal positive control gene; interleukin 2 
(Figure 4.4D). Genotyping was performed by technical staff in Professor Lee Smith’s group, 
Centre for Reproductive Health, University of Edinburgh.  
For a wider perspective on the impacts of single and double somatic cell ARKO, complete 
ARKO and LC-ARKO animals [108] were represented alongside SC-ARKO, SC-PTM-ARKO and 
the SC-LC-ARKO models. Where appropriate, WT littermate controls have been combined in 
analyses to aid comparisons between cell specific ARKO models. Time points at which Cre 
recombinase activity can be detected in each of the lines, as well as the time point of AR 
expression in each of the somatic cell types is represented in Figure 4.3.  
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Figure 4.3 Cre Activity in lines used to generate cell specific ARKO models. Schematic representing 
the age points at which Cre is active in each of the lines used to generate the single and double somatic 
cell ARKO models. Cre activity in a cell type is indicated by schematic drawing of that cell type. Also 
represented is the point at which AR is expressed in a WT mouse testis in Leydig cells (LC-AR), 
peritubular myoid cells (PTM-AR) and Sertoli cells (SC-AR). 
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Figure 4.4 Generation of Single and Double Somatic cell Androgen Receptor Knock Out using 
Aromatase-iCre and smMHC-eGFP-Amh-Cre.  (A) Generation of animals with a loss of AR in both 
Sertoli and Leydig cells (SC-LC-ARKO). (B) PCR analysis of genomic DNA isolated from WT littermate 
controls and SC-LC-ARKO ear clips. Bands at 330bp are representative of the Interleukin-2 internal 
positive control. Bands at 400bp indicate inheritance of Aromatase-iCre. No inheritance of Aromatase-
iCre was detected in WT littermate and Negative controls. No amplification of DNA was detected in 
Water controls. (C) Schematic illustrating the breeding strategy to generate animals with a loss of AR 
in Sertoli cells (SC-ARKO), peritubular myoid cells (PTM-ARKO) or both (SC-PTM-ARKO). (D) PCR 
analysis of genomic DNA isolated from WT littermate controls, SC-ARKO, PTM-ARKO and SC-PTM-
ARKO ear clips. Bands at 324bp are representative of the Interleukin-2 internal positive control. Bands 
at 239bp and/or 264bp indicates inheritance of Amh-Cre and/or smMHC-eGFP-Cre respectively. No 
inheritance of Amh-Cre or smMHC-eGFP-Cre was detected in WT littermate and Negative controls. No 
amplification of DNA was detected in Water controls 
Table 4.1 Table describing ARKO models, Cre lines used to generate and the nomenclature used to 
reference each model. 
ARKO Model Cre Lines Used Nomenclature 
Sertoli cell Androgen 
Receptor knock out Amh-Cre SC-ARKO 
Peritubular myoid cell 
Androgen Receptor knock out smMHC-eGFP-Cre PTM-ARKO 
Leydig cell Androgen Receptor 
knock out Fabp4-Cre LC-ARKO 
Sertoli and Peritubular myoid 
cell Androgen Receptor knock 
out 
smMHC-eGFP/Amh-Cre SC-PTM-ARKO 
Sertoli and Leydig cell 
Androgen Receptor knock out Aromatase-iCre SC-LC-ARKO 
 
 
4.3.3.2 Gross Morphology of Sertoli and Leydig cell double AR 
knock out alongside other ARKO models 
Lack of Androgen signalling, whether through a knockout of androgen receptor or as a result 
of a mutation in androgen receptor, results in a feminised phenotype; including a reduction 
in overall body weight and feminised external genitalia.  In contrast to the complete ARKO 
models, all single and double somatic cell ARKOs exhibited no differences in body weight in 
adulthood relative to WT controls (Figure 4.5A). However, anogenital distance (an indicator 
of androgen exposure during development) in PTM-ARKO and SC-PTM-ARKO was 
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significantly reduced (Figure 4.5B), suggesting a disruption in androgen signalling in the male 
reproductive tract during foetal development in these models.  
Previously published studies using SC-ARKO, PTM-ARKO and LC-ARKO mice reported 
significant reductions in testis weight. As expected, this was also clearly evident upon 
dissection and following testis weight recording for both SC-PTM-ARKO testis (75.75% 
reduction) and SC-LC-ARKO (68.17% reduction), compared to their respective controls 
(Figure 4.5C&D). This would suggest that the cellular composition of testis in both double 
somatic cell ARKOs has been compromised as a result of the disrupted androgen signalling.  
Cross sections of each of the somatic cell ARKO models illustrates the modifications in 
testicular histology as a result of AR loss. In particular the absence of elongated spermatids 
and loss of lumens in seminiferous tubules in both SC-PTM-ARKO and SC-LC-ARKO models 
mirroring that seen in both SC-ARKO and PTM-ARKO testis. Immuno-localisation of AR 
confirms a loss of AR expression in Sertoli and peritubular myoid cells in the SC-PTM-ARKO 
testis as well as some AR loss in Leydig cells in these testis. In SC-LC-ARKO, AR is seen to be 
lost in Sertoli cells and a proportion of Leydig cells, as expected. 
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Figure 4.5 Gross Morphology of Adult Single and Double Somatic cell ARKOs.  (A) Body weights of SC-
ARKO (n= 19), PTM-ARKO (n= 15), LC-ARKO (n= 3) SC-PTM-ARKO (n= 12) and SC-LC-ARKO (n= 11) in 
comparison to the WT controls (n= 4-23) of each respective ARKO model. (B) Measurements of 
Anogenital Distance (AGD) of SC-ARKO (n= 19), PTM-ARKO (n= 15), LC-ARKO (n= 8), SC-PTM-ARKO (n= 
11) and SC-LC-ARKO (n= 11) in comparison to the WT controls (n= 7-23) of each respective ARKO 
model. (C) Photographs of SC-ARKO, PTM-ARKO, SC-PTM-ARKO and SC-LC-ARKO and respective WT 
controls at dissection. (D) Testis weights of SC-ARKO (n= 19), PTM-ARKO (n= 15), SC-PTM-ARKO (n= 
12) and SC-LC-ARKO (n= 11) in comparison to the WT controls (n= 7-23) of each respective ARKO 
model. Bars represent mean ±SEM. For measurements of SC-ARKO, PTM-ARKO and SC-PTM-ARKO, 
Kruskal-Wallis one-way ANOVAs were performed followed by a Dunn’s multiple comparison tests to 
determine differences between groups. T-tests were used for WT vs LC-ARKO and WT vs SC-LC-ARKO 
measurements. (** denotes p=<0.01, *** denotes p=<0.001 and **** denotes p=<0.0001). Collection 
of tissue, measurements and staining’s were performed by Mr Martin O’Neil (SC-ARKO, PTM-ARKO, 
SC-PTM-ARKO), Dr Laura O’Hara (LC-ARKO) and Annalucia Darbey (SC-LC-ARKO).  
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Figure 4.6 Testicular Histology of Single and Double Somatic cell ARKOs in Adulthood. (A) 
Representative H&E stained and (B) AR immuno-staining of   testis sections from SC-ARKO, PTM-ARKO, 
LC-ARKO, SC-PTM-ARKO and SC-LC-ARKO adjacent to their respective WT littermate controls. (Open 
arrow = Sertoli cell with AR loss, closed arrow = Peritubular myoid cell with AR loss, open arrow heads 
= Leydig cell with AR loss – Note loss of AR from Leydig cells in PTM-ARKO and SC-PTM-ARKO testis) 
Scale Bars = 20µm.  
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4.3.3.3 Impacts of double somatic cell AR knockout on Sertoli Cells 
in Adult Testis 
Quantification of AR in Sertoli cells confirmed a significant reduction of Sertoli cell AR 
expression in both SC-PTM-ARKO and SC-LC-ARKO (Figure 4.7A), resulting in a reduction in 
tubule diameter in both SC-PTM-ARKO and SC-LC-ARKO testis compared to their respective 
controls, suggesting a disruption in Sertoli cell functions such as support of germ cell 
development and secretion of fluid essential for support of germ cells and lumen formation 
(Figure 4.7B).  
Signalling of androgens through Sertoli cell AR has been shown to be essential for progression 
of spermatogenesis past meiosis, potentially as a result of improper formation of the blood 
testis barrier (BTB) and reduced Sertoli cell fluid secretion into the lumen of the seminiferous 
tubules; reducing delivery of crucial factors necessary to support spermatogenesis [25, 48]. 
Alongside this, peritubular myoid cell AR has also been shown to impact Sertoli cell function 
with expression of Sertoli cell specific gene products being reduced in PTM-ARKO testis [52]. 
As seen in SC-ARKO and PTM-ARKO publications, the organisation of the seminiferous 
tubules appears to be disrupted in SC-PTM-ARKO and SC-LC-ARKO testis with 
immunolocalization of Sry box-9 (Sox9) demonstrating loss of polarity of the Sertoli cell at 
the basement membrane (Figure 4.7C) . The lack of polarity has been shown to influence the 
presence of germ cells in the seminiferous tubules due to impact on Sertoli cell functioning, 
reportedly via AR mediated peritubular myoid cell signalling. The disorganisation present in 
SC-PTM-ARKO and SC-LC-ARKO testis, would indicate that it may be a collaborative effort 
between these two major cell types that are influencing Sertoli cell positioning in the tubules 
(Figure 4.7C). 
Expression of Sertoli cell specific genes Desert hedgehog (Dhh) (known to be implicated in 
proper germ cell development) and Aquaporin-8 (Aqp8) (a transmembrane water channel 
protein believed to be essential for regulation of water homeostasis in a cell [466] and 
recently confirmed to be Sertoli cell specific [467]) were analysed to give an indication as to 
the impacts of double somatic cell ARKO on Sertoli cell function. Analysis of Dhh mRNA 
expression revealed a significant reduction in expression in SC-PTM-ARKO but not SC-ARKO, 
PTM-ARKO and SC-LC-ARKO testis (Figure 4.7D). This would suggest that AR signalling 
through either directly through Sertoli cell AR or indirectly through peritubular myoid cell AR 
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is sufficient to maintain Dhh expression in Sertoli cells. Aqp8 expression was also significantly 
reduced in all cell specific ARKOs  excluding LC-ARKO (Figure 4.7E), suggesting that Leydig cell 
AR expression, has no impact on the fluid production functions of Sertoli cells, but that both 
Sertoli and peritubular myoid cell signalling are crucial for this role.  
The Sertoli cell has a wide range of roles in both the spermatogenic and steroidogenic 
functions of the adult testis [5, 7, 9] and together these results indicate that AR expression, 
in particular in both Sertoli and peritubular myoid cells, may be involved orchestrating some 
of these functions; namely in supporting spermatogenesis and in the development of a lumen 
within the seminiferous tubules.  
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Figure 4.7 Impacts of double somatic cell ARKO on Sertoli cell function in the adult testis.  (A) SC-AR 
expression in SC-ARKO (n= 5), PTM-ARKO (n= 6), SC-PTM-ARKO (n= 5) and SC-LC-ARKO (n= 7) and WT 
controls (n= 5-8). For measurements of SC-ARKO, PTM-ARKO and SC-PTM-ARKO, Kruskal-Wallis one-
way ANOVAs were performed followed by a Dunn’s multiple comparison testis to determine 
differences between groups. For WT vs SC-LC-ARKO comparisons, a Mann Whitney U-test was used. 
(** denotes p=<0.01, *** denotes p=<0.001 and **** denotes p=<0.0001). (B) Tubule Diameters (µm) 
in SC-ARKO (n= 5), PTM-ARKO (n= 5), SC-PTM-ARKO (n= 5), LC-ARKO (n= 4) and SC-LC-ARKO (n= 8) 
testis compared to respective WT controls (n= 5-7) (SC-ARKO, PTM-ARKO and SC-LC-ARKO testis were 
analysed for statistical differences compared to WT littermates using a one-way ANOVA followed by a 
Dunnet’s multiple comparisons test, LC-ARKO testis; using an unpaired t-test and SC-LC-ARKO testis; 
using a Mann Whitney U-test). Bars represent mean ±SEM. (** denotes p<0.01 and **** denotes 
p=<0.0001). (C)Representative immunostaining of Sry box-9 (Sox9) WT, SC-ARKO, PTM-ARKO, LC-
ARKO, SC-PTM-ARKO and SC-LC-ARKO testis sections. Arrows indicate Sox9 positive cells located away 
from the basement membrane of the seminiferous tubule.  Scale Bars = 50µm mRNA expression of SC 
specific genes; (D) Desert hedgehog (Dhh) (one-way ANOVA followed by a Tukey’s multiple 
comparisons test) and (E) Aquaporin 8 (Aqp8) (Kruskal-Wallis followed by a Dunn’s multiple 
comparison test) in WT (n= 23), SC-ARKO (n= 9), PTM-ARKO (n= 7), LC-ARKO (n= 8), SC-PTM-ARKO (n= 
8) and SC-LC-ARKO (n= 5) adult testis. Bars represent mean ±SEM. (* denotes p<0.05 and **** denotes 
p=<0.0001). Measurements, staining’s and qRT-PCR was performed by Mr Martin O’Neil (SC-ARKO, 
PTM-ARKO, SC-PTM-ARKO), Dr Laura O’Hara (LC-ARKO) and technical staff from Professor Lee Smiths 
group (SC-LC-ARKO). Analysis was performed by Annalucia Darbey. 
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4.3.3.4 Impacts of double cell AR knockout on Peritubular Myoid 
cells in Adult Testis 
Peritubular myoid cells surround each of the seminiferous tubules and are known to be 
involved in the movement of tubular fluid aiding in the transport of spermatozoa within the 
tubules. Peritubular myoid AR signalling has been shown to have a significant impact on 
Sertoli cell function with a reduction in seminiferous tubule fluid, spermatogenesis and 
androgen dependant genes being reported in a PTM-ARKO testis [52]. However, it is unclear 
as to whether other testicular somatic cell AR have an impact on peritubular myoid cell 
function. Analysis of peritubular myoid cell specific genes, Desmin and Endothelin-1 (END1) 
revealed a significant reduction in peritubular myoid cell function as a result of ARKO in PTM 
cells alone and in both Sertoli and peritubular myoid cells but not in other single somatic cell 
ARKOs (Figure 4.8 A&B). This would indicate that these genes and their downstream effects 
are being regulated through autocrine actions of AR on the peritubular myoid cells. 
Conversely, Smooth Muscle Actin (SMA) expression was also analysed and was found to be 
significantly reduced in SC-PTM-ARKO but not in PTM-ARKO testis alone (Figure 4.8C). This 
could suggest some influence of Sertoli cell on SMA expression and the main contractile 
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Figure 4.8  Impacts of single and double somatic cell ARKO on PTM cell function.   Expression of PTM 
cell specific transcripts; (A) Desmin, (B) END1 and (C) SMA. Kruskal-Wallis one-way ANOVAs were 
performed followed by a Dunn’s multiple comparison test to determine differences between groups. 
T-tests were used for WT vs LC-ARKO and WT vs SC-LC-ARKO measurements. (** denotes p=<0.01 and 
*** denotes p=<0.001). Bars represent mean ±SEM. Between 6 and 22 animals for each of the groups 
were used in each of the animals. qRT-PCR was performed by Mr Martin O’Neil (SC-ARKO, PTM-ARKO, 
SC-PTM-ARKO), Dr Laura O’Hara (LC-ARKO) and technical staff from Professor Lee Smiths group (SC-
LC-ARKO). Analysis was performed by Annalucia Darbey. 
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4.3.3.5 Impacts of double cell AR knockout on Leydig Cells in Adult 
Testis 
The development of a complete adult Leydig cell population in the testis has been suggested 
to be dependent upon androgen signalling through Sertoli cell AR, with a reduction in adult 
Leydig cell numbers being reported in a SC-ARKO model [101]. In the present study, Leydig 
cell numbers were also all found to be significantly reduced in SC-LC-ARKO testis but 
surprisingly not in SC-PTM-ARKO testis (Figure 4.9). Quantification of Leydig cell AR revealed 
that the percentage of Leydig cells expressing AR was significantly reduced in SC-PTM-ARKO 
and SC-LC-ARKO testis, suggesting there may be some regulation of AR expression by other 
somatic cells of the testis (Figure 4.9). Surprisingly, despite the Aromatase-iCre targeting up 
to 24.78% of Leydig cells at postnatal d100 (as described in section 4.3.2.1), a 45% reduction 
in Leydig cell AR was observed compared to WT littermate controls, demonstrating that 
Leydig cell AR may also be regulating its own expression in an autocrine manner. 
 
Figure 4.9 Impact of single and double somatic cell ARKO on Leydig cell number and LC-AR 
expression (full caption on following page).  
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Figure 4.9 Impact of single and double somatic cell ARKO on Leydig cell number and LC-AR 
expression (full caption). Leydig cell numbers (Green bars) in SC-ARKO (n= 5), PTM-ARKO (n= 5) and 
SC-PTM-ARKO (n= 5) compared to WT controls (n= 5) (Kruskal-Wallis one-way ANOVA followed by a 
Dunn’s multiple comparison test) and SC-LC-ARKO (n= 7) compared to WT controls (n= 7) (Unpaired t-
test) and Leydig cell AR expression (Grey/Green striped bars) in SC-ARKO (n= 4), PTM-ARKO (n= 10) 
and SC-PTM-ARKO (n= 5) compared to WT controls (n= 5) (One-way ANOVA followed by Dunnet’s 
multiple comparisons test) and SC-LC-ARKO (n= 7) compared to WT controls (n= 7) (Unpaired t-test). 
Bars represent mean ±SEM. (* denotes p<0.05, ** denotes p<0.01 and **** denotes p=<0.0001). 
Quantification was performed by Mr Martin O’Neil (SC-ARKO, PTM-ARKO, SC-PTM-ARKO), Dr Laura 
O’Hara (LC-ARKO) and Annalucia Darbey (SC-LC-ARKO). Analysis was performed by Annalucia Darbey. 
The adult Leydig cell are primarily responsible for the production of testosterone from its 
precursor cholesterol. Therefore, to gain insight into the functioning of the adult Leydig cells 
in the double somatic cell ARKO testes, steroidogenic enzyme mRNA expression was analysed 
(Figure 4.10). For the conversion of cholesterol to testosterone, cholesterol must first be 
synthesised. The rate limiting enzyme for this process is encoded by the gene Hmgcr1. This 
enzyme was significantly reduced in SC-PTM-ARKO testis indicating that in these testes there 
may be a reduction in the production of starting product required for steroidogenesis (Figure 
4.10A). Transcript levels of Star were found to be significantly increased in LC-ARKO only, 
indicating that Leydig cell AR regulates this in an autocrine manner (Figure 4.10B). No 
significant differences were found in Cyp11a1 transcript expressions, indicating that AR 
signalling may not be required for the expression of this steroidogenic enzyme (Figure 4.10C). 
Interestingly, mRNA expression of Hsd3b1, the gene encoding 3beta-hydroxysteroid 
dehydrogenase-1 (HSD3B1); the enzyme responsible for conversion of pregnenolone to 
progesterone and marker of foetal Leydig cells, was significantly increased in both single and 
double somatic cell ARKOs involving peritubular myoid cell and Leydig cell AR. In particular, 
expression of Hsd3b1 mRNA in PTM-ARKO and SC-PTM-ARKO testis was over 40 and 38 fold 
respectively when compared to wild-type litter mate control testis (Figure 4.10D).  This would 
suggest that Leydig and peritubular myoid cell AR could be negatively regulating Hsd3b1 
mRNA expression in the adult WT testis. Cytochrome P450 17a1 (CYP17A1) is the enzyme 
responsible for the conversion of progesterone and subsequently 17α-hydroxyprogesterone 
to androstenedione. In the double somatic cell ARKO; SC-PTM-ARKO, expression of Cyp17a1 
mRNA is significantly reduced in the testis when compared to wild type littermate control 
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testis (Figure 4.10E).  The gene encoding the enzyme responsible for the final conversion of 
androstenedione to testosterone, Hsd17b3 was also significantly lower in SC-PTM-ARKO 
testis compared to WT littermate control testis (Figure 4.10F). Therefore, despite a potential 
increase of progesterone (like that reported in LC-ARKO testis following increased expression 
of Hsd3b1), this may not result in an increased conversion of steroidogenic compounds 
downstream as a result of the requirement of AR signalling to regulate the expression of 
genes encoding downstream steroidogenic enzymes. 
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Figure 4.10 Expression of Steroidogenic enzyme transcripts in single and double somatic cell ARKOs. 
mRNA expression of (A) HMGCR1, (B) Star, (C) Cyp11a1, (D) Hsd3β1, (E) Cyp17a1 and (F) Hsd17B3 in 
SC-ARKO, PTM-ARKO, LC-ARKO, SC-PTM-ARKO and SC-LC-ARKO adult testis. A, B, D and E were 
analysed for statistical differences using a one-way ANOVA followed by a Tukey’s multiple 
comparisons test. D and F we analysed for statistical differences using a Kruskal-Wallis one-way 
ANOVA followed by a Dunn’s multiple comparison test. Bars represent mean ±SEM. (* denotes p<0.05, 
** denotes p<0.01 and **** denotes p=<0.0001). Between 6 and 24 animals for each of the groups 
were used in each of the animals. qRT-PCR was performed by Mr Martin O’Neil (SC-ARKO, PTM-ARKO, 
SC-PTM-ARKO), Dr Laura O’Hara (LC-ARKO) and technical staff from Professor Lee Smiths group (SC-
LC-ARKO). Analysis was performed by Annalucia Darbey. 
With a disturbance at some key stages of the steroidogenic pathway in SC-PTM-ARKO testis, 
it could be expected that circulating serum testosterone levels may differ in comparison to 
WT littermate controls. The seminal vesicle weight (a biomarker of system androgen action) 
was significantly reduced in SC-PTM-ARKO, indicative of circulating low androgens/androgen 
signalling (Figure 4.11A). However, analysis of serum hormone levels revealed that this did 
not seem to be the case with both circulating testosterone and circulating LH levels in SC-
PTM-ARKO and SC-LC-ARKO animals being comparable to controls (Figure 4.11B&C). The 
reduction in seminal vesicle weight in PTM-ARKO mice has previously been reported in the 
literature and was attributed to the smMHC-eGFP-Cre also targeting the smooth muscle 
located within the seminal vesicle, impacting the secretory function of the seminal vesicle as 
well as its response to androgens [465]. As the SC-PTM-ARKO was also generated using the 
smMHC-eGFP-Cre, this reasoning can transferred when considering the reduction in seminal 
vesicle weight seen in these animals.  
Interestingly, the intratesticular testosterone (iTT) levels in SC-PTM-ARKO and SC-LC-ARKO 
testis was significantly greater than their respective WT controls (Figure 4.11D), suggesting 
that there may be an overproduction and/or accumulation of testosterone within these 
double somatic cell ARKO testis. The reasoning behind this is currently unclear, though 
observations in a previously published PTM-ARKO model revealed an accumulation of lipids 
within ‘abnormal’ Leydig cells,. In our double somatic cell ARKOs, the greater impact on AR 
signalling (particularly as the SC-PTM-ARKO also has significant reductions in Leydig cell AR 
expression) may result in this build-up of testosterone within the testis, though this still 
remains to be fully explored.  
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Figure 4.11 Impacts of single and double somatic cell ARKO on Circulating and Intratesticular 
Hormone Parameters in Adulthood. (A) Serum Luteinising Hormone (LH) and (B) Serum testosterone 
levels in adult SC-ARKO (n= 5), PTM-ARKO (n= 6-7), SC-PTM-ARKO (n= 6), LC-ARKO (n= 6-7) and SC-LC-
ARKO (n= 8-10) normalised to respective WT controls (n= 9-12). (C) Seminal Vesicle (SV) weight in WT 
(n= 7-23), SC-ARKO (n= 19), PTM-ARKO (n= 15), SC-PTM-ARKO (n= 12), LC-ARKO (n= 14) and SC-LC-
ARKO (n= 11) (A, B & C: SC-ARKO, PTM-ARKO and SC-PTM-ARKO were analysed for statistical 
differences compared to WT littermate controls using a Kruskal-Wallis one-way ANOVA followed by a 
Dunn’s multiple comparisons test, LC-ARKO and SC-LC-ARKO were analysed for statistical differences 
compared to WT controls using unpaired t-testis). (D) Intratesticular testosterone (iTT) levels in adult 
SC-ARKO (n= 5), PTM-ARKO (n= 7), SC-PTM-ARKO (n= 3), LC-ARKO (n= 7) and SC-LC-ARKO (n= 8) 
normalised to respective WT (n= 7-13) controls. (SC-ARKO, PTM-ARKO and SC-LC-ARKO testis were 
analysed for statistical differences compared to WT littermates using a one-way ANOVA followed by a 
Dunnet’s multiple comparisons test, LC-ARKO testis; using an unpaired t-test and SC-LC-ARKO testis; 
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using a Mann Whitney U-test). Bars represent mean ±SEM. (* denotes p<0.05 and ** denotes p<0.01). 
Dotted red line is representative of 1/WT values to which each model has been normalised.  
Finally, in previous LC-ARKO studies, Leydig cell AR was found to be essential for Leydig cell 
maturation and functioning. Expression of mRNA and detection using immunohistochemistry 
revealed that Insulin like 3 (Insl3); a marker for Leydig cell maturation, was significantly 
reduced in SC-PTM-ARKO testis comparable to that seen in previously published PTM-ARKO 
and LC-ARKO studies [108, 124] (Figure 4.12). Surprisingly, this wasn’t the case in SC-LC-ARKO 
testis with a no reduction in Insl3 mRNA expression and patchy expression of Insl3 in SC-LC-
ARKO testis sections (Figure 4.12A&C). This indicates that, despite a significant reduction in 
Leydig cell AR (Figure 4.9) the majority of Leydig cells underwent maturation as normal in the 
SC-LC-ARKO testis. Furthermore, mRNA expression of the gene encoding the steroidogenic 
enzyme 3beta-hydroxysteroid dehydrogenase-6 (HSD3β6) was significantly reduced in LC-
ARKO testis as previously reported but not in SC-LC-ARKO testis when compared to wild type 
littermate controls (Figure 4.12B). Taken together with the results in Figure 4.9, these results 
suggest that a threshold of Leydig cell AR expression is required in order for proper Leydig 
cell maturation to occur.  
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Figure 4.12 Leydig cell maturation in adult single and double somatic cell ARKO mice. mRNA 
transcript expression of Leydig cell maturation markers (A) Insl3 and (B) Hsd3b6 in WT, SC-ARKO, PTM-
ARKO, LC-ARKO, SC-PTM-ARKO and SC-LC-ARKO testis. Kruskal-Wallis one-way ANOVAs were 
performed followed by a Dunn’s multiple comparison testis to determine differences between groups. 
Bars represent mean ±SEM. (* denotes p<0.05, ** denotes p<0.01, *** denotes p=<0.001). (C) 
Immuno-staining of INSL3 in SC-ARKO, PTM-ARKO, SC-PTM-ARKO, LC-ARKO and SC-LC-ARKO testis 
alongside respective WT controls. (Arrows indicate INSL3 negative Leydig cells). Scale Bars = 100µm. 
qRT-PCR and staining’s were performed by Mr Martin O’Neil (SC-ARKO, PTM-ARKO, SC-PTM-ARKO), 
Dr Laura O’Hara (LC-ARKO) and technical staff from Professor Lee Smiths group (SC-LC-ARKO). Analysis 
was performed by Annalucia Darbey. 
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4.3.3.6 Schematic of AR roles in Adult Testis Function 
The generation of double somatic cell ARKO models have provided further insight into the 
roles of AR in both the steroidogenic and spermatogenic functions of the testis. The 
schematic denoted as Figure 4.13 illustrates some of the roles of somatic cell AR on testicular 
somatic cell functions including those in which more than one somatic cell AR may be 
involved in supporting that function, resulting in an ‘additive’ effect when knocked out from 
more than one cell type. 
 
Figure 4.13 Androgen receptor mediated functions in the adult mouse testis. Schematic of AR 
medicating signalling in the adult testis and the roles of specific somatic cell AR in these processes. 1 
– Seminiferous tubule lumen development and maintenance. 2 – SC polarity/ seminiferous tubule 
organisation. 3 – Peritubular myoid cell contractility. 4 – Leydig cell Maturation. 5 – Leydig cell AR 
expression. 6 – Steroidogenesis in Leydig cells. 7 – Secretion of testosterone from testis.  
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Testicular somatic cell expression of AR has been shown to be crucial for proper functioning 
of the adult testis. The overarching aims of this chapter were to generate a model that could 
be used to determine the practical uses of the viral vector injection protocols established in 
the preceding chapter. Alongside this, the model would also function as a comparator to 
single and double somatic cell ARKOs that have previously been generated. Each of the single 
somatic cell ARKOs; SC-ARKO [6, 24, 48, 101], PTM-ARKO [52, 124] and LC-ARKO [108], have 
been published in the literature. A double somatic cell ARKO in Sertoli and peritubular myoid 
cells (SC-PTM-ARKO) was previously generated but not yet published in Professor Lee Smith’s 
group (by Martin O’Neill, Centre for Reproductive Health, Edinburgh).  
To generate an additional ARKO model specifically from the Sertoli and Leydig cells, a recently 
published Aromatase-iCre was obtained from Fumel et al (published in 2015) and first bred 
to a YFP reporter line to determine location and timing of iCre expression in the testis [17]. 
Analysis of YFP expression in the testis revealed YFP expression from post-natal day (pnd) 0 
within Sertoli cells located in the tubular compartment of the testis.  From pnd18, YFP 
expression could be observed in HSD3β positive cells in the interstitial compartment, 
indicating Aromatase-iCre expression in the immature Leydig cells. Quantification of YFP 
expression in the Leydig cells revealed that Aromatase-iCre expression increased as mouse 
age increased up to d100, suggesting either that Aromatase-iCre was being activated as the 
Leydig cells were undergoing maturation or that the Aromatase-iCre was being expressed by 
d18 and subsequent proliferation of the targeted cells (and subsequent inheritance of YFP 
expression in daughter cells) resulted in 24.78% of the Leydig cell population expressing the 
reporter.  
To generate the SC-LC-ARKO animals, Aromatase-iCre males were mated with female mice 
homozygous for a floxed AR, producing animals with AR knocked out in both Sertoli and 
Leydig cells alongside wild type (Cre negative) littermates. Though Leydig cell targeting in this 
model may be relatively low, a SC-LC-ARKO model, generated using the Aromatase-iCre, 
would permit the comparison of adjacent Leydig cells, exposed to the same endocrine and 
paracrine environment (similar to the method practiced in the previously published LC-ARKO 
article), with the added factor of absence of SC-ARKO signalling. Alongside this, archived 
tissue from SC-ARKO, PTM-ARKO and SC-PTM-ARKO (another novel double somatic cell ARKO 
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previously generated, but not yet published), previously collected in the lab, was utilised for 
a side by side comparison, with the goal of providing a more complete picture of AR signalling 
in the adult testis. 
Analysis of the gross phenotype of the double somatic cell ARKO testis revealed similarities 
between the single somatic cell ARKO models with testis weight being significantly reduced 
in comparison to each models respective WT controls. A reduction in testis weight  and tubule 
dimeter may signify a reduction in sperm production and testis function [468-471], H&E 
staining of testis sections revealed striking differences in testicular histology, with both 
double somatic cell ARKO models being comparable to SC-ARKO and PTM-ARKO testis, both 
of which exhibited disrupted spermatogenesis.  
The PTM-ARKO model (generated using the smMHC-eGFP-Cre) and the impacts of PTM-
ARKO on Leydig cell function has previously been published and reports a weak AR signal in 
Leydig cells considered ‘abnormal’ due to impaired development as a result of PTM-ARKO 
[124]. In both PTM-ARKO and SC-PTM-ARKO testis, a high proportion of interstitial cells 
appeared to lack AR expression, suggesting that either peritubular myoid cell AR regulates 
expression of AR in Leydig cells or that the smMHC-eGFP-Amh-Cre was active in some Leydig 
cells and this was something that was taken into consideration when interpreting the 
subsequent data produced.  
Sertoli cells are crucial for the maintenance of testis function in the adult testis with ablation 
of Sertoli cells being shown to impact peritubular myoid cell activity, Leydig cell numbers and 
function, germ cell numbers and in supporting the vasculature system in the testis [5, 7-9]. 
As expected, Sertoli cell AR expression was significantly reduced in SC-ARKO, SC-PTM-ARKO 
and SC-LC-ARKO but not in PTM-ARKO testis, confirming that expression (or lack of) of AR on 
Sertoli cells has no impact on AR expression in other testicular cell types. Androgen signalling 
has been shown to have an impact of final Sertoli cell number, with the total ARKO testis 
having a significant reduction in Sertoli cell nuclear volumes and SC-ARKO testis having a 
small but significant reduction in Sertoli cell nuclear volume at pnd140 [24]. In WT testis, 
Sertoli cell nuclei usually migrates towards the basal region of the seminiferous tubule and 
loss of AR in SC-ARKO, PTM-ARKO, SC-PTM-ARKO and SC-LC-ARKO appeared to impact this, 
as evident from the presence of Sox9+ immunostaining within the centre of seminiferous 
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tubules as opposed to it being restricted to the periphery. The disruption in the organisation 
of the tubules is similar to that seen in the previously published SC-ARKO and PTM-ARKO 
studies and was attributed to altered signalling in peritubular myoid cells and a loss of Sertoli 
cell function with this study also suggesting a role of the paracrine signalling in the testis 
[472]. Similar disruptions to the polarity of Sertoli cells have also been seen in testis with 
Wilms tumour-1 (Wt1) -deficient Sertoli cells. Wt1 and its product WT1 is specifically 
expressed in Sertoli cells and has been shown to be involved in the regulation of Dhh 
expression in the testis [473] and Wt1 deficiency resulted in a down regulation of Wnt 
signalling genes, cell polarity genes, blood testis barrier (BTB) integrity and subsequent germ 
cell loss [474]. The role of the BTB in sustaining Sertoli cell polarity in the seminiferous tubules 
has also been implicated given the loss of Sertoli cell polarity and subsequent loss of the 
Sertoli cell epithelial phenotype seen in mice deficient of Claudin 11, a key junctional protein 
of the BTB [28]   
Desert hedgehog is a intercellular signal transducer secreted by the Sertoli cells with 
receptors (patched 1) found to be located on late primary spermatocytes, secondary 
spermatocytes, round spermatids, peritubular myoid cells and Leydig cells in the adult mouse 
testis and known to have a role in germ cell survival and in steroidogenesis in the adult mouse 
testis [473, 475]. Dhh is significantly reduced in SC-PTM-ARKO testis, but not in SC-ARKO or 
PTM-ARKO testis. This would suggest that Sertoli and peritubular myoid cell may be 
functioning in a synergistic manner through AR signalling.  WT1 has also been shown to bind 
to multiple sites in the AR promoter, resulting in transcriptional repression of AR promoter 
and downregulating androgen responsive genes suggesting that there may be some 
association between WT1, DHH and the paracrine mechanisms involved in AR signalling in 
the adult testis. 
Aquaporin 8, a water channel protein, has been shown to be expressed by Sertoli cells and is 
thought to be involved in the movement of water from the interstitial space into the lumen 
of the seminiferous tubules [467, 476, 477]. Analysis of Aqp8 mRNA expression in all 
testicular cell specific ARKO models, excluding LC-ARKO, revealed a significant reduction of 
expression. This would also suggest that Leydig cells have no influence on the fluid 
production of Sertoli cells, unlike the peritubular myoid cells which appear to be crucial for 
the movement of fluid/water from the interstitial compartment to the luminal compartment. 
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Considering lack of expression of Aqp8 in peritubular myoid cells, is indicative of the 
androgen mediated interactions between Sertoli and peritubular myoid cells.  
Peritubular myoid cells are smooth muscle cells surrounding the seminiferous tubules within 
the testis and are responsible for the contractility and movement of fluid and spermatozoa 
through the testis as well as being crucial for regulating spermatogenesis and steroidogenesis 
[52, 124, 478, 479]. Desmin and SMA are peritubular myoid cell and blood vessel specific 
proteins that are known to play critical roles in the structure and functioning of the 
contractile apparatus in the peritubular myoid cells whereas EDN1 is a protein known to be 
secreted by Sertoli cell with the ability to stimulate peritubular myoid cell contraction [122, 
128, 478, 480]. As previously reported, significant reduction of Desmin was found in PTM-
ARKO testis and in SC-PTM-ARKO revealing that peritubular myoid cells alone are regulating 
the expression of this gene through AR signalling. SMA expression was significantly reduced 
in SC-PTM-ARKO in comparison to wildtype litter mate controls. EDN1 was also significantly 
decreased in both PTM-ARKO and SC-PTM-ARKO testis, indicating that, despite EDN1 being 
a Sertoli cell secreted protein, the expression of EDN1 is still under androgen mediated 
peritubular myoid cell control. The relationship between Sertoli cell and peritubular myoid 
cell functionality has been well documented as peritubular myoid cell functioning is lost in 
the absence of Sertoli cells [7, 52, 481]. The reduced expression of SMA in SC-PTM-ARKO 
testis only is also testament to this, proposing that in SC-ARKO and PTM-ARKO testis, there 
may be some compensation for the loss of AR in one somatic cell type, compensation that 
can’t take place with knock out of AR in both.  
Androgen signalling via Sertoli cells has previously been shown to be essential for the 
development of a full complement of Leydig cells in the testis with the complete ARKO and 
SC-ARKO testis having a significant reduction in Leydig cell number [101, 109] and this 
reduction in Leydig cell was mirrored in SC-LC-ARKO testis. AR expression was found to be 
further reduced than expected in SC-LC-ARKO suggesting that Leydig cell AR may regulate its 
own expression in an autocrine manner.  
The main function of Adult Leydig cell is to produce testosterone from cholesterol through 
the process of steroidogenesis. The loss of AR from both Sertoli and peritubular myoid cells 
results in a reduction of Hmgcr1, Cyp17a1 and 17bhsd3 in the adult testis. Interestingly, 
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expression of HSD3β1, is significantly increased in SC-PTM-ARKO and SC-LC-ARKO; similar to 
the increase also seen in the single somatic cell ARKOS; PTM-ARKO and LC-ARKO. This would 
suggest an increase in the levels of progesterone in the testis; something that was confirmed 
in LC-ARKO testis [108] but would need confirming in the present study. The data could also 
benefit through reporting to the number of Leydig cells reported in the testis of each of the 
knock out models; permitting the examination of enzymatic gene expression per Leydig cell. 
A disruption in steroidogenic enzyme expression, in addition to the reduction in seminal 
vesicle weight in PTM-ARKO and SC-PTM-ARKO animals, would suggest an impact on 
testosterone production. However, this was not the case in any of the ARKO models, with 
serum testosterone and LH levels being comparable to controls in each. One reason for this 
may be, as suggested in O’Hara et al (2015)  that the proposed increase in bioavailability of 
progesterone within the testis may serve as a reservoir from which the residing populations 
of Leydig cells that retain AR expression can utilise for testosterone production. The potential 
relationship between the testicular vasculature and testicular somatic cell types such as the 
Sertoli and peritubular myoid cells has also been described in the literature [8]. With the 
smMHC-eGFP-Cre also reported to target the smooth muscle cells surrounding the 
vasculature [52], coupled with the influence of Sertoli cells on vascular function and retention 
[8], it is possible that AR mediated interactions between these cell types may function in the 
control of secretion of testosterone from the testis through the  vasculature, explaining the 
increase in intra-testicular testosterone in SC-PTM-ARKO and SC-LC-ARKO testis though this 
would benefit from further investigation. 
Insl3 expression was significantly downregulated at both the level of mRNA transcript and 
the protein level in PTM-ARKO, LC-ARKO and SC-PTM-ARKO testis revealing a compromise in 
the maturation of Leydig cells in these testis. Whether this is due to the reduction in Leydig 
cell AR or due to paracrine signals from peritubular myoid cells is still unclear. In the study by 
Welsh et al (2011), this was partly attributed to a reduction in SF-1 expression [124]. Further 
study into the mechanisms controlling SF-1 originating in peritubular myoid cells and 
potentially elsewhere (given the immature Leydig cells present in the LC-ARKO model despite 
peritubular myoid cell function remaining intact) would be beneficial alongside investigation 
into the roles of IGF-1 (given its role in Leydig cell development and maturation) [85, 86, 482]. 
The roles of FSHR in Leydig cell maturation in cell specific ARKO models may also prove 
interesting due to the link between FSHR signalling and Leydig cell development alongside 
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the potential AR mediated expression of metastasis-associated protein 2 (MTA2) in Sertoli 
cells and its role in FSHR expression in Sertoli cells [102]. Interestingly, Leydig cell maturation 
did not appear to be impacted in SC-LC-ARKO testis as expression levels of Insl3 in the testis 
were comparable to WT controls. This may be attributed to the numbers of AR retaining 
Leydig cells remaining in the testis, suggesting there may be some compensatory mechanism 
or threshold mechanism involved in Leydig cell maturation in which Leydig cells may 
contribute to their own maturation in an autocrine manner.  
The generation of double somatic cell ARKO models has provided further insight into the 
androgen mediated interactions between the somatic cells in the adult testis. Some of the 
cellular functions perturbed by AR ablation include Sertoli cell fluid secretion, influencing 
lumen development and maintenance, Leydig cell steroidogenesis and autocrine control of 
AR expression and maturation, peritubular myoid cell contractility and even potential 
secretion of testosterone from the testis. Given the results published previously describing 
the impacts of cell specific single cell ARKO in the testis, impacts on steroidogenic and 
spermatogenic functionality of the testis were expected, however, the androgen mediated 
paracrine manner in which all somatic cell types contribute the functions of the testis is 
described in more detail here using analysis of double somatic cell ARKOs within the context 
of single somatic cell ARKOs.  
The subsequent chapter will combine the methodology and techniques optimised in chapter 
3 along with the knowledge gained in the present chapter to present the practicalities of viral 
vector delivery to the adult testis. The cell-specific ARKO model chosen to determine the 
potential of gene repair or rescue with lentiviral vectors was the SC-ARKO model. Given the 
vast knowledge of the Sertoli cell functions in the testis and a recent study highlighting the 
importance of AR signalling for post-meiotic germ cell development specifically in adulthood 
[45], using the SC-ARKO testis would be an ideal model for repair through the re-delivery of 





Chapter 5 Demonstrating Practical Uses of 
Lentiviral Vector Delivery with the 
Replacement of Androgen Receptor 
in Sertoli Cell Androgen Receptor 
Knock out Testis. 
5.1 Introduction 
In Chapter 3, techniques for the targeting and delivery of viral vectors to the somatic cells of 
the adult testis were described, demonstrating some evidence for targeting Leydig cells with 
viral vectors and an improved methodology for targeting adult Sertoli cells with lentiviral 
vectors.  As discussed earlier, a handful of studies have demonstrated successful targeting of 
Sertoli cells and subsequent delivery of transgenes and/or rescue of male infertility 
phenotypes using adenoviral [334, 335], adeno-associated viral [348] and Lentiviral vectors 
[45, 397, 399]. However, in the three studies that have demonstrated repair of a phenotype 
using gene delivery, the treatment was delivered to the testis during the pre-pubertal stages 
of life [396, 397] and are therefore, could be considered as demonstrating a prevention of 
infertility as opposed to a rescue of infertility in adulthood.  
Currently, most cases of male factor infertility and hypogonadism remain idiopathic, in part 
due to the limited genetics testing into men with these conditions at the clinic. With the 
majority of males presenting at clinic in adulthood, and the increasing incidence of age-
related male infertility and hypogonadism, the importance of developing a technique that 
can be utilised in the adult male is increasingly important. Alongside this, gene editing 
technology is currently developing at an exponential rate and there are a number of gaps and 
contradictions remaining in the literature surrounding their potential for use in the testis. 
Therefore, the present study sought to confirm the potential applications of lentiviral 
delivered transgenes to the adult testis.  
First, a mouse model exhibiting testicular dysfunction was identified for gene repair or 
replacement (as described in Chapter 4). The models generated were cell specific knockouts 
of Androgen Receptor (AR) from single or double testicular somatic cells using Cre/LoxP 
technology, providing a tool from which both methods optimised for delivery of viral vectors 
to either of these cell types in the adult testis could be utilised. Other uses for the model 
were that they could also be used to gain further insight into some of the synergistic and 
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additive roles of the somatic cell types through AR mediated signalling in the adult testis. The 
well characterised Sertoli cell ARKO model was identified as the most suitable model to be 
used to demonstrate the potential of transgene delivery through Sertoli cell targeting with 
lentiviral vectors.  
It is well described in the literature that the AR expression Sertoli cells is known to have a 
number of key roles in both testis function and development [7-9]. As evident from previous 
studies and through the results described in Chapter 3, it is through AR that some of these 
crucial functions are mediated; in particular, the Sertoli cells support of complete 
spermatogenesis with spermatogenesis being halted before meiosis in the SC-ARKO testis 
[48]. An acute model of Sertoli cell AR ablation has been generated using the delivery of 
lentiviral vectors, demonstrating the importance of Sertoli cell AR for completion of post-
meiotic spermatogenesis [45]. However, it is not currently known whether the absence of AR 
through development (as is the case for the SCARKO mice studied) has a permanent impact 
on the Sertoli cells ability to function and consequently whether this is a reversible 
phenotype.  
Using lentiviral vector delivered mouse Androgen receptor cDNA and the low impact 
methodologies described in Chapter 3, it may be possible to address the unknown 
developmental impacts of Sertoli cell AR loss on testis function. Alongside this the practical 
uses of the methodology optimised and described in Chapter 3 can be established as a 
suitable technique for delivery of transgenics with the potential for restoration of a gene and 
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5.2 Hypothesis & Aims 
5.2.1 Hypothesis 
It is hypothesised that delivery of lentiviral vectors carrying mouse AR cDNA will target Sertoli 
cells of the adult SC-ARKO testis, restore Sertoli cell AR expression and subsequently restore 
spermatogenesis in the rescued tubules.   
5.2.2 Aims 
From this hypothesis, the aims of the experiments described in this chapter were established: 
Aim 1: To deliver an exogenous transgene (mAR) to the Sertoli cells of adult SC-ARKO testis 
following lentiviral injection 
Aim 2: To determine whether lentiviral delivered mouse AR is capable of restoring AR 
expression in Sertoli cells of SC-ARKOs and subsequently restoring spermatogenesis in SC-
ARKO testis.  
5.2.3 Approach 
To achieve these aims, Sertoli cell specific Androgen Receptor knock out (SC-ARKO) mice 
were generated as described in 2.1.3.3. Testis were injected at pnd100 (as described in 5.3.1), 
collected 50 days later and analysed in comparison to testis receiving no injection, injection 
of vehicle or injection of a mAR negative (control) lentiviral vector.  
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5.3.1 Generation of SC-ARKO mice and Injection of Lentiviral 
vectors carrying Mouse Androgen Receptor cDNA 
Sertoli cell specific AR knock out mice were generated as described in 2.1.3.3 and as depicted 
in the schematic in Figure 5.1A. PCR amplification of genomic DNA isolated from ear clips of 
SC-ARKO animals demonstrate the inheritance of Cre recombinase with a band present at 
239bp alongside the internal positive control gene Interleukin 2 (330bp band) (Figure 5.1B). 
At pnd100, lentiviral vectors carrying mouse AR and monomeric GFP (LV-mAR-moeGFP), or 
monomeric GFP alone (LV-moeGFP) downstream of a CMV promoter (lentiviral constructs 
depicted in Figure 5.1C) were introduced into the rete compartment of SC-ARKO testis (or 
those of WT littermates) as described in section 2.3.3. Figure 5.1D illustrates the plan used 
for injection in that one testis was used for LV-mAR-moeGFP injection and the contralateral 
was injected with LC-moeGFP control virus, serving as an internal control from which direct 
comparisons were able to be made. The same methodology also applied for vehicle injections 
where the contralateral testis was used as a non-injection control.  
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Figure 5.1 Generation of SC-ARKO animals for the injection of lentiviral vectors carrying mAR. (A) 
Generation of animals with a loss of AR in Sertoli cells using Amh-Cre positive males and females with 
a floxed AR. (B) PCR analysis of genomic DNA isolated from WT littermate controls and SC-ARKO ear 
clips. Bands at 330bp are representative of the Interleukin-2 internal positive control. Bands at 239bp 
indicate inheritance of Amh-Cre. No inheritance of Amh-Cre was detected in WT littermate and 
Negative controls. No amplification of DNA was detected in Water controls. (C) Schematic diagrams of 
the lentiviral vectors used; LV-moeGFP – a VSVG pseudotyped lentiviral vector carrying moeGFP, LV-
mAR-moeGFP - VSVG pseudotyped Lentiviral vector expressing mouse androgen receptor and a 
monomeric enhanced GFP downstream of the CMV promoter and separated with a P2A cleavage site. 
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(D) Schematic of plan for the injection of viruses described into adult WT and SC-ARKO testis. Mice 
were injected at pnd100 and collected 50dpi.  
5.3.2 Gross Morphology & Histology of WT and SC-ARKO 
Testis following Injection of Lentiviral Vectors carrying 
mAR and/or monomeric GFP 
To determine whether procedures had an impact on testis function, gross morphology of the 
reproductive system was observed on collection of the tissue. As expected, SC-ARKO testis 
exhibited a significant reduction in testis weight compared to WT control testis, regardless of 
treatment. There were no significant differences in weight between treated testis of the 
same genotype (Figure 5.2A). This would suggest that delivery of lentiviral vectors to the 
tubular compartment has no impact on testis weight and therefore, testicular cell survival 
and function. 
Both lentiviral vectors used in the present experiments included a monomeric GFP reporter 
within the construct, permitting the visualisation of transduced cells/tissue using a 
fluoroscope or with antibodies in fixed transduced cells/tissue. Visualisation of non-injected 
and vehicle injected using a fluoroscope with GFP filter revealed no GFP fluorescence, as 
expected. Strong GFP fluorescence was observed within the tubular compartment of LV-
moeGFP injected WT testis (Figure 5.2B), indicating integration and expression of lentiviral 
vectors into cells within the tubular compartment. GFP fluorescence was also detected in LV-
moeGFP injected SC-ARKO testis, though this appeared to be much weaker than that of signal 
in WT testis as it was only more clearly visible in image captures taken after an increased 
exposure to the GFP fluorescent light (Figure 5.2B). Surprisingly, no GFP expression was 
observed in LV-mAR-moeGFP injected WT and SC-ARKO testis (Figure 5.2B).  
There were no striking differences in the appearance of WT testicular histology, regardless 
of treatment, with spermatogenesis seemingly occurring as normal (Figure 5.2B). Control 
treated (No injection, vehicle injected and LV-moeGFP injected) SC-ARKO testis were 
comparable to one another, each with smaller tubules (compared to WT controls), a lack of 
lumen and no elongated spermatids present within the tubules (Figure 5.2B). This indicated 
that, despite a lack of lumen in SC-ARKO testis, that the introduction of substances into the 
tubules, via the rete, has no negative impacts on testis histology. SC-ARKO testis injected with 
LC-mAR-moeGFP, however, appeared to have a lumen present within the seminiferous 
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tubules, suggesting the tubular fluid producing mechanism, mediated by Sertoli cell AR, may 
have been restored (Figure 5.2C). 
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Figure 5.2 Gross Morphology and Histology of Testis following no injection or injection of vehicle or 
Lentiviral Vectors carrying mAR and/or monomeric GFP demonstrates no disruption of testicular 
histology in WT or SC-ARKO testis as a result of the procedure or introduction of a solution into the 
tubules.  (A) Testis weights of LV-moeGFP or LV-mAR-moeGFP injected WT or SC-ARKO testis at 
collection. Shared letters above columns indicate no significant difference (Kruskal Wallis; p=<0.0001). 
Bars are representative or averages ± SEM (B) Images of freshly dissected uninjected, vehicle, LV-
moeGFP and LV-mAR-moeGFP injected WT and SC-ARKO testis under brightfield (BF) or green 
fluorescent light (after 1.5 seconds and 10.5 seconds exposure). (C) Representative Haematoxylin and 
Eosin stained sections of uninjected, vehicle, LV-moeGFP and LV-mAR-moeGFP injected WT and SC-
ARKO testis. * indicate presence of a lumen in LV-mAR-moeGFP SC-ARKO testis. Scale bars = 20µm 
 
5.3.3 Adult SC-ARKO Testis injected with LV-mAR-moeGFP 
exhibit restoration of expression of AR in Sertoli Cells 
Due to the lack of moeGFP fluorescence observed in LV-mAR-moeGFP injected testis, 
detection of the GFP reporter in the testis was attempted but not successful in these samples. 
Therefore to determine whether the delivered AR transgene is being expressed by the 
targeted Sertoli cells, chromogenic immunostaining for AR was performed on both WT and 
SC-ARKO testis sections. AR expression in WT testis, regardless of treatment, was located as 
expected in Sertoli cells, peritubular myoid cells and Leydig cells (Figure 5.3A). In SC-ARKO 
control treated testis (no injection, vehicle injected, LV-moeGFP injected), AR expression was 
limited to peritubular myoid cells and Leydig cells and completely absent from Sertoli cells. 
Detection of AR staining within seminiferous tubules of SC-ARKO + LV-mAR-moeGFP testis 
indicates successful delivery and integration of the lentiviral vectors into the targeted Sertoli 
cell DNA (Figure 5.3A). Closer inspection of the AR expression in LV-mAR-moeGFP injected 
SC-ARKO testis further confirmed the localisation of the AR staining within the Sertoli cells, 
and also revealed what appeared to be elongated spermatids in the tubular compartment, 
in direct contact with Sertoli cells exhibiting restored AR expression (Figure 5.3B). 
Quantification of SC-ARKO testis injected with LV-mAR-moeGFP found that 100% of injected 
testis have some evidence of Sertoli cells expressing AR, and that SC-ARKO testis injected 
with LV-moeGFP exhibited no evidence of Sertoli cell AR expression (Figure 5.3C). Chi-
squared analysis confirmed that there was a significant association between genotype and 
treatment and whether presence of AR was observed (p=<0.0001).  
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Figure 5.3 AR Expression in LV-moeGFP or LV-mAR-moeGFP injected WT and SC-ARKO testis. (A) AR 
immunostaining in uninjected, vehicle, LV-moeGFP or LV-mAR-moeGFP injected WT and SC-ARKO 
testis. Arrows depict AR positive Sertoli cells in LV-mAR-moeGFP injected SC-ARKO testis. Scale bars = 
20µm. (B) A close up image of a SCARKO+LV-mAR-moeGFP testis demonstrates restoration of Sertoli 
cell AR expression. Arrows depict AR positive Sertoli cells. Scale bars = 8.3µm. (C) Visual representation 
of number of WT and SCARKO testis with evidence (through immunostaining) of Sertoli Cell AR. As 
expected all WT testis, regardless of injection, had evidence of Sertoli cell AR whereas LV-moeGFP 
injected SCARKO testis lacked any Sertoli Cell AR. 100% of the six SCARKO testis injected with LV-mAR-
moeGFP, had evidence of AR expression in Sertoli cells. Chi-squared analysis confirmed that there was 
a significant association between genotype and treatment and whether presence of AR was detected 
(p=<0.0001). 
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5.3.4 Restoration of Sertoli Cell AR expression in SC-ARKO 
testis results in repair of spermatogenic function of the 
testis.  
In addition to the AR staining visible in SC-ARKO + LV-mAR-moeGFP testis, morphologically 
mature spermatids were also visible in SC-ARKO+LV-mAR-moeGFP testis. To confirm this, 
chromogenic immunostaining of spermatid marker; PGK1/2 was carried out on both WT and 
SC-ARKO testis sections. SC-ARKO+LV-mAR-moeGFP testis exhibit a number of tubules with 
positively stained spermatids in comparison to SC-ARKO+ LV-moeGFP, which exhibit no 
PGK1/2 stained spermatids (Figure 5.4A). Male SC-ARKO mice have previously been reported 
to lack of PGK1/2 positive spermatids (indicating a halt of spermatogenesis post meiosis) [5], 
therefore, positive staining noted in these studies indicates a restoration of spermatogenesis 
as a result of mAR transgene delivery by lentiviral vector. The characteristic shape of the 
‘hook-headed’ mouse elongated spermatids are easily identifiable in LV-mAR-moeGFP 
injected testis (Figure 5.4B) further confirming a rescue of spermatogenic function. Elongated 
spermatids were detected in 66% of SC-ARKO testis injected with LV-mAR-moeGFP and in 
none of the SC-ARKO testis injected with LV-moeGFP (Figure 5.4C). Chi-squared analysis 
confirmed that there was a significant association between genotype and treatment and 
whether presence of elongated spermatids was observed (p=<0.0001). 
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Figure 5.4 Quantifying success of using lentiviral delivered mAR to rescue SCARKO testicular 
phenotype. (A) Representative immunostaining for Androgen Receptor (AR) and Phosphoglycerate 
Kinase 1+2(PGK1/2) in WT and SCARKO testis 50 days post procedure with either no injection or 
injection of LV-moeGFP or LV-mAR-moeGFP. Primary antibody negative controls are included (inset 
left). Scale bars = 10µm. (B) A close up of image of a testis section from a SC-ARKO testis injected with 
LV-mAR-moeGFP demonstrating restoration of spermatogenesis. (C) Visual representation of number 
of WT and SCARKO testis with/without presence of spermatids following injection with either LV-
moeGFP or LV-mAR-moeGFP. As expected, all WT testis exhibited presence of mature elongated 
spermatids regardless of lentiviral injection and LV-moe-GFP injected SCARKO testis lacked presence 
of mature elongated spermatids. Of the six SCARKO testis injected with LV-mAR-moeGFP, four testis 
(66.6%) exhibited evidence of mature elongated spermatids. Chi-squared analysis confirmed that 
there was a significant association between genotype and treatment and whether presence of mature 
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The overarching aim of the experiments described in this chapter was to demonstrate the 
practical uses of lentiviral delivery to the testis, in particular to demonstrate 
delivery/restoration of a transgene in a mouse model of testicular dysfunction. 
There has previously been two published studies demonstrating the rescue of gene using 
lentiviral vector delivered transgenes and as a consequence, fertility. The first by Ikawa and 
colleagues in 2002, in which full spermatogenesis was detected in Sl/Sld mutant mice resulted 
in the generation of offspring via microinsemination [397]. The second to do so was Li et al 
in 2013 [396]. However, this group were unable to produce progeny from their lentiviral 
injected PICK1 null testis. One reason for this may be that, unlike the study by Ikawa et al, Li 
et al did not attempt to generate offspring using assisted reproductive techniques such as 
intra cytoplasmic sperm injection (ICSI) and instead allowed the mice to mate naturally. This 
may be a due to an insufficient number of mature spermatids being produced due to 
relatively low Sertoli cell targeting of the lentiviral vector and/or due to an insufficient 
number of maturing spermatozoa reaching the epididymis for maturation. However, in both 
of these studies, mice were injected prior to the completion of testis maturation/puberty, 
with Ikawa et al injecting testis at between pnd 5-10 and Li et al injected testis between pnd 
21 and 42 [396, 397], whereas the aim of the experiments described in the present study 
were to demonstrate the potential of lentiviral vector delivery to the Sertoli cells in the adult 
testis.   
To determine whether it would be possible to rescue a phenotype in the adult testis, SC-
ARKO (and WT) testis were injected with a lentiviral vector carrying mAR and moeGFP (or 
control viruses carrying moeGFP alone). It was found that, despite control virus injected testis 
emitting signal under a GFP fluorescent lamp, this was not the case for those injected with 
lentiviral vector carrying mAR and moeGFP. The co-expression of multiple transgenes from a 
single Lentiviral vector was permitted with the incorporation of 2A “self-cleaving” peptide 
between the two transgenes of interest (Figure 5.1C – denoted as “P2A”). These self-cleaving 
peptides allow ribosomes to skip the formation of a glycel-prolyl peptide bond at the C-
terminus of the 2A peptide [483, 484]. Successful skipping of the ribosome allows the 
translation and cleavage co-translationally of two proteins. Therefore, failure of the 
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expression of the protein downstream of the P2A site may be due to the ribosome “falling 
off” the viral mRNA, discontinuing the translation of the gene downstream of the p2A 
cleavage site [484]. If this is the case, this would imply that the gene upstream of the p2a 
cleavage site; mAR, would still have been translated to protein successfully but not that 
downstream of the p2a cleavage site; GFP, affording explanation to the lack of GFP 
expression in LV-mAR-moeGFP injected testis. 
The lack of moeGFP expression in LV-mAR-moeGFP injected testis meant that visualisation 
of the lentiviral vectors was not possible using immunostaining methods with an antibody 
specific to moeGFP. However, in SC-ARKO testis, AR protein was detected in SCs using 
immunohistochemistry in all LV-mAR-moeGFP injected SC-ARKO testis, confirming successful 
delivery of the exogenous mAR transgene to the Sertoli cells in the adult SC-ARKO testis and, 
as a result, successful rescue of AR expression.  
As discussed in Chapter 4, one important AR mediated role of the Sertoli cells in the adult 
testis is the production and movement of water and fluids within the seminiferous tubules 
[467, 476, 477]. In LV-mAR-moeGFP injected SC-ARKO testis, there appeared to be a lumen 
developed within the seminiferous tubules, indicative of some rescue of Sertoli cell function, 
though this is yet to be quantified. The function of the luminal fluid, produced by the Sertoli 
cells, is not only for the transport of elongated spermatids towards the epididymis, but it also 
provides a favourable microenvironment for spermatogenesis to occur [485, 486].  Elongated 
spermatids were found to be present in 66% of LV-mAR-moeGFP injected SC-ARKO testis, a 
stage of spermatogenesis not previously seen in untreated SC-ARKO testis [48]. This 
demonstrates the rescue of spermatogenesis in the SC-ARKO testis following the restoration 
of mAR expression in the Sertoli cells. The results presented in this study also demonstrate 
the reversal of the SCARKO testicular phenotype in tubules targeted by the mAR expressing 
lentiviral vector. This suggests that absence Sertoli cell AR throughout development in SC-
ARKO testis does not appear to have a permanent impact on the Sertoli cells capacity to 
support spermatogenesis in adulthood following the restoration of mAR.  
The introduction of lentiviral vectors to the seminiferous tubules of the testis has been shown 
to be useful for the delivery of exogenous transgenes with adult knock out of genes [45] a 
rescue of gene knockout being demonstrated in the literature [396, 397].  Delivery of 
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lentiviral particles carrying mAR was shown to restore AR expression in SCs lacking AR and, 
consequently, spermatogenesis with evidence of elongated spermatids in tubules with 
rescue of AR expression. Furthermore, by delivering mAR to SCs in adulthood with lentiviral 
vectors, it has been shown that SC-ARKO does not impact SCs capacity to support 
spermatogenesis in adulthood. This is supportive of an adult SC-ARKO in which lentiviral 
delivered ARmiRNA induced the halt in post meiotic spermatogenesis seen in Cre/loxP 
derived SC-ARKO models, confirming the key role of SC-AR in the adult testis.  
This provides further evidence indicative of the potential of using lentiviral vectors for the 
targeting of SCs in the adult testis. Furthermore, the results discussed give some insight into 
the capacity of delivering transgenes into the testis with the purpose of either generating 
testis specific and/or rescuing transgenic models of testicular dysfunction. Some evidence is 
also provided considering the scope of lentiviral transgene delivery for therapeutic purposes 















Chapter 6 General Discussion & Future 
Perspectives 
 
The causes of male reproductive disorders are yet to be fully defined and our understanding 
of the genetics behind male hypogonadism and infertility remains limited. Despite significant 
advances in the management of infertility (with IVF) and hypogonadism (with androgen 
replacement) over the past two decades, treatments continue to focus upon addressing the 
symptoms presented at clinic as opposed to the underlying causes of these conditions.  
The advancements of gene delivery vectors over the past two decades has rejuvenated the 
prospects for the developments of clinical gene therapies. With the variety of DNA delivery 
vectors and the overlapping capacities of each of these vectors, the potential to develop 
treatments for a large scope of genetic disorders is becoming increasingly conceivable. 
Alongside this, the rapid expansion of gene editing technologies such as CRISPR/Cas9 has 
made the manipulation of genes in vivo more accessible to researchers, both for furthering 
knowledge of biological systems and for discovering potential routes to therapies. The use of 
these technologies for gene therapy is something that is already becoming a reality for some 
disorders with the number of successful clinical trials that are currently under assessment.  
Both DNA vector delivery systems and gene modification technologies have been 
demonstrated in the mammalian testis with varying rates of success. With the potential to 
target the germ line, use of these tools in the human testis remains controversial, therefore 
it is essential that further exploration of these techniques is carried out to fully define the 
potential they have for use in this system.  A number of studies have also demonstrated 
targeting of the somatic cells in testis; those responsible for both the production of 
testosterone and those responsible for the support of spermatogenesis. With intricate 
combinations of these tools, researchers could identify and thus discover a solution for the 
treatment of these clinically prevalent conditions potentially originating in these somatic cell 
types of the testis.  
The overarching hypothesis of the work described was that, following optimisation of viral 
vector delivery to the testis, targeting of the adult testicular somatic cell would be permitted 
in vivo, providing a tool from which (i) further insights into testicular function can be 




determined and (ii) the development of therapeutic techniques to treat male reproductive 
disorders could be established. This was then addressed in three stages of experiments; first 
an optimisation and validation of somatic cell targeting with viral vectors with the aim of 
delivering an exogenous transgene to specific cell types, taking care to avoid disturbance of 
the testicular micro-environment  as a result of the delivery procedure. Secondly, a model 
was required for the purpose of repair or replacement of a gene. Given the broad knowledge 
base already available in the field of androgen signalling in the testis, this gene was selected 
for replacement within an ARKO model. Generation of single and double somatic cell ARKO 
models permitted both the identification of a suitable model for repair and allowed a 
systematic comparison of models for assessment of androgen receptor mediated paracrine 
signalling in the adult testis. Finally, on the selection of a model for repair, the potential of 
lentiviral vector delivered transgenes to rescue a model of testicular dysfunction and 
infertility was determined.  
6.1 Establishment and validation of viral vector delivery to 
target the adult testicular somatic cells. 
The use of gene editing systems and the technology developed to deliver them is becoming 
increasingly common within scientific research. With regards to targeting the cell populations 
residing in the testis, the majority of studies have focussed on specifically targeting the germ 
cell population with aim of generating transgenic animals [363, 394-396, 487]. However, few 
studies have demonstrated a robust system for targeting the germ cell population in vivo to 
produce transgenic lines with a number of studies failing to demonstrate targeting of the 
germ cell population in vivo [361, 488, 489]. First attempted in 2004 using a Maloney 
leukaemia retrovirus, Shinohara et al demonstrated the transduction of SSC and subsequent 
generation of transgenic offspring following injection into juvenile testis (5 to 10 days old) 
with an average success rate of 2.8% [363]. The reasoning behind injecting juvenile testis in 
this study was due to the lack of tight junctions present in the seminiferous tubules at this 
age point; theoretically allowing easier access of the viral particles to the SSC population.  
Similarly, juvenile testis injections into both the seminiferous tubules [395] and into the 
interstitial compartment [394, 395] were utilised in later studies investigating lentiviral 
vector delivered transgenes for the generation of transgenic offspring and promoters driving 
delivered transgene expression [394, 395]. Both studies provided contrasting evidence for 
the generation of transgenic offspring; with Sehgal et al [394] reporting failure using a CMV 




driven transgene and success using an EF-1 driven transgene and Qin et al [395] reporting 
the contrary attributing this to transgene silencing through DNA methylation.  
Given the ambiguity of the published data using lentiviral vectors, we sought to repeat the 
studies to determine the likelihood of delivered transgenes being transmitted to offspring in 
future studies utilising lentiviral interstitial injections. Analysis of pups produced from ‘Pre-
Founders’ injected with lentiviral vectors expressing GFP under either the CMV or the EF-1 
promoter revealed that there had been no transmission of GFP to offspring. This would 
suggest that either the spermatogonial stem cell population is not being targeted or that, if 
they are targeted, lentiviral vectors are not able to integrate into the spermatogonial stem 
cell DNA, preventing the transmission of exogenous/foreign transgenes to progeny. This has 
previously been suggested by Takehashi (2007) in that male germ cells may acquire 
resistance to viral infection as they mature. Furthermore a number of studies have 
demonstrated the resistance or repression of viral DNA expression in different types of viral 
vector infected stem cells (embryonic, haematopoietic and germ line stem cells), indicating 
that using these viral vectors to induce stable integration, expression and, as a consequence, 
to generate transgenic animals, may come with great difficulty [490-492].  
For the purpose of developing an alternative therapeutic for the treatment of male 
reproductive disorders, the inability of the viral vector used for transgene delivery would be 
beneficial, particularly as editing of the human germ line is currently prohibited in 29 
countries [303]. Therefore, further in-depth investigation into the potential for germline 
transmission following delivery of these viral vectors in vivo, both interstitially and into the 
seminiferous tubules would be beneficial. 
Delivery of lentiviral vectors into the interstitial compartment resulted in uptake of the virus 
particles specifically by the Leydig cells. However, cells targeted with the lentiviral vector 
ultimately underwent apoptosis, potentially as a result of viral integration into the Leydig cell 
DNA involving the activation of DNA dependent protein kinases [493]. Previously published 
studies demonstrating Leydig cell lentiviral uptake have either collected 4dpi (prior to 
detection of apoptosis in the present study) or utilised a lentiviral vector delivered transgene 
under a different promoter; the EF1α promoter, the latter of which reporting a drop (but not 
complete loss) in transgene expression at 9dpi [188, 494]. 
 




Apoptosis was not seen in testis injected interstitially with adenoviral vectors, potentially due 
to adenoviral vectors being incapable of integration, though why apoptosis occurs in Leydig 
cells but not in Sertoli cells is unclear as yet.  
The relative success of adenoviral vector targeting of Leydig cells seen in the experiments 
described in this thesis are a validation of those seen in a study by Penny et al (2017), 
published during the time-frame of these experiments [175]. This would suggest that 
adenoviral vectors are more suitable than lentiviral vectors for Leydig cell targeting, though 
given the transient nature of the delivered transgene expression, and the inability to deliver 
more than once due to the high immunogenicity characteristics, they may only be suitable 
for delivery of gene modification and editing technologies within a research setting, for 
example for the delivery of Cre recombinase. 
Therefore, further study, into alternative vector types such adeno-associated viral vectors 
may be beneficial. Recently, a study has highlighted the capacity of these vectors to integrate 
into numerous somatic cell types in the testis, depending on the serotype used, but also 
demonstrated lack of germ line transmission. Given the reduced immunogenicity and the 
capacity for integration of adeno-associated viral vectors, further exploration into their uses 
in the testis would be valuable, particularly for the development of therapeutic strategies.  
Previous investigations into lentiviral delivery to the seminiferous tubules have utilised 
injections into the efferent duct of the testis. As the efferent duct is a fragile structure, crucial 
for the movement of mature spermatids from the testis into the epididymis, damage can 
incur catastrophic effects to the testicular function. This was evident in a number of testis 
following injection into the efferent duct and, as a result, prompted an optimisation of the 
injections into a different area of the testis. This area was chosen to be the rete testis, given 
the access of this area to the seminiferous tubules. Injections at lower pressures into this 
compartment were found to be less likely to induce negative impacts like those seen in 
previous studies in the group.  
Delivery of lentiviral vectors to the tubular compartment has been shown to specifically 
target the Sertoli cells with next to no consequences of lentiviral integration, as 
demonstrated in a number of published studies [45, 396, 397]. Given the apparent success 
of this, future prospects of this technique are deemed to be promising, in both research and 
in clinic, as evident from the number of lentiviral vector based therapies currently reaching 




the stages of clinical trials (196 at the time of writing) 
(http://www.abedia.com/wiley/vectors.php). Further investigation to increase targeting 
efficiencies in the testis, and to establish methods of targeting peritubular myoid cells 
(potentially through adeno-associated viral vectors as suggested in the aforementioned 
study [348]) would provide options for targeting all somatic cell types, in singular or in 
combination, permitting both investigation and study of the primary somatic cell types at any 
time point in the adult testis. 
6.2 Identifying a model of testicular dysfunction and 
gaining further insight into androgen signalling in the 
adult testis 
Having successfully optimised a technique to target and deliver exogenous transgenes to the 
Sertoli cells, a tool in which this technique could be tested and validated was required. Given 
the extensive knowledge of the roles of AR available, a cell specific ARKO was chosen for 
rescue. Single and double cell specific ARKOS were generated to identify the most 
appropriate model for gene rescue with lentiviral vectors. This also permitted an in parallel 
characterisation of the double somatic cell ARKO models alongside the previously published 
single cell specific ARKOs, affording further insight into the androgen receptor mediated 
autocrine and paracrine networks that may be at play in the somatic cell in the adult testis. 
In the adult testis, the proper functioning and positioning of both the Sertoli cells and 
peritubular myoid cells is key for providing support of spermatogenesis and for formation of 
the BTB, implicating the close relationship these two somatic cells have.  This partnership 
between these two somatic cells was evident following analysis of SMA in single and double 
somatic cell ARKOs. Transcript expression of SMA was significantly reduced in SC-PTM-ARKO 
testis but not in any single cell specific ARKO testis and thus emphasising the collaboration 
between Sertoli cell and peritubular myoid cells. As a result of AR loss in peritubular myoid 
and/or Sertoli cells, Sertoli cells also begin to lose their polarity, evident from movement of 
the Sertoli cell nucleus away from the periphery of the seminiferous tubule. One reason for 
this could be a disruption in the production of extracellular matrix components, a key role of 
both Sertoli and peritubular myoid cells and for the cell to cell association patterns and 
polarity maintenance in these cell types [120, 121, 495]. Therefore, analysis of these 
components, through immuno-staining and through transcript analysis, along with the 




apparent associations with AR signalling, using the single and double somatic cell ARKO testis 
would merit further investigation. 
Signalling through Sertoli cell AR is known to be essential for the integrity of the BTB. It has 
been suggested that WT1 and AR, both of which are expressed by Sertoli cells, may 
functionally interact during testis development [31, 42, 496]. In mice deficient of WT1, AR 
expression is not impacted, but integrity of the BTB is lost with reduction in expression of 
tight junction proteins [497]. The same researchers also demonstrated that the loss of the 
WT1 in adulthood results in a reduction in the expression of DHH and subsequently a 
reduction in steroidogenic gene expression [473]. In SC-PTM-ARKO testis, but not in single 
ARKO knockouts, transcript expression of DHH was significantly reduced, as were a number 
of steroidogenic enzyme transcripts.  This suggests an androgen mediated role for the 
peritubular myoid cells in paracrine signalling associated with Dhh between Sertoli cells and 
Leydig cells, though further investigation into this and the status of the BTB would be 
beneficial for a further understanding of the mechanisms involved.  
Each of the cell specific ARKO models revealed no significant differences in serum 
testosterone levels, suggesting the lack of spermatogenesis in all models (excluding LC-
ARKO), is a either a result of lack of Sertoli cell AR or signalling through the peritubular myoid 
cells and not through any additional factors produced by Leydig cells. Alongside this, for SC-
ARKO and SC-LC-ARKO testis, a reduction in LC numbers and few changes in steroidogenic 
enzymes may signify that the Leydig cells remaining in the testis are each expressing 
steroidogenic genes and producing testosterone at an increased rate compared to those in 
other cell specific ARKO models and to WT testis, though serum LH levels are not significantly 
increased in any of the cell specific ARKO models. This could be examined by stimulating a 
maximal output from Leydig cells using human chorionic gonadotrophin, with a lack of 
additional response being indicative of the Leydig cells already functioning to their maximum 
output.  
Another observation made was the reduction of AR expression in Leydig cells in the double 
somatic cells ARKO testes. For the SC-PTM-ARKO testis, it is not yet clear whether the 
significant reduction of Leydig cell AR is a result of the smMHC-eGFP targeting Leydig cell 
progenitors early in testis development or whether it is a true impact of reduced androgen 
signalling in Sertoli and peritubular myoid cells on the expression of AR in Leydig cells. Indeed, 




in the PTM-ARKO testis there is not a significant reduction in AR positive Leydig cells, though 
any true significant reduction may be masked by the large variances seen in this model.  
Leydig cell AR expression was also significantly reduced in SC-LC-ARKO testis, but not in SC-
ARKO testis. Though a reduction in Leydig cell AR expression was expected, it was not 
expected to be as great a reduction as the one observed. This could suggest that expression 
of AR in Leydig cells may be influenced by Leydig cell AR expression in an autocrine manner. 
Interestingly, despite this reduction in AR, the expression of Leydig cell maturation markers; 
Insl3 and Hsd3β6 were not impacted in SC-LC-ARKO like that seen in a published LC-ARKO 
study [108]. Immunostaining of INSL3 revealed a lack of expression in a small majority of 
Leydig cells, suggesting that these cells have not undergone full maturation. Given the lack 
of Leydig cell AR expression in the SC-LC-ARKO, this was surprising and could indicate that a 
threshold of Leydig cell AR may be required for maturation of the Leydig cell population. 
The experiments described were able to provide some additional information permitting a 
wider perspective as to the autocrine and paracrine signalling networks present in the testis 
in adulthood with the use of double somatic cell ARKO models. 
Development of cell specific targeting systems like those described in chapter one and those 
published in the literature to allow knock out of AR in single and multiple cell types in the 
adult testis specifically would allow further dissection of the signalling networks at play in the 
testis in adulthood [45]. This would permit researchers to distinguish between cell specific 
roles in development and those in adulthood. 
Considering the wealth of knowledge available for the role of Sertoli cell androgen receptor 
in development and in adulthood testicular function and the improved methodology for 
targeting Sertoli cells with lentiviral vectors, the Sertoli cell ARKO testis was chosen to be 
utilised for gene rescue using lentiviral vector delivered transgenes.  
6.3 Determining the potential of viral vectors to rescue 
fertility in the adult SC-ARKO testis 
Delivery of viral vectors to testicular somatic cells has been demonstrated previously with 
the purpose of restoring gene expression. However, each of the studies injected the viral 
vectors into the testis of juvenile mutant mice [348, 396, 397]. Though gene expression 




appeared to be successfully restored in these experiments, the delivery of viral vectors to 
pre-pubertal testis may give a false impression as to the capability of a lentiviral vector to 
target an adult somatic cell population and deliver an exogenous transgene. Theoretically, 
targeting pre-pubertal cells still undergoing proliferation, could result in what appears to be 
an increased proportion of the adult somatic cell population compared to targeting later in 
life. Alongside this, testicular boundaries such as the BTB is yet to have developed in the pre-
pubertal testis, potentially making it appear as if lentiviral vectors can breach the barrier in 
adulthood. It is therefore important to determine the practicalities of using this technology 
in the adult testis.  
The experiments described in chapter five were carried out to determine the potential of 
lentiviral vector delivered transgenes to repair or rescue a SC-ARKO testis in adulthood. To 
do so, lentiviral vectors carrying mouse AR cDNA were delivered to the rete compartment in 
the testis, using the low pressure injections optimised in chapter three. Inspection of sections 
of SC-ARKO testis injected with lentivirus carrying AR revealed what appeared to be the 
development of lumen within the seminiferous tubules. As demonstrated in chapter four, 
signalling via Sertoli cell AR is essential for the production of tubular fluids and for thus the 
development of a lumen.  
Targeting and integration of the lentiviral vector into the Sertoli cells was confirmed with the 
re-expression of AR in all LV-mAR-moeGFP injected SC-ARKO testis but not in those injected 
with AR negative control lentivirus. As a result of this re-expression of AR in the Sertoli cells, 
spermatogenesis appeared to continue past the final stages of meiosis with the presence of 
elongated spermatids being observed in LV-mAR-moeGFP injected SC-ARKO testis and not in 
those injected with mAR negative lentiviral vectors. The presence of elongated spermatids 
was noted in four out of six of the LV-mAR-moeGFP injected SC-ARKO testis and was noted 
in tubules in which AR expression had been restored.  
Further study using this system of rescuing AR expression in Sertoli cells and intracytoplasmic 
sperm injection would be beneficial to determine whether the resultant mature spermatids 
are capable of producing viable offspring. Regardless, further investigation of control virus 
injected WT testis would also be beneficial to determine the potential of germ line 
transmission to offspring; something of particular importance if the technique were to be 
considered for use as an option for human therapeutics.  




The re-introduction of Sertoli cell AR to SC-ARKO testis has confirmed that the absence of 
Sertoli cell AR throughout development does not appear to have an impact on Sertoli cell 
function and that its key role is the support of spermatogenesis through androgen signalling. 
It also endorses the results seen in an adult knock down of AR, produced using lentiviral 
vector delivered Cre in AR floxed testis, revealing that ablation of Sertoli cell AR in adulthood 
resulted in a lack of progression of spermatogenesis past meiosis [45]. Additional 
experiments into the impacts of Sertoli cell loss and rescue on Leydig cell function would be 
interesting to perform and could be done so following optimisations to increase targeting 
efficiency and by injecting the viral vectors into both testis (thereby avoiding compensatory 
mechanisms from the contralateral testis).  
Furthermore, restoration of the fertility phenotype in the adult testis confirms the great 
potential of lentiviral vector transgene delivery for both the development of adult specific 
transgenic mouse models and for the potential of therapeutics for the treatment of male 
reproductive disorders. Though this study has demonstrated that only a small number of SC 
need to express AR to produce mature elongated spermatids, further investigation to 
increase the targeting efficiency would be advantageous from both the perspective of 
research uses and for the development of therapeutics. Additionally, further analysis into the 
potential for transgene transmission to the germ line is crucial following injection of viral 
vectors into the seminiferous tubules.  
Further development of viral and non-viral targeting of somatic cells could permit the 
generation of adult or age specific (following optimisation of injection techniques in younger 
testis) mouse models of testis dysfunction. Alongside this, combination of the vector delivery 
techniques with the rapidly expanding tools for gene editing technology, including the 
CRISPR/Cas9 system, will allow tailored strategies for knock down and re-expression of one 
or multiple genes within one organ. Improvements in both the diagnosis and the 
development of possibilities for bespoke treatment options, like those described here, would 
be beneficial for the millions of men afflicted with reproductive disorders such as infertility 
and/or hypogonadism. 
 






The hypothesis of the experiments described is that the optimisation of viral vector delivery 
into the testis will permit targeting the adult testicular somatic cells in vivo, providing a tool 
from which (i) further insights into testicular function can be determined and (ii) the 
development of therapeutic techniques to treat male reproductive disorders could be 
established. 
Novel observations to support this hypothesis include: 
1. Injection of substances at low pressure into the rete compartment of the 
testis reduce the negative side effects seen in testis injected at high pressure 
into the efferent duct, resulting in a technique more suited to the purpose 
of gene delivery and repair. 
2. Delivery of androgen receptor to Sertoli cells in the adult SC-ARKO testis 
results in re-expression of androgen receptor and subsequently the 
production of elongated spermatids; a stage of spermatogenesis not 
previously seen in a SC-ARKO testis. 
3. Delivery of androgen receptor to Sertoli cells in the adult SC-ARKO testis also 
revealed that the loss of AR during development has no permanent impact 
on the functioning of the Sertoli cell following reintroduction of AR. 
Additional novel observations reported in thesis include: 
1. The detection of markers of apoptosis and subsequent loss of targeted 
Leydig cells could suggest that the use lentiviral vectors to target Leydig cells 
may be unsuitable. 
2. There may be an androgen mediated role for the peritubular myoid cells in 
paracrine signalling associated with Dhh between Sertoli cells and Leydig 
cells in adulthood. 
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